CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 17 February 2021Janssen Research & Development *
Clinical Protocol
Phase 2, Randomized, Double -blind, Placebo- controlled Study to Evaluate the Efficacy and 
Safety of Sirukumab in Confirmed Severe or Critical COVID -19 Disease
Protocol CNTO136COV2001 ; Phase 2
AMENDMENT 5
CNTO136  (sirukumab )
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited toJanssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, 
BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland
UC; Janssen Biopharma Inc.;or Janssen Research & Development, LLC. The term “sponsor” is used 
throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact 
Information page that accompanies the protocol.  
EudraCT NUMBER:         2020 -003056 -32
Status: Approved
Date: 17 February 2021
Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV   
EDMS number: EDMS- ERI-207794964, 13.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipient
will maintain the confidentiality of the information under applicable statutes, regulations, rules, protective orders or 
otherwis e.
[STUDY_ID_REMOVED]
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,Date: 17 February 2021PROTOCOL A MENDMENT S UMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date
Amendment 5 This document
Amendment 4 15 September 2020
Amendment 3 23 July 2020
Amendment 2 17 June 2020
Amendment 1 24 April 2020
Original Protocol 14 April 2020
Amendment 5 (This document)
Overall Rationale for the Amendment: The protocol has been amended tolimit the study population to 
a subset of the currently eligible population, ie, those with confirmed critical COVID -19 disease .
Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.1Synopsis
1.2Schema
3OBJECTIVE S AND ENDPOINTS
4.1Over allDesign
4.2Scientific Rationale for Study 
Design
5.1Inclusion Criteri a
8.1.1 Six-point Ordinal Clinical 
Recovery Scale
9.1Statistical Hypotheses
9.2Sample Size Determination
9.3Populations for Analys isSets
9.4.4 Other Secondary Endpoints
9.5Interim Analysis
10.4.6 Committees StructureThe participants with confirmed severe 
COVID -19 disease will no longer be 
eligible for this study as the study 
population will be limited to participants 
with confirmed critical COVID -19 disea se.
Definition of critical COVID -19 is more 
clearly defined under Sections 5.1 and 
8.1.1 .
The primary objective of this study will
evaluate the clinical response of sirukumab 
(administered as a single IV dose) + SOC 
compared to placebo + SOC in confirmed 
critical COVID -19 disease.
Sample size and population in scope for the 
primary and the key secondary objectives
have been modified accordingly. Form er 
primary and key secondary objective in 
confirmed severe or critical COVID -19 
disease becom e additional secondary 
objective s. All other secondary objectives
will be analyzed in the confirm ed (a) 
critical and (b) severe or critical 
COVID -19 disease.Based on the rapidly evolving 
space of COVID -19 therapeutics 
focusing on the highly impacted 
population of critical patients 
together with the results from the 
interim analysis, the study 
population will be limited to a 
subset of the currently eligible 
population, ie, those with 
confirmed critical COVID -19 
disease . 
1.1Synopsis
9.4.6 Safety Ana lyses
9.4.7 Other Analyses
10.1 Appendix 1: Abbreviations and 
DefinitionsThe increase of ALT or AST combined 
with increase of bilirubin will be 
investigated by means of evaluation of 
drug-induced serious hepatotoxicity 
(eDISH) plots.Alignment with Statistical 
Analysis Plan.
Update on tables to be generated for the 
clinical laboratory tests.
Removal of analysis of the physical 
examination.
The coefficient of variation (CV) will not 
be analyzed for the biomarker analysis.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.2Schema
1.3Schedule of Activities (SoA)
5 STUDY POPULATION
8STUDY ASSESSMENTS AND 
PROCEDURES
10.3 Appendix 3: Clinical and 
Laboratory Assessments Described per 
DayThe ECG assessment has been added in the 
protocol text for clarification. Minor update to allow more 
flexibility toassess eligibility, 
based on local standard of care 
practices .Footnote g was added to the 
screening/baseline ECG assessment. 
5.2Exclusion Criteria Exclusion criteria based on medical history 
or on past/current medications are 
pragmat ic criteria. Deviation post 
randomization from these criteria due to 
late awareness of medical history and/or 
comedications are not intended to be 
qualified as major protocol deviations.Clarification.
6.1Study Intervention (s)
AdministeredClarify that placebo is to be provided 
locally and no tcentrally.Clarification since the study is 
not intended to be performed 
outside of the United States of 
America. 
6.2
Preparation/Handling/Storage/Account
abilityTo remove details on the preparation, 
handling, and storage of the study 
intervention .To avoid errors on the 
preparation, handling, and 
storage of the study intervention , 
referenc e is made to the IPPI
only. 
6.8Prestudy and Concom itant Therapy The use of bamlanivimab, and casirivimab 
plus imdevimab is disallowed during the 
study.Per CDC guidelines, monoclonal 
antibodies are not considered to 
be standard of care for 
COVID -19. 
Administration of a COVID -19 vaccine 
during the study is not allowed at any time 
betw een screening and the discharge visit.Per CDC guidelines, vaccination 
of persons with known current 
SARS -COV -2 infection should 
be deferred until the person has 
recovered from the acute illness .
For the purpose of this study , 
recovered from acute illness is 
considered as ready for 
discharge .
7.3Lost to Follow -up Clarify that publicly available vital status 
information is not to be documented when 
a participant has withdrawn consent. This 
participant will be considered lost to 
follow -up.Clarification on the rules of data 
handling consistent with GCP.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
8.1.1 Six-point Ordinal Clinical 
Recovery ScaleEdits are made to the 6-point ordinal 
clinical recovery scale to clarify that:
For participants not hospitalized 
(category 1), a distinction will be 
made betw eenparticipants 
discharged andinneed of(score 1.2) or 
not in need of(score 1.1)oxygen 
supplementation as indicated by the 
investigator on the discharge 
questionnaire.
Regardless of the device used: 
Hospitalized participants with a FiO 2
below  50% corresponds to a category 
3.
Hospitalized participants with a FiO 2
of 50% or higher corresponds to a 
category 4.Clarification on category 1.
Clarifications on categories 3 and 
4 to make category 3 fully 
consistent with category 4,which 
is using the FiO2 as a threshold 
and making the allocation to 
category 3 or 4 independent of 
the device used.
8.1.4 Supplemental Oxygen Use Clarify that the use of CPAP at home for 
obstructive sleep apnea syndrome will not 
be reported as a need for supplemental 
oxygen information.Clarification.
10.1 Appendix 1: Abbreviations and 
DefinitionsDefinitions of critical and severe 
COVID -19 disease have been added to the 
definitions of terms.Clarification.
1.1Synopsis
1.3Schedule of Activities (SoA)
4.1Over allDesign
10.2 Appendix 2: Clinical Laboratory 
Tests
10.3 Appendix 3: Clinical and 
Laboratory Assessments Described per 
DayMinor rew ording.
Corrections for respiratory and vital signs 
assessments to be performed once weekly 
after Day 28 if still hospitalized.Clarification. 
Throughout the protocol Minor formatting and m inor updates made .Minor errors w ere noted .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Status: Approved ,Date: 17 February 2021TABLE OF CONTENTS
PROTOCOL A MENDMENT S UMM ARY OF CHA NGES T ABLE ............................................................... 2
TABLE OF CONTENTS ............................................................................................................................... 5
LIST OF IN -TEXT T ABLES A ND FIGURES ................................................................................................ 7
1. PROTOCOL SUMMA RY..................................................................................................................... 8
1.1. Synopsis ........................................................................................................................................... 8
1.2. Schema .......................................................................................................................................... 17
1.3. Schedule of Activities (SoA) ........................................................................................................... 18
2. INTRODUCTION ................................................................................................................................ 25
2.1. Study Rationale .............................................................................................................................. 25
2.1.1. Background ................................................................................................................................ .25
2.2. Dose Rationale ............................................................................................................................... 37
2.3. Benefit -Risk Assessment ............................................................................................................... 38
2.3.1. Risks for Study Participation ....................................................................................................... 38
2.3.2. Benefits for Study Participation .................................................................................................. 38
2.3.3. Benefit -Risk Assessment for Study Participation ....................................................................... 39
3. OBJECTIVES A ND ENDPO INTS ..................................................................................................... 40
4. STUDY DESIGN ................................................................................................................................ 42
4.1. Overall Design ................................................................................................................................ 42
4.2. Scientific Rationale for Study Design ............................................................................................. 43
4.2.1. Study-Specific Ethical Design Considerations ........................................................................... 45
4.3. Justification for Dose ...................................................................................................................... 46
4.4. End of Study Definition ................................................................................................................... 46
5. STUDY POPUL ATION...................................................................................................................... 46
5.1. Inclusion Criteria ............................................................................................................................ 47
5.2. Exclusion Criteria ........................................................................................................................... 48
5.3. Lifestyle Considerations ................................................................................................................. 52
5.4. Screen Failures .............................................................................................................................. 52
6. STUDY INTERVENTION AND CONCOMIT ANT THERAPY ............................................................ 53
6.1. Study Intervention(s) Administered ................................................................................................ 53
6.2. Preparation/Handling/Storage/Accountability ................................................................................ 54
6.3. Measures to Minimize Bias: Randomization and Blinding ............................................................. 55
6.4. Study Intervention Compliance ...................................................................................................... 56
6.5. Dose Modification ........................................................................................................................... 56
6.6. Continued Access to Study Intervention After the End of the Study ............................................. 56
6.7. Treatment of Overdose .................................................................................................................. 56
6.8. Prestudy and Concomitant Therapy .............................................................................................. 56
7. DISCONTINUA TION OF STUDY INTERVENTION A ND PA RTICIPA NT 
DISCONTINUA TION/WITHDRA WAL............................................................................................... 59
7.1. Discontin uation of Study Intervention ............................................................................................ 59
7.2. Participant Discontinuation/W ithdrawal From the Study ................................................................ 60
7.2.1. Withdrawal From the Use of Research Samples ....................................................................... 60
7.3. Lost to Follow -up............................................................................................................................ 61
8. STUDY A SSESSMENTS AN D PROCEDURES ............................................................................... 61
8.1. Efficacy  Assessments .................................................................................................................... 63
8.1.1. Six-point Ordinal Clinical Recover y Scale .................................................................................. 63
8.1.2. Level of Consciousness .............................................................................................................. 64
8.1.3. Virology Assessments ................................................................................................................ 65
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Status: Approved ,Date: 17 February 20218.1.4. Supplemental Oxygen Use ......................................................................................................... 66
8.1.5. Resting SpO 2.............................................................................................................................. 66
8.1.6. Arterial Blood Gas Test ............................................................................................................... 67
8.2. Safety Assessments ....................................................................................................................... 67
8.2.1. Physical Examinations ................................................................................................................ 67
8.2.2. Vital Signs ................................................................................................................................... 68
8.2.3. Electrocardiograms ..................................................................................................................... 68
8.2.4. Clinical Safety Laborator y Assessments .................................................................................... 69
8.2.5. Pregnancy Testing ...................................................................................................................... 69
8.2.6. Vital Status .................................................................................................................................. 69
8.2.7. Self-reported Oxygen Need ........................................................................................................ 69
8.3. Adverse Events, Serious Adverse Events, and Other Safety Re porting ....................................... 69
8.3.1. Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event 
Information .................................................................................................................................. 70
8.3.2. Method of Detecting Adverse Events and Serious Adverse Events .......................................... 70
8.3.3. Follow -up of Adverse Events and Serious Adver se Events ....................................................... 71
8.3.4. Regulatory Reporting Requirements for Serious Adverse Events ............................................. 71
8.3.5. Pregnancy ................................................................................................................................... 71
8.3.6. Adverse Events of Special Interest ............................................................................................. 72
8.4. Pharmacokinetics and Immunogenicity ......................................................................................... 73
8.4.1. Evaluations ................................................................................................................................ .73
8.4.2. Analytical Procedures ................................................................................................................. 74
8.4.3. Pharmacokinetic Parameters and Evaluations ........................................................................... 74
8.4.4. Immunogenicity Assessments .................................................................................................... 74
8.5. Genetics and Pharmacogenomics ................................................................................................ .74
8.6. Biom arkers ..................................................................................................................................... 74
9. STATISTICA L CONSIDER ATIONS .................................................................................................. 75
9.1. Statistical Hypotheses .................................................................................................................... 75
9.2. Sample Size Determination ........................................................................................................... 75
9.3. Populations for Analy sis Sets ........................................................................................................ 76
9.4. Statistical Analyses ........................................................................................................................ 76
9.4.1. General Considerations .............................................................................................................. 77
9.4.2. Primary Endpoint ........................................................................................................................ 77
9.4.3. Secondary Endpoints .................................................................................................................. 78
9.4.3.1. Key Secondary Endpoints ....................................................................................................... 78
9.4.4. Other Secondary Endpoints ....................................................................................................... 78
9.4.5. Explorator y Endpoint(s) .............................................................................................................. 79
9.4.6. Safety Analyses .......................................................................................................................... 79
9.4.7. Other Analyses ........................................................................................................................... 80
9.5. Interim Analysis .............................................................................................................................. 81
10. SUPPORTING DOCUMENT ATION A ND OPERA TIONA LCONSIDERA TIONS ............................ 83
10.1. Appendix 1: Abbreviations and Definitions .................................................................................... 83
10.2. Appendix 2: Clinical Laboratory Tests ........................................................................................... 86
10.3. Appendix 3: Clinical and Laborator y Assessments Described per Day ......................................... 88
10.4. Appendix 4: Regulatory, Ethical, and Study Oversight Considerations ....................................... 101
10.4.1. Regulatory and Ethical Considerations .................................................................................... 101
10.4.2. Financial Disclosure .................................................................................................................. 104
10.4.3. Informed Consent Process ....................................................................................................... 104
10.4.4. Data Protection ......................................................................................................................... 105
10.4.5. Long- Term Retention of Samples for Additional Future Research .......................................... 106
10.4.6. Committees Structu re............................................................................................................... 106
10.4.7. Publication Policy/Dissemination of Clinical Study Data .......................................................... 107
10.4.8. Data Quality Assurance ............................................................................................................ 108
10.4.9. Case Report Form Completion ................................................................................................ .109
10.4.10. Source Documents ................................................................................................................... 109
10.4.11. Monitoring ................................................................................................................................ .110
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Status: Approved ,Date: 17 February 202110.4.12. Audits ........................................................................................................................................ 111
10.4.13. Record Retention ...................................................................................................................... 111
10.4.14. Study and Site Start and Closure ............................................................................................. 112
10.5. Appendix 5 : Adverse Events, Serious Adverse Events, Product Quality C omplaints, and 
Other Safety Reporting: Definitions and Procedures for Recording, Evaluating, Follow -up, 
and Reporting ............................................................................................................................... 113
10.5.1. Adverse Event Definitions and Classifications ......................................................................... 113
10.5.2. Attribution Definitions ................................................................................................................ 114
10.5.3. Severity Criteria ........................................................................................................................ 114
10.5.4. Special Reporting Situations .................................................................................................... 114
10.5.5. Procedures ............................................................................................................................... 115
10.5.6. Product Quality Complaint Handling ......................................................................................... 116
10.5.7. Contacting Sponsor Regarding Safety, Including Product Quality ........................................... 116
10.6. Appendix 6 : Contraceptive and Barrier Guidance ...................................................................... 117
10.7. Appendix 7: Risks Associated with Sirukumab ............................................................................ 119
10.8. Appendix 8: DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES ( DMID) 
ADULT TOXICITY TABLE45–NOVEMBER 2007 ....................................................................... 121
10.9. Appendix 9: The New York Heart Association Classification System ......................................... 130
10.10. Appendix 10: General Guidelines for Measuring Vital Signs and SpO 2...................................... 131
10.11. Appendix 11: Protocol Am endm ent History ................................................................................. 133
11. REFERENCES ................................................................................................................................ .143
INVESTIGA TOR A GREEME NT............................................................................................................... 148
LIST OF IN -TEXT TABLES A ND FIGURES
TABLES
Table 1: Treatment Half -life and 5 Half -lives .......................................................................................... 57
Table 2: Events of Interest for a Single IV Dose of Interest .................................................................... 72
FIGURES
Figure 1:Schematic Overview of the Study up to Protocol Amendment 4 .............................................. 17
Figure 2: Schematic Overview of the Study as of Protocol Amendment 5 .............................................. 17
Figure 3 IL-6 signaling ............................................................................................................................. 28
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Status: Approved ,Date: 17 February 20211. PROTOCOL SUMMARY
1.1. Synopsis
Phase 2, Randomized, Double- blind, Placebo -controlled Study to Evaluate the Efficacy and Safety of 
Sirukumab in Confirmed Severe or Critical COVID -19 Disease
Sirukumab (also known as CNTO136) is a human anti-IL-6 immunoglobulin G1 kappa (IgG1κ) 
monoclonal antibody (mAb). Sirukumab binds with high affinity and specificity to human IL-6 and as a 
result inhibits IL -6-mediated signaling and the biological effect s of IL -6.
OBJECTIVES AND ENDPOINTS
The primary and secondary objectives and endpoints are listed below. For the full list of objectives 
and endpoints see Section 3 OBJECTIVE S AND ENDPOINTS .
Objectives Endpoints
Primary
To evaluate the clinical response of 
sirukumab (administered as a single IV 
dose) + SOC compared to placebo + 
SOC in confirmed critical COVID -19 
disease Time to improvementaof at least 2categories relative to 
Baseline on the 6-point ordinal clinical recovery scale 
(up to Day 28)
Key Secondary
To evaluate the clinical response of 
sirukumab + SOC compared to placebo 
+ SOC in confirmed critical COVID -19 
disease Proportion of participants with an improvement on Day 
28 of at least 2 categories relative to Baseline on the 6 -
point ordinal clinical recovery scale 
 Incidence of all -cause mortality (up to Day 28)
Other Secondary
To evaluate the clinical response of 
sirukumab (administered as a single IV 
dose) + SOC compared to placebo + 
SOC in confirmed severe or critical 
COVID -19 disease Time to improvementaof at least 2categories relative to 
Baseline on the 6-point ordinal clinical recovery scale 
(up to Day 28)
To evaluate the clinical response of 
sirukumab + SOC compared to placebo 
+ SOC in confirmed severe or critical 
COVID -19 disease Proportion of participants with an improvement on Day 
28 of at least 2 categories relative to Baseline on the 6 -
point ordinal clinical recovery scale 
 Incidence of all -cause mortality (up to Day 28)
To evaluat e the safety of sirukumab + 
SOC compared to placebo + SOC in 
confirmed (a) critical and (b) severe or 
critical COVID -19 disease Incidence of SAEs (up to Day 28)
 Incidence of related AEs (up to Day 28)
 Proportion of participants with severe or life-
threaten ing bacterial, invasive fungal, viral or 
opportunistic infections (other than SARS -CoV -2) (up 
to Day 28).
                                                
aThe improvement should be sustained until Day 28 (or discharge/discontinuation). 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Status: Approved ,Date: 17 February 2021Objectives Endpoints
 Incidence of grade 3 and 4 neutropenia and 
lymphocytopenia (up to Day 28)
 Incidence of increased ALT ≥3xULN combined with 
increased bilirubin >2xULN (up to Day 28)
To evaluate the clinical response of 
sirukumab + SOC compared to placebo 
+ SOC in confirmed ( a) critical and(b) 
severe or critical COVID -19 disease Time to improvementaof at least 1 category relative to 
Baseline on the 6-point ordinal clinical recovery scale 
(up to Day 28)
 Proportion of participants with an improvement on 
Day 28 of at least 1 category relative to Baseline on the 
6-point ordinal clinical recovery scale 
 Time from study intervention to end of oxygen 
supplementation (up to Day 28)
 Time from study intervention to hospital discharge 
among the surviving participants (up to Day 28)
 Total length of hospitalization among the surviving 
participants (up to Day 28)
 Number of ventilation free days (up to Day 28)
 Participant’s clinical status at Day 7, 14, 21, 28 (6 -point 
ordinal clinical recovery scale)
 Total time on invasive mechanical ventilation
 Proportion of participants with a worsebcategory 
relative to Baseline on the 6-point ordinal clinical 
recovery scale (up to Day 28)
 Propor tion of participants on extracorporeal membrane 
oxygenation (ECMO) over time 
 Total time on ECMO 
To evaluate the safety during follow -up
for (a) critical and (b) severe or critical 
COVID -19 disease Proportion of alive participants at Day 28, Week 8, and
Week 16
 Proportion of alive participants that required 
readmission at Week 8 and Week 16 (if previously 
discharged) 
 Incidence of SAEs up to Week 16
                                                
aThe improvement should be sustained until Day 28 (or discharge/discontinuation).
bClinical recovery scale score worsened with at least 1 category between Day 5 and Day 28.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Status: Approved ,Date: 17 February 2021Hypothesis
The primary hypothesis of this study is that sirukumab in combination with SOC results in a statistically 
significant shorter time to improvement (defined as an improvement of at least 2 categor iesrelative to 
Baseline on the 6-point ordinal clinical recovery scale) versus placebo in combination with SOC, in 
confirmed critical COVID -19 disease. 
OVERALL DESIGN
This is a randomized, double -blind, placebo -controlled, multicenter, interventional Phase 2 study in 
hospitalized participants with confirmed COVID -19 disease, at risk for progressing to severe ARDS. 
Up to protocol amendment 4, a target of approximately 270 participants with confirmed severe or critical 
COVID -19 diseas e was to be randomly assigned in a 2:1 ratio to receive 1 of the following 2 treatments: 
Treatment Arm: sirukumab 5 mg/kg IV single dose infusion on Day 1 + SOC treatment 
Control Arm: placebo IV single dose infusion on Day 1 + SOC treatment . 
As ofprotocol amendment 5, the study aims to enroll approximately 111 participants with confirmed critical 
COVID -19 disease overall in the study . The primary and key secondary analyses will be tested on the 
participants with confirmed critical COVID -19 disease. 
At the time of release ofprotocol amendment 5, approximately 100 participants with confirmed severe 
COVID -19 disease hadbeen enrolled. The overall population of participants with confirmed severe or 
critical COVID -19 disease will be analyzed as part of secondary objectives of the study.
Randomization isstratified by age (<65 and ≥65 years of age) and by use of invasive mechanical ventilation 
(yes/no) at the time of randomizat ion.
The study will include a Screening Phase, a ‘Day 1 to Day 28’ Phase and Post Day 28 Follow -up Phase 
(phone calls on Week 8, Week 12 and Week 16). The entire study duration for each participant will be 
16 w eeks with daily study assessments up to Day 28or day of discharge (whichever comes first), and phone 
call assessments thereafter, ie, at Day 28 in case of discharge prior to Day 28, at Week 8, 12 and 16. The 
assessment schedule will be on a weekly basis for participants still hospitalized after Day 2 8. The study is 
considered completed with the completion of the last study assessment (phone call assessment at Week 16) 
for the last participant in the study or the discontinuation of the last participant in the study, whichever 
comes last.
NUMBER OF PART ICIPANTS
A target of approximately 111 participants with confirmed critical COVID -19 disease will be randomized.
At the time of release ofprotocol amendment 5, approximately 100 participants with confirmed severe 
COVID -19 disease had been enrolled. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Status: Approved ,Date: 17 February 2021INTERVENTION GROUPS AND DUR ATION
Description of Interventions
Intervention Name Sirukumab (CNTO136)
Type Drug
Dose Form ulation Solution for infusion
Unit Dose Strength(s) Sirukumab: 100mg/mL 
Dosage Level(s) Sirukumab: 5 mg/kg single dose
Route of Adm inistration IV infusion
Use Intervention  
Investigational Medicinal Product (IMP) Yes
Non-Investigational Medicinal Product/Auxiliary Medicinal 
Product (NIMP/AxMP)No
Sourcing Provided centrally by the sponsor
Packaging and Labeling
(Labels will contain information to meet the applicable regulatory 
requirements.)Each unit will be labeled with unique 
medication ID number.
Not in child resistant packaging
Delivery Instructions Refer to IPPI for instructions on IV infusion
Food/Fasting Requirement Regardless of food intake 
EFFICACY EVALUATIONS
Efficacy assessments will include 6 -point ordinal clinical r ecovery scale, level of consciousness ( Glasgow 
coma scale ), virology assessment, supplemental oxygen use, resting SpO 2, arterial blood gas results, and 
pulmonary imaging . 
SAFETY EVALUATIONS
Safety evaluations will include monitoring of adverse events and serious adverse events, physical 
examinations, vital signmeasurements , electrocardiograms, clinical laboratory tests, pregnancy testing, and 
checking of vital status.
PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
Serum samples will be used to evaluate the pharmacokinetics of sirukumab , IL-6, as well as antibodies to 
sirukumab. Serum collected for pharmacokinetic and immunogenicity analyses may additionally be used 
to evaluate biomarkers, safety or efficacy aspects that address scientific questions relating to sirukumab or 
SARS -CoV -2 infection. 
GENETICS AND PHARMACOGENOMIC S
An optional pharmacogenomic (host DNA) blood sample may be collected (preferably at baseline) from 
those participants who gave consent to allow for host pharmacogenomic research, where local regulations 
permit. Pharmacogenomic research may include expressi on quantitative trait locus (eQTL) mapping, 
single -nucleotide polymorphisms (SNPs) mapping and whole genome sequencing that is related to the IL-6 
gene, study intervention ,and/or SARS -CoV -2 infection.
BIOMARKER EVALUATIONS 
Blood samples will be collected to evaluate biomarkers that may be associated with the safety, efficacy and 
PK of sirukumab and/or with the SARS -CoV -2 infection . Evaluations may include, but are not limited to, 
IL-6, procalcitonin, CRP, ferritin, LDH, and D-dimer concentrations. In addition, humoral immunity to 
SARS -CoV -2 will be evaluated by measuring SARS -CoV -2 specific antibodies.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 12
Status: Approved ,Date: 17 February 2021The study also includes collection of blood samples for exploratory analysis of host biomarkers at the host 
RNA, protein and cell level. Samples may be analyzed under the supervision of the sponsor and results 
might be reported separately.
STATISTICAL METHODS
The primary analysis will be done when all participants reached Day 28 or discontinued earlier.
The final analysis will be done when all participants co mpleted the study. 
A hierarchical testing strategy will be used for the primary and key secondary endpoints. 
First, the primary endpoint will be tested for superiority of sirukumab over placebo at the 2-sided 5% 
significance level. If superiority is shown on the primary endpoint, then the proportion of participants with 
a clinical improvement of at least 2 catego ries at Day 28 will be tested at the 1-sided 5% significance level. 
If superiority on this endpoint is shown, the mortality by Day 28 will be tested, again at the 1-sided 5%
significance level.
The inclusion of a Data Monitoring Committee (DMC) consisting of internal and external members will 
ensure oversight of patient safety. The DMC will regularly evaluate the cumulative safety data of all 
participants in the study. As soon as the first 30 participants with confirmed severe or critical COVID -19 
disease had received study intervention and had at least 7 days of follow -up after study intervention, the 
DMC perform edan interim data review focused on safety. All data available at the time of the interim data 
review were included. During this data review enrollment wascontinued, however, recruitment would have 
beenhalted should 60 patients had been enrolled before the outcome of the data review was known. In case 
recruitment was halted, it would have been resumed upon a positive a ssessment of results of these interim 
data by the DMC.
While futility or stopping of the study is tobe based on totality of emerging safety data, the DMC has to
consider either of the following non -binding futility criteria as recommendation for stopping the study: 
-Excess mortality in the treatment arm, beyond the realm of chance (Fisher’s Exact test at a 1 -sided 
significance level of 10%).
-Excess in “Worsening by at least 1 category” in the treatment arm, beyond the realm of chance 
(Fisher’s exact test at a 1- sided significance level of 10%).
In addition, an IA wasperformed by the sponsor on the primary endpoint when approximately 20% of th e 
planned number of participants with confirmed severe and critical COVID -19 disease had reached Day 28 
or discontinued earlier (see Synopsis subsection Interim Analysis for more detail s). Results have been
discussed with the DMC.
The above DMC set-up and non-binding futility criteria havebeen implemented in the study for the 
participants with confirmed severe or critical COVID -19 disease. No additional non-binding futility 
analyses are planned for the participants with confirmed critical COVID -19 disease in the study.
The efficacy endpoints will be analyzed on the Intent -to-Treat -(ITT) and by randomized treatment. The 
ITT set consists of all participants who were randomized and treated. These analyses will be performed in 
the participants with confirmed (a) critical and (b) severe and cr itical COVID -19 disease .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 13
Status: Approved ,Date: 17 February 2021All safety analyses will be made on the Safety Population. The safety population , consisting of all 
participants who received study drug,will be analyzed by actual treatment. These analyses will be 
performed in the participants with confirmed (a) critical and (b) severe and cr itical COVID -19 disease .
For all participants who receive study drug descriptive statistics will be provided. All demographic 
characteristics (eg, age, race, ethnicity, height, body weight, body mass index) and other initial participant 
characteristics (eg, medical and surgical history, concomitant diseases) will be tabulated and analyzed 
descriptively.
Subgroup analyses will be performed based on the stratification factors (age [<65 and ≥65 years of age] 
and use of invasive mechanical ventilation [yes/no]) andaselection of the m ajor baseline parameters.
Sample Size Determination
The study was targeted to enroll 270 participants with confirmed severe or critical COVID -19 disease in a  
2:1 manner, with approximately 180 participants in the sirukumab treatment arm and approximately 
90participants in the control arm. However, based on the rapidly evolving space of COVID -19 therapeutics 
focusing on the highly impacted population of critical patients together with the results from the interim  
analysis, the study population is being limited with protocol amendment 5 to a subset of the currently 
eligible population, ie, those with confirmed critical COVID -19 disease.
At the time of release ofprotocol amendment 5 approximately 100 participants with confirmed severe 
COVID -19 disease had been enrolled.
The study aim sto enroll approximately 111 participants with confirmed critical COVID -19 disease overall 
in the study , with approximately 74 participants in the sirukumab treatment arm and approximately 
37participants in the control arm. 
The primary endpoint in this study is thetime to im provement of at least 2categor iesrelative to Baseline
on a 6-point ordinal clinical recovery scale ,with participants who die prior to Day 28 treated as right 
censored at Day 28.For the sample size calculation on the primary endpoint, the following assumptions are 
used for survivors and participants who die prior to Day 28:
 For survivors in the control arm, it is assumed that the log transformed time to improvement (days) 
follows a normal distribution with mean of log 28 and a standard deviation 0.9. Sirukumab is assumed 
to reduce the median time to clinical improvement from 28 days to 16.8 days (40% reduction) in the 
surviving participants, and i sassumed to have the same standard deviation of 0.9.
 For t he mortality in the control arm, 40% by Day 28 is assumed. Sirukumab is assumed to reduce the 
mortality with an absolute dif ference of 20%: from a mortality rate of 40% in the control arm to 20% 
in the sirukumab arm (50% relative reduction) .
Under these assumptions, at least 111participants with confirmed critical COVID -19 disease are required 
to have at least 80% power to demonstrate a difference with the log -rank test , at a significance level of 5% 
two-sided . 
The proportion of participants with a clinical improvement of at least 2 categories at Day 28 is a key 
secondary endpoint. Based on simulations using the above a ssumptions, the ratewith clinical improvement 
at Day 28 in the control arm is expected to be 30%. T he targeted treatment effect is an absolute increase of 
25% (from 30% in the control arm to 55% in the sirukumab arm) on this key secondary endpoint .The 
mortality by Day 28 is considered another key secondary endpoint. The targeted treatment effect is an 
absolute reduction in mortality by 25% (from 40% in the control arm to 15% in the sirukumab arm). Under 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 14
Status: Approved ,Date: 17 February 2021the aforementioned assumptions and with a samp le size of 111 participants , at least 80% power is obtained 
for both key secondary endpoints a 1 -sided significance level of 5% .
Analysis of the Primary Endpoint
The primary efficacy analysis will be based on the ITT analysis set restricted to participants with confirmed 
critical COVID -19 disease and the primary efficacy endpoint is the ‘time to improvement of at least 2 
categor iesrelative to Baseline on a 6-point ordinal clinical recovery scale’. The improvement should be 
sustained until Day 28 (or discharge/discontinuation) . Time to clinical improvement will be assessed during 
the 28-day period after study drug administration, with failure to reach clinical improvement or death before 
Day 28 considered as right -censored at Day 28. 
This primary parameter will be analyzed by a stratified log-rank test (using the stratification factors). 
Kaplan- Meier curves, overall and by stratum will be used to graphically present the primary parameter. The
sensitivity analyses will be defined in the stati stical analysis plan (SAP) .
Analys is of Secondary Endpoint s
If superiority is shown on the primary endpoint, then the proportion of participants with a clinical 
improvement of at least 2 categories at Day 28 will be tested at the 1-sided 5%significance level. If 
superiority on this endpoint is shown, the mortality by Day 28 will be tested, again at the 1-sided 5%
significance level. 
The key secondary endpoints will be analyzed using the Cochrane -Mantel- Haenszel (CMH) test for 
difference in proportions.
Key and other secondary endpoints will be analyzed graphically and descriptively as described in the SAP. 
For continuous variables, descriptive statistics (n, mean, SD, median, minimum, maximum , and 95% 
confidence intervals [CIs] ) will be calculated. For categorical variables, frequency tables and corresponding 
95% CIs will be presented.
The primary and secondary endpoint evaluation will be conducted on the ITT population and on the ITT 
population restricted to the population with confirmed critical COVID -19 disease. Analyses of qualitative 
comparison between pre-interim analysis and post-interim analysis for treatment effect in the population 
with confirmed critical COVID -19 disease will be conducted to check the consistency in the study. This 
qualitative assessment will be limited to primary and key secondary endpoints only.
Safety analyses
All safety analyses will be made on the Safety Population and on participants with confirmed (a) critical 
and (b) severe or critical COVID -19 disease .
All reported AEs will be included in the analysis. For each AE, the percentage of participants who 
experience at least 1 occurrence of the given event will be summarized by intervention group.
Summaries, listings, datasets, or participant narratives may be provided, as appropriate, for those 
participants who die, who discontinue intervention due to an AE, or who experience a grade 3 or 4 AE ,a 
serious AE, or an adverse event of special interest (AEOI) .
Theincidence of participants with SAEs, the incidence of participants with grade 3 or 4 AEs, the incidence
of participants with severe or life-threatening, bacteri al, invasive fungal, viral or opportunistic infections 
(other than SARS -CoV-2), the incidence of grade 3 and 4 neutropenia and lymphocytopenia, and the 
incidence of increased ALT ≥3xULN combined with increased bilirubin >2xULN will be reported. Increase 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Status: Approved ,Date: 17 February 2021ofALT or AST combined with increase of bilirubin will be investigated by means of evaluation of drug-
induced serious hepatotoxicity (eDISH) plots .
Descriptive statistics will be calculated for clinical laboratory parameters, ECG parameters, and vital signs 
parameters .
Statistical testing might be applied to the secondary endpoints.
Interim Analysis
A non- binding unblinded IA for futility was performed by the sponsor on the primary endpoint when 
approximately 20% of the planned number ofparticipants with confirmed severe and critical COVID -19 
disease had reached Day 28 or discontinued earlier.
The randomization codes and the translation of randomization codes into treatment and control groups was
disclosed to those authorized and only for those participants included in the IA.The following 
implementation was followed for the non-binding IA for futility while considering the participants with 
confirmed severe and critical COVID -19 disease in the study. 
The futility criterion was based on the conditional power approach for the primary endpoint. The 
conditional power was calculated for the primary hypothesis using the observed data and assuming a 
mortality rate of 30% in the control arm versus 21% in the sirukumab arm in the remainde r of thestudy . 
The effect size and outcomes for the primary endpoint in the survivors wassimulated as used for the study 
sample size calculation. A non-binding futility stopping boundary of 80% for the conditional power was
used. Assuming the outcome forthe primary endpoint as used for the sample size calculations was true, 
with a 30% mortality rate in the control arm, the chance of stopping for futility at the time of the IAwas
2.5%. Otherwise, if the null hypothesis was true and again with a 30% morta lity rate in the control arm, the 
chance of stopping for futility was60%. If, at the time of the IA, the probability of a successful study was 
lower than the futility boundary, the sponsor could have takenthe decision to stop for futility after 
evaluatio n of all available data. In addition to the conditional power calculations, descriptive analyses of 
the primary and key secondary endpoints were performed on the available data. The safety outputs planned 
for the regular DMC safety reviews will be provided too.
No additional non-binding IA for futility is planned for the critical participants to be enrolled in the 
remainder of the study.
Other Analyses
-SARS -CoV -2 viral load in NP swabs and in endotracheal, blood, and stool samples will be 
measured by a qRT-PCR assay. These data will be analyzed graphically and descriptively as 
described in the statistical analysis plan. 
-Serum sirukumab concentrations will be summarized using descriptive statistics. The 
concentrations below the lowest quantifiable sample concentration of the assay will be treated as 
zero in the summary statistics. All concentrations below the lowest quantifiable sample 
concentration of the assay or missing data will be labeled as such in the concentration data listing 
or statistical analysis dataset. 
-The incidence of antibodies to sirukumab will be summarized for all participants in the ITT 
population with appropriate samples for detect ion of antibodies to sirukumab (ie, participants with 
at least predose and the Day 28 sample obtained ). 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Status: Approved ,Date: 17 February 2021- Analysis of the relationship between various blood biomarkers, such as cytokines, and viral 
parameters, immunogenicity, safety and clinical outcome m ay be conducted. Descriptive statistics 
for actual values and (relative) changes from baseline for the different blood biomarkers assessed, 
will be tabulated for each biomarker
-Statistical approaches to explore correlations between clinical outcome and bl ood biomarkers vary 
and depend on the different data types of the applied technology platforms, as well as on the extent 
of observed differences between participants.
-Associations between baseline levels of biomarkers, immunogenicity tests, PK parameters and 
clinical response (primary endpoint and a selection of secondary endpoints) will be explored.
-DNA samples will be analyzed if it is hypothesized that this may help resolve issues with the 
clinical data. 
-DNA samples will be used for research related to sirukumab or COVID -19. Pharmacogenomic 
research may consist of the analysis of one or more candidate genes, of the analysis of genetic 
markers throughout the genome, or the analysis of the entire genome (as appropriate) to evaluate 
potential genetic associations with prognosis of clinical outcomes in patients and prediction of 
responsiveness to active treatment .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Status: Approved ,Date: 17 February 20211.2. Schema
Figure 1: Schematic Overview of the Study up to Protocol Am endment 4
COVID-19: coronavirus disease 2019; DMC : Data Monitoring Committee, EOT: end of trial, ICU: intensive care unit, IV: intravenous, PBO: 
placebo, SOC: standard of care
*Randomization will be stratified by age (<65 and ≥65 years of age) and by use of invasive mechanical ventilation (yes/no) at the time of 
randomization.
#Up to Day 28 or until hospital discharge or study discontinuation, whichever comes first. I f a participant is discharged befo re Day 28, a phone 
call visit will be performed at Day 28.
§SOC treatment (during study treatment and follow -phase) is determined by the investigator based on local practice and consists of supportive 
care. 
SARS -CoV -2 PCR positivity at any time before screening will be accepted. Results from local laboratory, ECG, and pulmonary imaging 
assessments taken up to 2 days prior to screening will be accepted for screening assessments. 
Screeningaassessments start after signing of the I CF and can continue on the next calendar day, if needed. All screening and baseline a ssessments 
may also take place on the same day.  
Participants need to receive study intervention preferably within 4 hours but no later than 6 hours after randomization.
aIf the participant is on invasive mechanical ventilation or veno -venous ECMO, duratio n may not be >48 hours at time of screening.
During the period covered up to and including protocol amendment 4: 
 The DMC reviewed the interim data as soon as the first 30 participants with confirmed severe or critical COVI D-19 disease had been dosed 
and h ad had at least 7 days of follow -up after study intervention.
 An IA for futility was performed when approximately 20% of the planned number of participants with con firmed severe or critical COVI D-
19 disease have reached Day 28 or discontinued earlier.
Figu re 2: Schematic Overview of the Study as of Protocol Am endment 5
As of protocol amendment 5, participants with confirmed severe COVID -19 disease are no longer enrolled in the study and the 
study aims to enroll approximately 111 par ticipants with critical COVID -19 overall in the study. At the time of release of protocol 
amendment 5, approximately 100 participants with confirmed severe COVID -19 disease had been enrolled.
Footnotes :seeFigure 1.

CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Status: Approved ,Date: 17 February 20211.3. Schedule of A ctivities (SoA )
Safety  laboratory  testing (hematology , chemistry , and coagulation tests)will routinely  be performed by local laboratories (refer to Sectio n
10.2 Appendix 2: Clinical L aboratory  Tests and Section 10.3 Appendix 3: Clinical and Laboratory  Assessments D escribed per Day ).
Screening
PhaseaPhase Day 1 to Day 28 Post Day 28 
Follow -up Phone 
Calls
Day Screening Baselinea
Day 1 Day 2 to Day 28b                                                             
or day of discharge from  hospitalaa,
or study discontinuation, whichever comes firstDay 28 Visit 
if discharged 
earlier
(Phone Call) 
Day 28
±3 daysDay 56, Day 84, 
Day 112 
±7 days
Week Week 1 Week 1 (Day 2) to Week 4 Week 4 Week 8, 12, 16
General Screening/Baseline assessments
ICFcX
Inclusion/exclusion criteria X Xd
Dem ographics, medical historyeX
Targeted physical exa mhX Any clinically significant findings to be reported
Treatm ent administration
RandomizationiX
Administration of study 
interventioni X
Concom itant medication
Concomitant medication recording X X Throughout the study XnXn
Respiratory function related assessments
Type of supplemental oxygen X X Once per day
Resting SpO 2, FiO 2(if any)jX X Minimum 4 times per day
Arterial pH, PaO 2, PaCO 2jAs available
Level of consciousness (Glasgow  
coma scale score)k X X Once per day while in the ICU
Pulmonary X -ray (or CT imaging 
or lung ultrasound if X-ray not 
available) Xg,bbAs per SOC, report upon w orsening and last available
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Status: Approved ,Date: 17 February 2021Screening
PhaseaPhase Day 1 to Day 28 Post Day 28 
Follow -up Phone 
Calls
Day Screening Baselinea
Day 1 Day 2 to Day 28b                                                             
or day of discharge from  hospitalaa,
or study discontinuation, whichever comes firstDay 28 Visit 
if discharged 
earlier
(Phone Call) 
Day 28
±3 daysDay 56, Day 84, 
Day 112 
±7 days
Week Week 1 Week 1 (Day 2) to Week 4 Week 4 Week 8, 12, 16
General safety related assessments
Standard 12 -lead ECG Xg,bbone ECG is to be taken between Day 4and Day 8
Vital signs (body temperature, 
pulse, SBP/DBP, respiratory rate)X XAs per SOC, minimum 4 times per day while in the ICU, afterw ards 
once per day
Any AE X X Throughout the study XnXn
Record discharge from ICU, 
discharge from hospitalAs applicable
Safety laboratory assessment sdd
Hem atologyl, XgX Day 3, Day 7, Day 14, Day 21, Day 28cc
Chemistrylgeneral safety XgX Day 3,Day 7,Day 14, Day 21, Day 28cc
Chem istry-Total Cholesterol, 
LDL, HDL, TriglyceridesXgX Day of discharge
Coagulation : PT/INR or aPPT ,
fibrinogenXg,X Day of discharge
Urine Pregnancy assessmentfXgX Day 28 or at day of discharge 
Bacterial, fungal, viral infection 
testing (blood, other)m As per local SOC, any new infection is to be reported as AESI
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Status: Approved ,Date: 17 February 2021Screening
PhaseaPhase Day 1 to Day 28 Post Day 28 
Follow -up Phone 
Calls
Day Screening Baselinea
Day 1 Day 2 to Day 28b                                                             
or day of discharge from  hospitalaa,
or study discontinuation, whichever comes firstDay 28 Visit 
if discharged 
earlier
(Phone Call) 
Day 28
±3 daysDay 56, Day 84, 
Day 112 
±7 days
Week Week 1 Week 1 (Day 2) to Week 4 Week 4 Week 8, 12, 16
Virology Assessments
Nasopharyngeal swab for 
infections testing (PCR 
quantification of SARS -CoV- 2 and 
multiplex PCR for detection of co -
infections)p,q
If participants are intubated, an 
endotracheal sample for 
quantification of SARS -CoV-2 is 
to be taken in addition to the NP 
swabtXr,qXs,● Day 3, Day 7, Day 10, Day 14, Day 21, Day 28u,v,●
Optional: Day 4, Day 5, Day 8● Xv,●
Stool sample (if feasible)●
Xbb           Day 3, Day 7, Day 10, Day 14, Day 21, Day 28
Optional: Day 4, Day 5, Day 8
Blood sample for SARS -CoV -2 
viremia● X Day 7, Day 14, Day 28cc
Biom arker/Pharmacology Assessment sdd
CRP, Ferritin, D -dimer,
Procalcitonin● X Day 3, Day5, Day 7, Day 14, Day 21, Day 28cc
Blood samples for cytokines, 
chemokines● X Day 5, Day 14, Day 21, Day 28
Blood samples for various 
biomarkers,● X Day 5, Day 28
Blood sample for SARS -CoV -2 
specific antibodies● X Day 14, Day 28
Blood samples for 
pharmacologyw,● X Day 14, Day 21, Day 28
Blood samples for cellular 
profiling● X Day 5,Day 28
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Status: Approved ,Date: 17 February 2021Screening
PhaseaPhase Day 1 to Day 28 Post Day 28 
Follow -up Phone 
Calls
Day Screening Baselinea
Day 1 Day 2 to Day 28b                                                             
or day of discharge from  hospitalaa,
or study discontinuation, whichever comes firstDay 28 Visit 
if discharged 
earlier
(Phone Call) 
Day 28
±3 daysDay 56, Day 84, 
Day 112 
±7 days
Week Week 1 Week 1 (Day 2) to Week 4 Week 4 Week 8, 12, 16
Exploratory Biom arkers/Pharm acogenomics●,dd
PAXgene blood for RNA 
profilingx,● X Day 5,Day 28
Whole blood for DNA profiling
(optional)y,● Xz
Phone call assessments
Record vital statusoXnXn
Self-reported oxygen needed 
(yes/no)XnXn
Self-reported pregnancy status XnXn
Record readmission(s) post 
discharge and reasonXnXn
●Laboratory testing to be performed centrally
Note : If multiple assessments are scheduled for the same timepoint, it is recommended that procedures be performed in the following sequence: ECG, oxygen satur ation, 
vital signs, blood sampling.
Abbreviations: AE: adverse event, AESI: adverse event of special interest; aPPT: activated partial throm boplastin time; CRP: C-reactive protein; CT: computed 
tomography; DBP: diastolic blood pressure; FiO 2:percentage of inspired oxygen; ECG: electrocardiogram; HDL: low -density lipoprotein; ICF: informed consent form; 
ICU: intensive care unit; INR: international norm alized ratio; LDL: low-density lipoprotein; PaCO 2: partial pressure of carbon dioxide in arterial blood; PaO 2: partial 
pressures of oxygen in arterial blood; PCR: polymerase chain reaction; PT: prothrom bin time; SAE: serious adverse event ; SBP: sy stolic blood pressure; SOC: standard 
of care; SpO 2: peripheral capillary oxygen saturation.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Status: Approved ,Date: 17 February 2021Footnotes:
a.Screening assessments start after signing of the ICF and can continue on the next calendar 
day, if needed. All screen ing and baseline assessments may  also take place on the same day . 
Screening/Baseline assessments required to verify  study eligibility  and data collection for 
assessment of the 6-point ordinal clinical recovery  category  should take place prior to 
randomizat ion. All Screening/Baseline procedures should take place prior to study  drug 
administration.
b.The assessment schedule will be on a weekl y basis for participants still hospitalized after Day 
28.For the required assessments, refer to Section 10.3, Appendix 3: Clinical and Laboratory  
Assessments D escribed per Day .
c.Conse nt to be obtained before the first study -related activity . An exception is in the case of an 
emergency  enrollment in which the informed consent can be obtained as soon as possible.
d.If a participant's clinical status changes after screening but before rando mization such that he 
or she no longer meets all eligibility  criteria, then the participant should be excluded from 
participation in the study .
e.Medical history  should include collecting onset of COVID -19 symptoms, prior therap y, and 
date of SARS -CoV -2 diag nosis if available.
f.A urine pregnancy  test is to be performed in women of childbearing potential only .
g.Results from the blood chemistry , hematology , and coagulation test, pregnancy  test, ECG, and 
pulmonary  imaging , completed as SOC, taken up to 2 days prior to screening will be accepted 
as screening assessments. 
h.Targeted physical examination is to be performed as per local SOC and includes, if feasible, 
lung auscultation and any examination as indicated by the patient’s medical history .Height 
and body  weight are only to be measured at screening if not alread y available in the 
participant’s chart and if practicall y feasible. If not feasible, weight for dose calculation can 
be verball y reported b y the participant or a famil y member.
i.Participants need to receive study  intervention preferabl y within 4 hours but no later than 6 
hours after randomization.
j.Supplemental oxygen/percentage of inspired oxygen (FiO 2) use (if any) will be measured 
(simultaneously  with SpO 2, and at any time of arterial blood gas measurements) to monitor 
the patient’s status regarding gas exchange as applicable. The following will be recorded:
-Oxygen delivery  device (eg, nasal cannula, simple face mask, nonrebreather mask, high 
flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, 
extracorporeal life support, etc).
-Oxygen flow rate in liters/min.
-Record FiO 2 and SpO 2data 4 times per day, and at any time of arterial blood gas 
measurements. Record values that are sustained for at least 1 hour. 
-If a patient is using more than one device (eg, extracorporeal life support and invasive 
ventilation), the worst value of FiO 2 (and the corresponding SpO 2-and PaO 2if available -)
on the highest level of intervention will be recorded. The worst (highest) value of FiO 2(and 
the corresponding SpO 2-and PaO 2if available -) on each device will also be recorded 
separately .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Status: Approved ,Date: 17 February 2021-If a patient does not need oxy gen supplementation, this should also be recorded.
k.The final worst score of the Glasgow Coma Scale of the day needs to be recorded in the eCRF. 
The level of sedation of the participant will be derived from the t ype of medication entered for 
indication sedation on the Concomitant Medication page of the eCRF.
l.Laboratory  testing to be performed includes:
-Hematology : hemoglobin, hematocrit, platelet count, red blood cell (RBC) count, RBC 
indices (mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], % 
reticulocy tes), white blood cell (WBC) count with differential (neutrophils, lymphocy tes, 
monocy tes, basophils, eosinophils).
-General safety  chemistry : total protein, albumin, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, glucose, sodium, 
potassium, calcium, phosphate, magnesium, chloride, bicarbonate, creati nine, blood urea 
nitrogen (BUN), creatine phosphokinase (CPK), lactate dehy drogenase (LDH), lactate, and 
troponin. If ALT or AST >3xULN or 3x the entry  level (if entry  levels were >ULN) ,also 
provide conjugated bilirubin (direct), unconjugated bilirubin (indirect).
m.Culture results (bacterial, fungal, or viral) including site of infection and specimen source 
(bronchoalveolar lavage [BAL ], tracheal aspirate, sputum, blood, urine, etc.), performed as 
part of patients’ workup for new infections, should be reported. Analy ses will be performed 
by the local laboratory .
n.For participants discharged or who discontinued the study  prior to Day 28 and did not 
withdraw consent, phone calls will be condu cted on Day 28 and during the post Day 28 
Follow -up Phase to record concomitant medication, the vital status, the occurrence of AEs, 
self-reported oxygen need, self-reported pregnancy  status and the history  of readmission since 
last contact.
o.Whenever possi ble, vital status will be recorded if the patient is alive. If the participant is 
deceased, date and cause of mortality  should be recorded in the eCRF. Death should be 
documented as SAE.
p.NP swabs will be used to collect secretions from participants to explore quantification of viral 
load of SARS -CoV -2. For each participant, NP sampling should be done at approximately  the 
same time (±4 hours) on each sampling day  and from the same nostril.
q.If an NP sample for detection of SARS -CoV -2 (local SOC) will be collected on the same day 
as the NP sample for quantification of SARS -CoV -2 (central lab), only one NP sample should 
be collected. The sample should be aliquoted and the remaining aliquots of the NP samples 
should be stored and sent to the central lab for quantification of SARS- CoV -2.
r.SARS -CoV -2 positivity  should be documented based on local testing on any specimen, by 
RT-PCR, any time before randomization. This might require a local test using an NP swab 
obtained at screening.
s.After randomization, SARS -CoV -2 po sitivity  will be confirmed in a central lab by quantitative 
RT-PCR. The baseline sample needs to be collected predose, as close as possible to dosing.
t.If the participant is intubated, endotracheal samples need to be taken at the same time as the 
NP swab. If taking both NP and endotracheal samples is not feasible, the NP sample should 
be given priorit y.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Status: Approved ,Date: 17 February 2021u.Lab testing for detection of SARS -CoV -2 on the NP swab at day of hospital discharge. If 
SARS CoV -2 positive, an additional NP swab will be taken every  7days, if feasible for the 
site and tested, until SARS -CoV -2 negative .
v.If viral RNA is detected in NP samples at day of discharge, all possible efforts will be made 
to follow -up participants and collect samples every  7  d ays until viral RNA is negative, 
considering the current pandemic and related logistical challenges. If possible, home visits by 
a healthcare professional may  be conducted to collect samples during the follow -up period.
w.Includes serum samples for measurement of PK, antibodies to sirukumab , and IL-6. On Day 1, 
a predose and a postdose (within 30 minutes after the end of infusion) sample should be 
collected. The postdose sample should be collected from the arm contralateral to that used for 
IV infusion. On Day 1 (predose) and Day 28 the PK, antibodies to sirukumab, and IL-6 will 
be evaluated. On Day  1 (postdose), Day  14, and Day  21 the PK and IL -6 will be evaluated.
x.PAXgene RNA tubes should alway s be used last for an y blood draw.
y.An optional pharmacogenetics blood sample (DNA) will be obtaine d from those participants 
who gave consent (where local regulations permit).
z.Sample can be also taken at an y other time point after study drug intervention on Day 1.
aa.For those participants discharged prior to Day 28, all Day 28 assessments should be done at 
day of discharge. Laboratory, virology, relevant respiratory function related assessments, and 
biomarker/pharmacology assessments completed maximum 1 day before discharge do not 
need to be repeated on the day of discharge provided that no clinically  relevant changes were 
noted in the results and the participant was declared ‘read y to be discharged’ on the day before 
discharge .
bb.Assessments done at screening do not need to be repeated at baseline.
cc.For participants still hospitalized post Day 28, additional blood sampling should be done every 
7 day s(±1 day ) and at day  of discharge.
dd.For all laboratory  tests done on Day 21, Day 28,and every  week thereafter as needed ,a 
window of ± 1 day  for all sampling is allowed.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Status: Approved ,Date: 17 February 20212. INTRODUCTION
Sirukumab (also known as CNTO136) is a human anti-IL-6 immunoglobulin G1 kappa (IgG1 κ) 
monoclonal antibody  (mAb). Sirukumab binds with high affinity  and specificity  to human IL-6 
and as a result inhibits IL-6-mediated signaling and the biological effects of IL-6.
For the most comprehensive nonclinical and clinical information regarding sirukumab , refer to the 
latest version of the Investigator's Brochure (IB)forsirukumab .29
The term “study  intervention” throughout the protocol, refers to sirukumab or placebo as defined 
in Section 6.1,Study  Interventions Administered. 
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
The term "participant" throug hout the protocol refers to the common term "subject".
2.1. Study Rationale
Current management of COVID -19 is supportive, and respiratory  failure from acute respiratory 
distress syndrome (ARDS) is the leading cause of mortality .53Currently , no treatment of 
COVID -19 has been established. Many trials (eg, with antivirals) are currently  ongoing. While an
understanding of the epidemiology  and clinical spectrum of COVID -19 is still evolving during the 
ongoing pandemic, the current knowledge of the disease burden highlights the urgent medical need 
to develop a treatment. Learnings from SARS -CoV, initial COVI D-19 data17,51and preclinical 
mouse model data indicate that IL-6 might be a key driver of the acute lung injury  (ALI)and 
ARDS observed in COVID -19. More severe COVID -19 patients from an initial study  in China 
had elevated levels of IL-6.67Tocilizumab (Actemra /roActemra®) is a human mAb that binds the 
IL-6 receptor (IL-6R) and blocks the IL-6 pathway .1,52It is approved to treat cytokine release 
syndrome (CRS) due to chimeric antigen receptor T (CAR -T)cell therap yand has shown 
anecdotal preliminary  benefit in treating ARDS in patients with COVID -19. N oncontrolled, 
interim data from patients being treated with sarilumab (Kevzara®, another mAb that binds to 
IL-6R)35also provide some early  reports of possible benefit to patients. Sirukumab blocks the IL -6 
signaling pathway  by binding and neutralizing IL-6, whi ch warrants a study  to assess its utility  as 
an additional treatment option for patients with COVID -19-associated ARDS. 
2.1.1. Background
SARS -CoV -2 Virology and COVID -19 Disease Burden
SARS -CoV -2, the causative agent of coronavirus disease 2019 (COVID -19), is an enveloped, 
positive -sense, single -stranded RNA betacoronavirus.18,75It was first identified following reports 
of a cluster of acute respiratory  illness cases in Wuhan, Hubei Province, China in December 
2019.39Epidemiological investigations indicated that the majority  of early cases were linked to a 
seafood market, with patients infected through zoonotic or environmental exposure, followed by 
the subsequent spread of infection by human- to-human transmission among close contacts.39
Genomic sequencing was performed on bronchoalveolar lavage fluid samples collected from 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Status: Approved ,Date: 17 February 2021patients with viral pneumonia admitted to hospitals in Wuhan, which identified a novel RNA virus 
from the family  Coronaviridae .43,75Phylogenetic analysis of the complete viral genome revealed 
that the virus, SARS -CoV -2, is part of the subgenus Sarbecovirus of the genus Betacoronaviru s, 
and is most closely  related (approximately  88% identity ) to a group of SARS- like coronaviruses 
previously  sampled from bats in China.43
SARS -CoV -2has spread rapidly  and globall y since its emergence.15,18,23,39,43,75The World Health 
Organization (WHO) declared that the outbreak constituted a public health emergency  of 
international concern on January  30, 2020, and declared the outbreak to be a pandemic on 
March 11, 2020.70,72,73,74As of April 4,2020, this pandemic has infected over 1,289,380people 
with over 70,590 associated deaths worldwide .34
Symptoms of infection may appear from 2 to 14 days following exposure, with the spectrum of 
illnesses ranging from mild symptoms to severe illness or death.8Severe clinical presentations 
have been reported for as many  as 20–25% of laboratory -confirmed cases.25In a  study of 
99 patients in a single center in Wuhan with SARS -CoV -2 infection confirmed by real-time 
reverse -transcriptase polymerase chain reaction (RT-PCR), the most commonly  reported clinical 
manifestations were fever (83%), cough (82%), shortness of breath (31%), and muscle ache 
(11%).15In chest x-rays and CT scans, 75% of patients showed bilateral pneumonia and 14% of 
patients showed multiple mottling and ground-glass opacities. In a further study  of 138patients 
with novel coronavirus- induced pneumonia in a single center in Wuhan, common symptoms 
included fever (98.6%), fatigue (69.6%), and dry cough (59.4%).66Lym phopenia occurred in 
70.3% of patients, and chest CT scans showed bilateral patchy  shadows or ground -glass opacities 
in the lungs of all patients. Thirty -six patients (26%) were transferred to the intensive care unit 
(ICU)because of complications, including ARDS , arrhythmia, and shock. Broadl y, similar 
findings were noted in other case studies, eg, in the Seattle region in the US.6At present, it appears 
that individuals aged 65 years or older, especiall y those with comorbid diseases, are subject to the 
highest incidence of morbidity  and mortalit y.10In contrast, a study  of 2,143 children aged <18 
years in China with laboratory -confirmed (34.1% of cases) or suspected (65.9% of cases) COVID -
19 indic ated that the clinical manifestations of the disease may be less severe in children than 
adults, with approximately  94% of cases being asymptomatic, mild, or moderate.23However, 
young children, particularly  infants, were susceptible to severe disease, with the highest proportion 
of severe and critical cases by  age group reported for children aged <1 year (10.6% of cases) and 
1-5years (7.3% of cases). Also, new evidence has emerged from China indicating that a large 
number of infections do not result in sy mptoms.20
The identification of SARS- CoV -2 follows the emergence of 2 other novel betacoronaviruses 
capable of causing severe human disease over the past 18years: SARS -CoV and Middle East 
respiratory  syndrome coronavirus (MERS- CoV), which have nucleotide sequence identity  with 
SARS -CoV -2 of approx imately  79% and 50%, respectivel y.43The first known cases of SARS 
occurred in Southern China in November 2002.74The etiological agent, SARS- CoV, is believed 
to be an animal virus that crossed the species barrier to humans followed by human- to-human 
transmission, leading to SARS cases in >25 coun tries. The MERS -CoV was isolated from a patient 
in Saudi Arabia who died of severe pneumonia and multi- organ failure in June 2012.82MERS -CoV 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Status: Approved ,Date: 17 February 2021is considered to be a zoonotic virus infecting bats and camels capable of non-sustained 
human- to-human transmission. Since 2012, sporadic cases and community  and health- care-
associated clusters of infected individuals have been reported in the Middle East.
Patien ts with SARS or MERS present with various clinical features, ranging from asymptomatic 
or mild respiratory  illness to fulminant severe acute respiratory  disease with extrapulmonary  
manifestations.12,82Both diseases have predominantly  respiratory manifestations, but 
extrapulmonary  features may occur in severe cases. By July 2003, the international spread of 
SARS -CoV resulted in 8,098 SARS cases and 774 deaths (case -fatality -rate: 10%) with 
substantial social, economic and health service disruption in some affected countries.12,74The 
case-fatalit y rate of MERS -CoV infections is estimated to be 35%.12
Interleukin -6 as a Key Target of ARDS
IL-6, a biomarker for inflammation and a high-level immune response, is a pleiotropic cytokine 
that can have multi- faceted effects on multiple cell types and organs.61,68There can be both 
systemic (acute phase response) and local effects in activating and amplify ing the immune 
response. Published studies have demonstrated the involvement of IL-6 in various inflammatory 
disease processes including asthma, lupus ery thematosus, rheumatoid arthritis, anemia of chronic 
inflammation, insulin resistance, cance r, major depressive disorder, giant cell arteritis and 
virus -induced ARDS. In addition, IL-6 has been implicated as a central mediator of toxicity  in 
cytokine release sy ndrome (CRS), a potentially  life-threatening, sy stemic inflammatory  response 
that can b e triggered b y a variet y of factors including viral infections.  
IL-6 is a soluble, glycosylated protein expressed by a  v ariety of immune (T-cells, B-cells, 
macrophages, and microglia) and nonimmune cell types (fibroblasts, endothelial cells, adipocy tes, 
myocytes, and neurons). IL-6 facilitates diverse physiological processes such as T-cell-activation, 
induction of immunoglobulin secretion, initiation of hepatic acute -phase protein synthesis, and 
stimulation of hematopoiesis. IL -6 signals via a receptor c omplex comprising its specific receptor, 
the IL-6 receptor (IL6R) and glycoprotein (gp)130, the signal transducing subunit. The IL-6Rα 
exists in 2 forms; a membrane -bound form and a soluble form. Once a monomer of IL-6 binds a 
monomer of either form of the IL-6Rα (termed “classic” signaling when using the membrane 
bound form and “trans” signaling when using the soluble form), the IL-6-IL-6Rα complex is 
engaged by a gp130 homodimer. While gp130 is present on most if not all cells of the body , the 
membrane -bound form of the IL -6R is only present on some cells, mainly  hepatocy tes and several 
leukocy tes, such as monocy tes, macrophages, B cells and subtypes of Tcells. Cells, which only 
express gp130 are refractory  to IL -6 signals. This facilitates the selective activation of target cells 
and differentiates between the two different signaling pathway s.68Activation of IL-6 signal 
transduction is initiated and mediated by gp130 -associated Janus activated kinases (JAKs) and 
phosphory lation of signal transducer and activator of transcription 3 (STAT -3), resulting in 
subsequent intracellular signaling ( Figure 3).
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Status: Approved ,Date: 17 February 2021Figure 3 IL-6 signaling
While the expression of IL -6 and other cy tokines isa component of the normal immune response, 
excessive expression of cytokines such as IL- 6 and the ensuing immune inflammation can lead to 
disease pathology . This excessive systemic release of proinflammatory  cytokines, termed a 
“cytokine storm”, can occur in a number of non-infectious conditions such as graft -versus -host 
disease (GVHD), CAR -Tcelltherap y55, and ARDS as well as several infectious diseases such as 
sepsis, Ebola and other viral hemorrhagic fevers, avian influenza, and smallpox .48,59
Actemra/Ro Actemra®(tocilizumab), an IgG1 mAb that binds to both soluble and 
membrane -bound IL-6 receptors blocking IL-6 mediated signaling, is indicated for the treatment 
of adults and childr en with severe or life-threatening CRS due to CAR -T cell therapy . Approval 
was based upon a retrospective anal ysis of pooled outcome data from clinical trials indicating that 
blocking the IL-6 pathway  with tocilizumab resulted in resolution of severe or life-threatening 
CRS in patients receiving CAR -Tcell therapies for hematological malignancie s.1,52
Coronaviruses, Acute Respiratory Distress, and IL-6
Coronaviruses infect a variety of host species, including humans and several other animal species. 
In their natural hosts, these viruses predominantly cause respiratory  and intestinal tract infections 
producing a wide range of clinical manifestations. Coro naviruses infecting the respiratory  tract 
have long been recognized as significant pathogens in animals and as the cause of mild and severe 
respiratory  illness in humans. Highl y pathogenic human coronaviruses such as SARS -CoV and 

CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 29
Status: Approved ,Date: 17 February 2021MERS -CoV similarly  cause a wide spectrum of clinical manifestations in humans. Ty picall y, the 
majority  of patients develop a short period of moderate clinical illness; however, a small but a 
substantial number of patients develop severe pneumonia often associated with rapid virus 
replication, massive inflammatory  cell infiltration and elevated proinflammatory 
cytokine/chemokine responses resulting in ALI and ARDS.13
It has been well documented for many ye ars that infection by several members of the 
Coronaviridae family  both in vitro and in vivo in humans and animals is associated with increases 
in the production of IL-6.1,4,22,27,31,38,42,50,60,77,78,81This induction of IL -6 expression can be caused 
by productive viral infection, non-productive infection, noninfectious virus -like particles5, and 
even individual coronavirus proteins such as the spike or nucleocapsid proteins .24,47,80,63,64
Elevated IL-6 levels in the fluid of the lungs have been associated with a poor prognosis for 
individuals with ARDS .7,65
In the case of SARS, increased levels of IL-6 have been reported to be a prognostic indicator 
associated with more severe pulmonary  disease in both animal models14,19,30,56as well as in 
individuals infected with SARS -CoV .3,32,37,62,69,79Learnings from SARS -CoV, initial COVID -19 
data17,51and preclinical mouse model data indicate that IL-6 might indeed be a key driver of the 
ALI and ARDS observed in COVI D-19. More severe COVID -19 patients from an initial study  in 
China had elevated levels of IL -6.67
Since blocking the IL -6 pathway  in CAR -T induced CRS with tocilizumab is clinically beneficial, 
it is hypothesized that IL-6 might play a key role in the cytokine storm associated with serious 
adverse outcomes in COVID -19patients, and that blocking IL-6 would b e a suitable therapeutic 
target for these patients .54
Initial non-peer reviewed results from a single -arm, observational, non-controlled, 21-patient 
Chinese study  showed that COVID -19 participants experienced rapidl y reduced fevers and 75% 
of patients (15 out of 20) reduced their need for supplemental oxygen within days of receiving 
tocilizumab.76The utility  of blocking the IL-6 pathway  using the IL-6R mAbs tocilizumab 
(Actemra /roActemra®)1and sarilumab (Kevzara®)35is now being investigated in an open -label 
clinical trial (Study Registry ID: [REMOVED]). The primary  outcome measure is the 
time to independence from supplementary  oxygen therapy  up to 30 days from enrollment. 
Secondary  outcome measures (30 day s from enrollment) include the number of deaths, number of 
days out of hospital and alive, number of ventilator free daysalive and out of hospital , and CRP 
level s. 
Sirukumab is a human anti-IL-6 IgG1κ mAb that binds to human IL-6 with high affinity  and 
specificit y. The high affinity  binding of sirukumab to IL-6 (equilibrium dissociation constant [Kd]
= 0.175 pM) prevents t he association of IL-6 with the IL -6R, thereby  blocking receptor signaling 
and biological activities attributed to IL-6 both in vitro and in vivo. In vitro bioassay s show that 
sirukumab neutralizes both cis-and trans -signaling of human IL-6 (mediated via cell surface IL-6R 
and soluble IL-6R, respectivel y) in a concentration -dependent manner. Sirukumab also blocks 
human IL-6-induced expression of the acute phase proteins haptoglobin and serum amyloid A 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Status: Approved ,Date: 17 February 2021(SAA) in mice; this effect is sirukumab -specific and dose-dependent. As such, treatment of 
patients with confirmed COVID -19 severe disease with sirukumab could reduce pulmonary  and 
systemic levels of IL -6 resulting in a clinicall y meaningful benefit . 
Some studies allow for a second (and third) dose of the dru g, in case of insufficient response (eg, 
[STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED] , all with tocilizumab, an IL-6R blocking 
antibody ). IL-6R blocking antibodies bind IL-6R (~2.5 nM for tocilizumab) with similar affinity 
as IL-6 (0.5-34 nM) and compete with IL-6 for IL-6R binding.45At 5 mg/kg IV dose of sirukumab, 
serum C maxis ~125 ug/mL and at Week 4, serum sirukumab concentration is ~10 ug/mL which is 
substantially higher than the serum IL-6 level in COVID -19 and ARDs patients. In combination 
with potent affinit y of sirukumab for IL -6 (~0.175 pM), it is anticipated that sirukumab levels after 
a single dose will be sufficiently  high to bind circulating IL-6 levels (pg/mL up to ng/mL  in ARDS)
for at least 4 weeks , and that an additional dose will not be required to block the IL-6 pathway 
effectivel y.
Nonclinical Studies
No preclinical studies have been performed to assess the potential activity  of siruku mab in 
SARS -CoV -2 infection.
Sirukumab does not neutralize guinea pig, beagle, rat, or murine -derived IL-6. As such, preclinical 
testing utilized an analogous mAb that was shown to bind and neutralize murine IL-6. Prophy lactic 
treatment of New Zealand Black/W F1 lupus- prone mice with anti-murine IL-6 mAb reduced 
anti-dsDNA autoantibody production and suppressed renal damag e in a murine model of systemic 
lupus.40Treatme nt with the anti-murine IL-6 mAb was also effective in reducing the incidence and 
severit y of arthritis and joint histopathology in a mouse model of collagen -induced arthritis.41
Pharmacologic Profile
Sirukumab is a human IgG1κ mAb monoclonal antibody  with a molecular weight of approximately 
150,000 Daltons. Sirukumab binds to and neutralizes human IL-6 and subsequently  attenuates IL-6 
signaling and the biological effects of IL-6. Sirukumab also binds to and neutralizes cy nomolgus 
monkey  IL-6. Because of this, the cynomolgus monkey  was selected as a pharmacologicall y 
relevant species for the evaluation of the nonclinical pharmacokinetics (PK) and toxicology  of 
sirukumab.
Toxicology
Toxicology  results from the 3-and 6-month multiple IV and subcutaneous (SC)dose studies 
conducted in cy nomolgus monkey s showed no adverse effects that were considered related to the 
administration of sirukumab in clinical signs and measurements and clinical/anatomic pathology 
parameters. The no -observed -adverse- effect -level (NOAEL) in the related toxicology studies was 
50mg/kg weekly .
Standard genotoxicity studies are generally  inappropriate for biotechnology -derived 
pharmaceuticals and therefore, mutagenesis and carcinogenesis studies have not been con ducted. 
Evaluation of reproductive potential in sexually  mature male cynomolgus monkey s by 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 31
Status: Approved ,Date: 17 February 2021measurement of testicular volume, sperm count, motility  and morphology, and histopathology  of 
male reproductive organs identified no adverse effects. Studies conduct ed in mice given an anti-
mouse IL -6 mAb showed no adverse effects on male or female fertility . 
Data from an embryo -fetal developmental toxicity  study  demonstrated that in the 50 mg/kg group
(IV once weekl y for 98 days), the abortion/embry o-fetal death ratio was increased, and it was 
considered that the increased abortion/embry ofetal death ratio in this group was possibl y 
sirukumab -related. The NOAEL in dams and fetuses was 10mg/kg once weekl y for a total of 
15administrations.
Pharmacokinetic and Immunogenicity Profile
The PK/toxicokinetics (TK) and immunogenicity  of sirukumab have been investigated in 
cynomolgus monkey s following multiple IV administrations of sirukumab at doses of 10and 
50mg/kg, and multiple SC administrations of sirukumab at a dose o f 50mg/kg. Please refer to the 
IB for more information regarding the PK, TK, and immunogenicit y of SC sirukumab.29
After IV administrations, systemic exposure of sirukumab increased in an approximately  dose-
proportional manner over the dose range of 10 to 50 mg/kg. The mean terminal half-life(T1/2) of 
sirukumab ranged from 10 to 19days across all IV dose groups. The mean accumulation ratios 
were 3.34 and 2.45 for once -weekl y IVadministrations at 10 and 50mg/kg, respectivel y.All 
animals from all dosing groups tested negative for antibodies to sirukumab.
When administered to pregnant monkey s (IV 10 and 50 mg/kg/week), serum sirukumab 
concentrations in the maternal animals increased in an approximately  dose-proportional 
manner and sirukumab was also detected in the fetal circulation on the day of cesarean section 
(during the third trimester). The mean ratios of the fetal to maternal serum sirukumab 
concentrations were 1.33 (10mg/kg) and 1.36 (50mg/kg). All dams who had milk samples 
collected (n=25) between lactation day (LD) 30 and LD 75 had non-detectable sirukumab 
concentration samples except 1 monkey  in the 50 mg/kg IV group. Sirukumab was also detected 
in the infant at birth (LD 0-LD 3) with serum concentrations similar to those of the dams; these 
serum levels were still detected 3 to 6 months post- birth.
Clinical Studies
At time of writing the protocol, 1 4interventional studies with administrati on of sirukumab for the 
treatment of systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus 
nephritis (LN), rheumatoid arthritis (RA) , Major Depressive Disorder (MDD) and Giant -cell 
Arteritis (GCA) were complete d. 
As of 23 October 2018, overall, 251 healthy  participant s and an estimated 5,044 participant s with 
RA, 71 participant s with lupus, 193 participant s with MDD ,and 161 participant s with GCA have 
been exposed in the sirukumab clinical program; of these, 3,495 participant s have received 
sirukumab (IV or SC) in company -sponsored interventional clinical trials (227 health y 
participant s, 3,120 participant s with RA, 54 participant s with lupus, and 94 participant s with 
MDD) and 111 participants have received sirukumab in business partner -sponsored clinical trials. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 32
Status: Approved ,Date: 17 February 2021Of the total 3,606 participant s who have received sirukumab, 272 participant s were in the Phase 1 
studies , 297 participant s were in the Phase 2 studies , and 3,037 participant s were in the Phase3 
studies .
Of the participants included in the clinical program, a total of 107 participant s received sirukumab 
IV.Of these, 55 received a dose that was higher than the dose of 5 mg/kg that will be administered 
in the current stud y. 
Relevant pharmac okinetic and immunogenicit y results on IV administration of sirukumab in the 
clinical program are presented below. More detailed information of all clinical studies performed 
with sirukumab are described in the IB .29
Human Pharmacokinetics and Immunogenicity
The PK of sirukumab has been evaluated in healthy  participant s following a single IV 
administration (C0136T01) . Sirukumab exhibited linear PK over a dose range of 0.3 to 10.0 mg/kg 
following a single IV administration to healthy  participant s. Following a single IV administration 
of sirukumab 0.3 to 10.0 mg/kg, the mean volume of distribution (Vz)ranged from 121 to 248 
mL/kgand the mean total systemic clearance (CL) appeared to be dose independent and ranged 
from 3.8 to 6.1 mL/day/kg. Mean T 1/2 values in healthy participants were 15 to 32 day s. The mean 
T1/2 at the dose level of 5 mg/kg was estimated to be about 21 days.
In participants with CLEor SLE,following 4 biweekl y IV administration of 1, 4, or 10 mg/kg 
sirukumab, systemic exposure of sirukumab (Cmaxand AUC 0-14d) increased in an approximately  
dose-proportional manner (study  C0136T03). Mean T1/2 values in participant s with CLE or SLE 
were estimated to be 16 to 23 day s. 
In participant s with LN, following IV administration of sirukumab 10 mg/kg q4w, serum 
concentrations of sirukumab reached steady -state by Week12 (study  CNTO136LUN2001). The 
mean trough serum concentra tion of sirukumab was 20.63 μg/mL at Week 12 and was maintained 
through Week 24 (22.65 μg/mL). Mean Cmaxand AUC 0-28d values were 239.65 μg/mL and 
1421.26 μg*day /mL and 259.47 μg/mL  and 1864.92 μg*day /mL following the first and last 
administrations of 10 m g/kg sirukumab, respectively . Mean accumulation ratios following IV 
administration of sirukumab 10 mg/kg q4w were 1.08 for Cmaxand 1.24 for AUC 0-28d, which 
indicated minimal drug accumulation. Mean values of CL and volume of distribution at 
steady -state (Vss) were 5.10 mL/day/kg and 87.03 mL/kg, respectivel y. Mean T1/2 values were 
comparable between healthy  participants (19to 30days), and participants with CLE/SL E (16 to 
23 day s) or participants with L N (16 day s) following IV administration.
Immunogenici ty of IV sirukumab has been evaluated in 2 Phase 1 and 1Phase 2 studies as of 
16August 2017, including: studies C0136T01, C0136T03, and CNTO136LUN2001. None of the 
participant s with evaluable serum samples tested positive for antibodies to sirukumab in studies 
C0136T01 (0/31) and C0136T03 (0/32). In study CNTO136LUN2001, 1(5.0%) of the 
20sirukumab -treated participant s with evaluable samples (5.0%) tested positive for antibodies to 
sirukumab.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 33
Status: Approved ,Date: 17 February 2021Clinical Efficacy
No efficacy  data are available on the use of sirukumab to treat COVID -19 induced ARDS.
In 2016, the s ponsor filed a Biologics License Application with the FDA seeking approval for the 
use of SC sirukumab in the treatment of RA based upon data from the RA clinical development 
program. During the review of the BLA, the FDA convened an Advisory  Committee meeting, held 
in 2017. While the Advisory Committee felt that sirukumab convincingl y demonstrated efficacy 
in RA, it could not definitely  attribute the imbalance in overall mortality  to chance or the study  
design, and given the availability  of other drugs forRA, the Advisory  Committee did not 
recommend approval of sirukumab for RA. As a result, the sponsor did not pursue further 
development of SC sirukumab in RA. Refer to latest version of the IBfor a summary  the efficacy 
results in RA and other indications .29
Clinical Safety
The clinical safet y of sirukumab has been evaluated in 107participant s receiving IV administration 
(34 participant s in C0136T01, 33 participant s in C0136T03, 21 participant s in 
CNT O136L UN2001 , and 19participant s in CNTO136NAP1003 [Note : 1 participant discontinued 
participation] ) as well as in 3,500participant s who have received sirukumab SC. 
Risks associated with sirukumab includ e infections, hypersensitivity  reactions, gastrointestinal 
perforations, hematologic events such as neutropenia andthrombocy topenia, and changes in lipid 
profiles and elevations of liver enz ymes. These risks are not dissimilar to those observed with other
biologics that target the IL-6 pathway  such as tocilizumab1and sarilumab35which also include 
serious infections, gastrointestinal perforations, and changes in neutrophils, platelets, lipids, and 
liver function tests. In addition, tocilizumab and sarilumab both have black box warnings for risk 
ofserious infections leading to hospitalization or death including tuberculosis (TB), bacterial, 
invasive fungal, viral, and other opportunistic infections. The utility  of blocking the IL-6 pathway 
using the IL-6R mAbs tocilizumab and sarilumab (KEVZARA®) is now being investigated in 
several clinical trials (ClinicalTrials.gov Identifiers: [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]).
Relevant safety  results on IV administration of sirukumab in the clinical program are presen ted 
below. More detailed information of all clinical studies performed with sirukumab are described 
in the IB.29
Safety in 3 Phase I studies with IV administration
Study  C0136T01 was a Phase 1, double -blind, placebo -controlled, ascending single -dose study 
evaluating the safet y, PK, and immunogenicity of IV administered sirukumab in healthy 
participant s. A total of 34 participant s received a single dose of either 0.3, 1.0, 3.0, 6.0, or 10.0 
mg/kg IV siruk umab and 11 participant s received placebo. 
Sirukumab was generally well tolerated in the 34healthy  participant s who received single IV 
infusions of sirukumab. The most common AE across all sirukumab treatment groups was 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 34
Status: Approved ,Date: 17 February 2021phary ngolary ngeal pain (5/34, 14.7%). There was 1 SAE not related to study  agent. Thirteen of 
34(38.2%), sirukumab -treated participant s had 1 or more AEs considered related to study  agent 
by the investigator. The most common drug-relate d AE was phary ngolaryngeal pain. No deaths 
were reported in the study. Overall, there were no dose- related safety  concerns.
There were no noteworthy  differences among cohorts in mean neutrophils values over time, and 
the mean values remained within the normal range. However, there was a dose-dependent decrease 
in median change from baseline in neutrophils in CNTO136-treated participant s compared to 
placebo, with a nadir at Week 4. At Week 4, Cohort 6 (10.0 mg/kg) had the largest decrease from 
baseline, with a median of –1.8 x109 (approximately  -28%). 
Of the CNTO136 -treated participant s, 4 (2 in the 3 mg/kg and 2 in the 6 mg/kggroup) had 
abnormally  low lymphocy te values vs one participant in the placebo group .Three treated 
participant s (one each in the 1, 3, and 6 mg/kg group) had abnormall y low neutrophil values .These 
episodes were generall y isolated and transient in duration and none were considered by the 
investigator to be of clinical significance, or were reported as AEs. The participant in the 6.0 mg/kg 
group, had a low neutrophils count (1.69 x 109/L [LLN 1.5 x 109/L]) Day –1 prior to dosing. He 
experienced a marked abnormally  low lymphocy te count of 0.81 x 109/L at Week 12, which 
returned to within normal range b y Week 16 (2.28 x 109/L).
Study  C0136T03 was a 2-part Phase 1 study . Part A was a multicenter/multinational, randomized, 
double -blind, placebo- controlled, staggered -parallel, 3 ascending -dose cohort study  of multiple IV 
administrations of sirukumab in which 23/31 participant s with CLEreceived either 1, 4, or 10 
mg/kg IV sirukumab biweekl y over 6 weeks (8/31 participant sreceived placebo) .Part B was a 
multicenter/ multinational, randomized, double -blind, placebo- controlled, single -dose level cohort 
study  of multiple IV administrations of sirukumab in which 10/ 15 participants with SL Ereceived 
10 mg/kg IV sirukumab biweekl y(5/15 participan tsreceived placebo) .
Six SAEs were reported in Part A and 3 SAEs were reported in Part B. Thesingle death in this 
study , due to a car accident, was considered to be not related to the administration of sirukumab. 
Two SAEs of infection were reported: pneu monia that was considered to be probabl y related to 
sirukumab administration and a bacterial infection of an iatrogenic wound that was considered to 
be unlikely  related to sirukumab administration. Neutropenia and thrombocy topenia were reported 
more freque ntly in participant s in the sirukumab groups than in the placebo groups in both lupus 
populations. Compared with the placebo group, participant s with CLE in the 1 and 4 mg/kg 
sirukumab groups reported a relativel y higher number of skin -related AEs that wer e considered to 
be reasonabl y related to sirukumab, whereas the 10 mg/kg group did not report any reasonabl y 
related skin events. 
Participants who received sirukumab showed immediate stable and sustained decreases in WBC, 
ANC, and platelets at all individ ual dose levels, while participant s in the placebo group showed 
no change in results. The decreases were not dose dependent. There was little to no clear temporal 
association between low neutrophil counts and the occurrence of infections. Two participant s in 
the Part B SLE cohort were discontinued from administration because of low ANC and platelet 
counts, but no immediate apparent clinical symptoms were associated with these low values. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 35
Status: Approved ,Date: 17 February 2021Fasting lipids showed minor elevations of total cholesterol in the coh orts that received sirukumab. 
Complement C3 and C4 decreased in both CLE and SLE participants in all sirukumab groups, but 
not in the placebo group. In Part A, WBC, ANC, and platelets showed decreases compared with 
baseline for the CNTO 136 combined group and at all individual dose levels. Participant s in the 
placebo group showed no changed results for all 3 parameters. For WBC and ANC, some (but not 
complete) recovery  was observed at the Week 22 follow -up visit. For platelets, recovery  at the 
Week 22 follow-up visit was less clear. The decreases were not dose dependent. The effect on 
platelets and ANC was alread y seen at Week 2 and the decreases observed during subsequent visits 
remained of the same order of magnitude. In Part B, median values for WBC, ANC, and platelets 
showed decreases from baseline for the CNTO 136 group compared with the placebo group. For 
all 3parameters, median values reached stable levels upon continued dosing, and there was no 
clear recovery  to baseline values at the Week 22 follow -up visit. The decrease in ANC was 
observed for most participant s after the initial dose administration.
CNTO136NAP1003 was a Phase 1, randomized, open -label, parallel- design study  to assess 
absolute bioavailability  and single -dose PK following SC administr ation of sirukumab delivered 
by a pre -filled s yringe fitted with UltraSafe Passive™ Delivery S ystem (PFS -U) or a SmartJect™ 
Autoinjector (PFS -AI) in healthy  male participant s. As a comparator arm, 19/144 participant s 
received a single IV administration of 100 mg sirukumab .Note that 1of the 19 participant s who 
received IV sirukumab 100 mg terminat edstudy  participation early (due to lost to follow -up).
Of the 144 participant s who received sirukumab, 68 (47.2%) had at least 1 AE during the study .
The incidence of participant s with AEs was higher in the IV 100 mg group (11 participant s 
[57.9%]) as compared with the SC treatment groups (50 mg PFS-AI group: 6 participant s [31.6%], 
50 mg PFS-U group: 9 participant s [47.4%], 100 mg PFS -AI group: 22 participant s [51.2%], and 
100 mg PFS-U group: 20 participant s [45.5%]). 
Of the 19 participant s who received IV 100 mg sirukumab, 11 participant s (57.9%) reported 1 or 
more AEs with no apparent pattern in any system-organ class . None of the participant s who 
received IV 100 mg sirukumab ha dan SAE or discontinued due to an AE. No deaths occurred.
No infusion reaction AEs were reported after IV infusion of sirukumab 100 mg in any of the 
participant s. 
Safety in a Phase II study with IV administration
Study  CNTO136LUN2001 was a randomized, double -blind, placebo -controlled, parallel group, 
multicenter proof -of-concept study  of sirukumab in 25 participant s aged between 18 and 70 years 
(inclusive) with a diagnosis of SLE and a biopsy -proven ISN/RPS Class III or IV LN within 
approximately  14 months prior to randomization who were not on cyclophosphamide therapy 
within 3months of randomization and who were receiving stable maintenance treatment with 
either mycophenolate mofetil or azathioprine, with or without corticosteroids. Of the 
25participant s, 21 participant s received sirukumab 10 mg/kg IV and 4 participant s received 
placebo IV. Study  treatments were administered every  4 weeks (at Weeks 0, 4, 8, 12, 16, 20, and 
24).
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 36
Status: Approved ,Date: 17 February 2021The most frequentl y reported AEs were observed in the System Organ Class of Infections and 
infestations (17 of 21 participant s [81.0%] in the sirukumab group and 2 of 4 participant s [50.0%] 
in the placebo group) and Gastrointestinal disorders (10 of 21 participant s [47.6%] in the 
sirukumab group and 1 of 4 participant s [25.0%] in the placebo group. The majority  of AEs were 
mild to moderate in intensity . No participant reported severe AEs in the placebo group whereas, 
in the sirukumab group 7participant s reported severe AEs, of which 3 participant sreported a 
severe AE of lupus nephritis.
Approximately  half of the sirukumab –treated participant s(10of the 21 participant s [47.6%]) 
reported at least 1 SAE. The most frequently  reported SAE was lupus nephritis, followed by 
pneumonia (including pneumonia haemophilus), and cellulitis. No deaths were reported during the 
study .
No discontinuation sdue to AEs were reported in the placebo group whereas, 5 of 
21participant s(23.8%) in the sirukumab group discontinued due to AEs. The AEs that led to 
discontinua tion were pneumonia haemophilus, hepatic enzy me increased, anaph ylactic reaction, 
neutropenia, and lupus nephritis.
Eight of 21 participant s(38.1%) from the sirukumab group and no participant from the placebo 
group reported treatment –emergent serious infections. All serious infections occurred after patients 
had received at least 4 doses of sirukumab at Week 12.The most frequentl y reported 
treatment -emergent serious infections were pneumonia (3of 21 participant s[14.3%] reported 
pneumonia and 1 of 21 participant s[4.8%] reported pneumonia haemophilus), and cellulitis 
(2of 21 participant s [9.5%]). In addition, 1 participant had a severe infusion reaction (anaph ylactic 
reaction) following the first administration of sirukumab.
A higher reduction in absolute neutrophils count and WBC count from baseline was observed in 
the CNTO136 group as compared with the placebo group over time. No noteworthy changes from 
baseline were observed in other hemat ology  parameters. For neutrophils, there was a 24.88% 
decrease from baseline at Day 4 and a 27.67% decrease at Week 4. Further decrease varied during 
the study  until Week 40 with a decrease of 31.56%. For neutrophils (decreased), there were no 
toxicities observed in the placebo group whereas, all toxicities grades were observed in the 
CNTO136 group: Grade 1 (4 of 21 participant s [20.0%]), Grade 2 (8 of 21 participant s [40.0%]), 
Grade 3, and Grade 4 (each observed in 1 of 21 participant s [5.0%]). For WBC (decreased), no 
Grade 4 toxicity  was observed in either of the treatment groups. A similar percentage of 
participant s had Grade 1 toxicity  (5 of 21 participants [25.0%] in the CNTO 136 group and 1 of 4 
participant s [25.0%] in the placebo group). No Grade 2 or3 toxicities were observed in the placebo 
group whereas, 10 of 21 participant s (50.0%) had Grade 2, and 2 of 21 participant s (10.0%) had 
Grade 3 toxicity  in the CNTO 136 group. For lymphocy tes (decreased), no Grade 4 toxicity  was 
observed in the placebo group whereas, 1 of 21 participant s (5.0%) had Grade 4 toxicity  in the 
CNTO 136 group. A higher percentage of participant s had Grade 2 and Grade 3 (each observed in 
6 of 21 participant s [30.0%]) toxicities in the CNTO 136 group whereas, in the placebo group 1 of 
4 participant s (25.0%) had Grade 2 toxicity  and 2 of 4 participant s (50.0%) had Grade 3 toxicity . 
There were few participants in the sirukumab group with elevated toxicity  grades for liver function 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 37
Status: Approved ,Date: 17 February 2021tests (AL T, AST, and alkaline phosphatase) as compar ed with no participant with liver toxicity  in 
the placebo group. No clinically  relevant changes in vital signs and posttreatment ECGs were 
observed in the treatment groups during the study .
2.2. Dose Rationale
The sirukumab dose proposed to be evaluated in sever elyand critically  ill participants with 
confirmed COVID -19 disease is 5 mg/kg administered as a single IV infusion. 
It has been demonstrated that a single IV dose of sirukumab at 0.3 to 10 mg/kg was generally well
tolerated in healthy  participant s (C0136T01) without showing evidence ofsafety  concerns . In 
addition, multiple IVdoses of sirukumab at 1, 4 or 10 mg/kg every 2 weeks (q2w) or every 4weeks
(q4w) were investigated in participant s with systemic lupus erythematosus or cutaneous lupus 
erythematosus (n=33, C0136T03), and in participant s with lupus nephritis (n=21, 
CNTO136LUN2001). The proposed IV dose of 5 mg/kg is 2- fold lower than the highest dose (ie, 
10 mg/kg IV) evaluated in completed studies of sirukumab. Furthermore, the safet y margins at 
5mg/kg as a single -dose IV administration are sufficiently  large (~20 based on C maxand ~10 based 
on AUC) compared to the PK exposure at the IV NOAEL dose of 50 mg/kg/week in a 6-month 
GLP toxicology  study  in cy nomolgus monkey s.
The affinit y of sirukum ab for IL-6 (0.175 pM) is >1,000- fold higher than that of IL-6R for IL-6 
(0.5-34 nM).6At 5 m g/kg IV dose of sirukumab, serum C maxis predicted to be ~125 µg/mL and at 
week 4, serum sirukumab concentration is predicted to be ~10 µg/mL, which is substantially higher 
than the serum IL-6 level in COVI D-19 and ARDS patients (in pg/mL  magnitude). Molar ratios 
(serum sirukumab:IL -6) will remain high for at least 4 weeks. In RA patients, a dose at or above 
25 mg every  4 weeks inhibited CRP levels for > 4 weeks. For a 70 kg subject, a 5 mg/kg sirukumab 
dose would translate to 350 mg, which is 14 -fold higher than 25 mg (C1377T04) . Therefore , even 
with increased IL-6 levels in COVID -19 as compared to RA, inhibition of IL -6R signaling (read -
out by  drop in CRP levels) is expected to last at least 4 weeks.
Based on the preliminary findings reported, the baseline blood IL -6 level issignificantly elevated 
to hundreds pg/mL magnitude in sever elyand critical ly illCOVID -19 patients16,76, which ismuch 
higher than the baseline IL-6 levels seen in RA participant s.33In addition, IL-6 levels in 
bronchoalveolar lavage fluid in patients at risk for ARDS and with established ARDS could raise 
to thousands pg/mL and remain above the normal range for up to 3 weeks in patients with persistent 
ARDS .49Given the acute nature of the disease for COVID -19 patients, IV administration is 
considered necessary for sirukumab treatment to rapidly suppress the elevated IL -6 levels in these 
patients. Subcutaneous absorption of sirukumab would be significantly slower to reach Cmax
compared to IV administration. A 5mg/kg IV dose of sirukumab is expected to provide sufficient 
exposure to bind IL-6 efficiently in patients with confirmed severe or critical COVID -19 disease 
who are at risk of ARDS . A physiologically  based pharmacokinetics -pharmacod ynamics 
(PBPK -PD)model predicted treatment with an IV dose of 5 mg/kg sirukumab would suppress 
elevated IL-6 levels to the normal range (ie, <10 pg/mL) in sever elyand critically  ill COVID -19 
patients who are at risk of ARDS.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Status: Approved ,Date: 17 February 2021In summary , sirukumab 5 mg/kg administered as a single IV infusion is expected to be effective 
with acceptable risks in rapidly  suppressing the free IL-6 levels for at least 4 weeks in partici pants 
with confirmed severe and critical COVID -19disease .
2.3. Benefit -Risk Assessment
2.3.1. Risks for Study  Participation 
Potential risks for participants treated with sirukumab single IV dose are the occurrence of infusion
reactions , hypersensitivity , serious infections, liver enzymes increase, and 
neutropenia/thrombocy topenia (see Section 8.3.6 ). Of these the most significant risks relate to the 
complications associated with immunosuppression, essentially  bacterial, fungal and viral 
infections.
The following risk mitigations are in place:
The study population will be under continuous monitoring in a hospital/intensive care setting. 
The protoc ol prevents patients with the most severe COVID -19 disease (eg, on invasive
mechanical ventilation or veno -venous ECMO for >48hours) and pre -existing comorbidities 
(including non-COVID -19-related active infections , severe COPD, steroid dependency , being 
on renal replacement therapy , chronic liver disease, malignanc y), patients 85 years of age,
from participating. 
To further protect the participants from the immunomodulatory  effects of sirukumab that may 
predispose them to infections, the investigators are referred to the local guidelines for the 
concomitant use of antibacterial sand/or agents that are intended to inhibit SARS -CoV -2 viral 
activity  for management of community  acquired pneumonia, COVI D-19 pneumonia, or 
secondary  infections. Open -label or off -label use of agents that are intended to inhibit 
SARS -CoV -2 viral activity , with demonstrated in-vitro effect, as mentioned in the CDC 
guidelines on Therapeutic Options for patients with COVID- 19 are permitted in the study .6
The co-administration of convalescent plasma introduces an additional protein load of 2.4 to 
8g/L.25,35This may be a concern in patients with renal impairment , however it is noted that the
following risk mitigations are in place:
The exclusion criteri on 10 prevent s patients with an estimated glomerular filtration rate 
(eGFR) ≤30mL/min/1.73 m2 or requiring renal replacement therap yfrom participating.
The study  population will be under continuous monitoring in a hospital/intensive care 
setting.
The inclusion of a Data Monitoring Committee (DMC) will ensure oversight of patient safet y(see 
Section 10.4.6 , Committee Structure).
2.3.2. Benefits for Study  Participation
There are currentl y no established pharmacologic therapies that are effective in the treatment of 
COVID -19 infection or associated ARDS. The potential benefit of sirukumab is to fulfill an urgent 
medical need for patients by  reducing progression of ARDS and associated mortality .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Status: Approved ,Date: 17 February 2021Additionally , there are potential benefits to global public health in establishing effective therapies 
with expediency . Given the burden that the COVID -19 pandemic has placed on global health 
resources in terms of demand for healthcare professionals to treat those hospitalized with COVI D-
19, the worldwide demand for ventilators, and the overall mortality  in those with COVI D-19
severe disease , particularly  those who are older and have pre-existing comorbidities, sirukumab 
has the potential to have a positive impact on the COVID -19 pandemic and on the overwhelmed 
healthcare systems by, eg, reducing duration of mechanical venti lation and of length of stay in 
ICU/hospital ward. 
2.3.3. Benefit -Risk A ssessment for Study  Participation
The sponsor is of the opinion that the potential benefits of treatment with sirukumab outweigh an y 
associated risks of treatment. This is based upon the fo llowing:
There are no established treatments for COVID -19. The proposed target patient population 
consists of individuals who have hypoxemia and who are at risk of ARDS. These are the 
patients with the most urgent medical need who are at the greatest risk of dying. The current 
mortality  due to COVID -19-associated pulmonary  complications for hospitalized patients 
with hypoxemia and pulmonary  involvement ranges from approximately  20-50% depending 
upon the age of the individual and pre -existing comorbidities.
Access of patients to investigational therapeutics to mitigate the disease is limited in this 
pandemic setting, andthis study will offer the potential to access a therapeutic in the context 
of a clinical stud y.
The proposed dosing is a single IV administ ration of 5mg/kg. During the clinical development 
program, study participants have received upto10mg/kg sirukumab IVq2w andnodose-
limiting toxicity hasbeen observed. In addition, multiple I V doses of sirukumab at 1, 4 or 10 
mg/kg q2w or q4w were administered to lupus patients (C0136T03 and CNTO136LUN2001).
In the placebo -controlled trial CNTO136LUN2001, 21participant s (men or women) aged 
between 18 and 70 years (inclusive) with a diagnosis of SLE and a biopsy -proven LN received 
sirukumab up to 10mg/kg IV q4w for 24 weeks. Eight of 21 participant s (38.1%) from the 
sirukumab group and 0/4participant sfrom the placebo group reported treatment –emergent 
serious infections. All serious infections occurred after patients had received at least 4 doses of 
sirukumab at Week 12. In Part A of C0136T03, the first 2 cohorts (1 and 4 mg/kg) consisted 
of 8 participant s each (6 receiving sirukumab and 2receiving placebo) and the highest dose 
cohort (10 mg/kg) consisted of 10 participant s (8receiving sirukumab and 2 receiving 
placebo). A total of 4 doses were to be administered q2w over a 6-week period. In Part B, 15 
participant s (10receiving sirukumab and 5 receiving placebo) received 10mg/kg biweekly 
over a 6 -week period. Two SAEs of infection were reported: pneumonia that was considered 
to be probabl y related to sirukumab administration and a bacterial infection of an iatrogenic 
wound that was considered to be unlikely  related to sirukumab administration.
The risks associated with sirukumab are largel y based upon data from studies in immune -
mediated diseases which involved chronic repeat dosing over an extended period of time (eg, 
1 year).
The known risks associated with sirukumab are not dissimilar to those of other approved agents 
that target the IL -6 pathwa y. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 40
Status: Approved ,Date: 17 February 2021The study  population will be under careful monitoring in the hospital setting with several risk 
mitigations strategies in place. 
The inclusion of a D MC will ensure oversight of patient safet y.
More detailed information about the known and expected benefits and risks of sirukumab can be 
found in the IB.29
3. OBJECTIVE S ANDENDPOINTS
Objectives Endpoints
Primary
To evaluate the clinical response of 
sirukumab (administered as a single IV 
dose) + SOC compared to placebo + 
SOC in confirmed critical COVID -19 
disease Time to improvementaof at least 2categor iesrelative to 
Baseline on the6-point ordinal clinical recovery scale 
(up to Day 28 )
Key s econdary
To evaluate the clinical response of 
sirukumab + SOC compared to placebo 
+ SOC in confirmed critical COVID -19 
disease Proportion of participants with an improvement on 
Day 28 of at least 2 categories relative to Baseline on 
the 6 -point ordinal clinical recovery scale 
 Incidence of all -cause mortality (up to Day 28)
Other Secondary
To evaluate the clinical response of 
sirukumab (administered as a single IV 
dose) + SOC compared to placebo + 
SOC in confirmed severe or critical 
COVID -19 disease Time to improvementaof at least 2categories relative to 
Baseline on the 6-point ordinal clinical recovery scale 
(up to Day 28)
To evaluate the clinical response of 
sirukumab + SOC compared to placebo 
+ SOC in confirmed severe or critical 
COVID -19 disease Proportion of participants with an improvement on 
Day 28 of at least 2 categories relative to Baseline on 
the 6 -point ordinal clinical recovery scale 
 Incidence of all -cause mor tality (up to Day 28)
To evaluate the safety of sirukumab + 
SOC compared to placebo + SOC in 
confirmed (a) critical and(b) se vere or 
critical COVID -19 disease Incidence of SAEs (up to Day 28)
 Incidence of related AEs (up to Day 28)
 Proportion of participants with severe or life-
threatening bacterial, invasive fungal, viral or 
opportunistic infections (other than SARS -CoV -2) (up 
to Day 28)
 Incidence of grade 3 and 4 neutropenia and 
lymphocytopenia (up to Day 28)
 Incidence of increased ALT ≥3xULN combined with 
increased bilirubin >2xULN (up to Day 28)
                                                
aThe improvement should be sustained until Day 28 (or discharge/discontinuation).
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 41
Status: Approved ,Date: 17 February 2021Objectives Endpoints
To evaluate the clinical response of 
sirukumab + SOC compared to placebo 
+ SOC in confirmed (a) critical and(b) 
severe or critical COVID -19 disease Time to improvementaof at least 1 category relative to 
Baseline on the 6-point ordinal clinical recovery scale 
(up to Day 28)
 Proportion of participants with an improvement on Day 
28 of at least 1 category relative to Baseline on the 6-
point ordinal clinical recovery scale 
 Time from study intervention to end of oxygen 
supplementation (up to Day 28)
 Time from study intervention to hospital discharge 
among the surviving participants (up to Day 28)
 Total length of hospitalization among the surviving 
participants (up to Day 28)
 Number of ventilation free days (up to Day 28)
 Participant’s clinical status at Day 7, 14, 21, 28 (6 -point 
ordinal clinical recovery scale)
 Total time on invasive mechanical ventilation
 Proportion of participants with a worsebcategory 
relative to Baseline on the 6-point ordinal clinical
recovery scale (up to Day 28)
 Proportion of participants on extracorporeal membrane 
oxygenation (ECMO) over time 
 Total time on ECMO
To evaluate the safety during follow -up
for (a) critical and (b)severe or critical
COVID -19 disease Proportion of alive participants at Day 28, Week 8, and 
Week 16
 Proportion of alive participants that required 
readmission at Week 8 and Week 16 (if previously 
discharged) 
 Incidence of SAEs up to Week 16
Exploratory
To evaluate biomarkers that may be 
associated with respo nse to or 
complications of sirukumab treatmentEvaluations may include, but are not limited to, IL-6, 
procalcitonin, C-Reactive protein (CRP), ferritin, LDH 
and D -dimer serum concentrations (through Day 28) 
To explore changes in SARS -CoV -2 
viral load and viral genome Time to SARS -CoV -2 undetectable viral load by 
RT-PCR (up to Day 28)
 SARS -CoV -2 viral load over time by RT-PCR (up to 
Day 28)
                                                
aThe improvement should be sustained until Day 28 (or discharge/discontinuation).
bClinical recovery scale score w orsened w ith at least 1 category between Day 5 and Day 28.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 42
Status: Approved ,Date: 17 February 2021Objectives Endpoints
 Proportion of participants with undetectable viral load
(at multiple time points up to Day 28)
 Development of SARS -CoV-2 variants
To evaluate the incidence of 
SARS -CoV -2 viremia Proportion of participants with SARS -CoV -2 viremia 
(at multiple time points up to Day 28)
To evaluate pharmacokinetics following 
sirukumab 5 mg/kg treatment Sirukumab serum concentrations 
To evaluate immunogenicity following  
sirukumab treatment Proportion of participants with sirukumab antibodies 
(Day 28 or at discharge if discharged after Day 28)
To evaluate SARS -CoV -2 humoral 
immunity Serum levels of SARS -CoV -2 specific antibodies 
Refer t o Section 8, Study Assessments and Procedures for evaluations related to endpoints.
At the time of data analysis, additional endpoints may be considered for analy sis in function of the 
evolution in scientific knowledge on COVID -19.
HYPOTHESIS
The primary  hypothesis of this study  is that sirukumab in combination with SOC results in a 
statistically  significant shorter time to improvement (defined as an improvement of at least 
2categor iesrelative to Baseline on the 6-point ordinal clinical recovery  scale) versus placebo in 
combination with SOC, in participants with confirmed critical COVID -19 disease .
4. STUDY DESIGN
4.1. Over allDesign
This is a randomized, double -blind , placebo- controlled ,multicenter, interventional Phase 2 study
in hospitalized participants with confirmed COVID -19 disease , at risk for progressing to severe 
ARDS . 
Up to protocol amendment 4, a target of approximately  270 participants with confirmed severe or 
critical COVID -19 disease was randomly  assigned in a 2:1 ratio to receive 1 of the following 
2treatments: 
Treatment Arm: sirukumab 5 mg/kg IV single dose infusion on Day  1 + SOC treatment
Control Arm: placebo IV single dose infusion on Day  1 + SOC treatment
More information on the SOC treatment is provided in Section 6.8Prestudy  and Concomitant 
Therap y.
As ofprotocol amendment 5, the study  aims to enroll approximately 111 participants with 
confirmed critical COVID -19 disease overall in the study . The primary  and key secondary  analyses 
will be tested on the participants with confirmed critical COVID -19 disease. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Status: Approved ,Date: 17 February 2021At the time of release ofprotocol amendment 5, approximately  100 participants with confirmed 
severe COVID -19 disease had been enrolled. The overall population of participants with 
confirmed severe or critical COVID -19 disease will be analy zed as part of secondary  objectives of 
the study .
Randomization is stratified by  age (<65 and ≥65 y ears of age) and by  use of invasive mechanical 
ventila tion (y es/no) at the time of randomization.
The study  will include a Screening Phase , a ‘Day 1 to Day  28’Phase and Post Day  28 Follow -up 
Phase (phone calls on Week 8, Week 12and Week 16). The entire study  duration for each 
participant will be 16 weeks with daily study  assessments up to Day 28 or day of discharge 
(whichever comes first) , and phone call assessments thereafter, ie, at Day 28 in case of discharge 
prior to Day 28, atWeek 8, 12 and16. The assessment schedule will be on a weekly  basisfor 
participants still hospitalized after Day 28. The study  is considered complete dwith the completion 
of the last study  assessment (phone call assessment at Week 16)for the last participant in the study  
or thediscontinuation of the last participant in the study, whichever comes last.For details, refer 
to the Schedule of Activities (SoA) . 
The impact of a single dose treatment with sirukumab on Day 1 +SOC on confirmed critical
COVID -19 disease will be evaluated throughout the study . Refer to the Schedule of Activities 
(SoA) and Section 8, Study  Assessments and Procedures for details. 
The primary  endpoint is the time to improvement of at least 2categor iesrelative to Baseline on 
the6-point ordinal clinical recovery scale (up to 28 days). The improvement should be sustained 
until Day 28 (or discharge/discontinuation) .For details, refer to Section 8.1.1 , Six-point Ordinal 
Clinical Recovery  Scale . 
The primary  anal ysis will be done when all participants reached Day  28or discontinued earlier. 
The final analy sis will be done when all participa nts completed the study . 
The DMC review edthe interim data after the first 30 participants with confirmed severe or critical 
COVID -19 disease had been dosed and have had at least 7 days of follow -upafter study 
intervention . Details regarding the D MC are provided in Committees Structure in Sectio n 10.4.6 .
A non-binding unblinded IA for futility  was performed by the sponsor on the primary  endpoint 
when approximately  20% of the planned number of participants with confirmed severe or critical 
COV ID-19 disease had reached Day 28 or discontinued earlier. Additional IAs on participants 
with confirmed critical COVID -19 disease are not planned for the study .
A diagram of the stud y design is provided in Section 1.2, Schema.
4.2. Scientific Rationale for Study  Design
There is currently  no treatment for COVI D-19. Many  drugs are currentl y under investigation, but 
none so far have proven efficacy . Current treatment is therefore only supportive, as per SOC. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Status: Approved ,Date: 17 February 2021Sirukumab will be administered on top of SOC, and placebo in combination with SOC will 
constitute the control group in this Phase 2 exploratory  study.Concomitant medications for 
consideration as part of SOC are provided in Section 6.8, Prestudy  and Concomitant Therap y.
Blinded, Control led,Randomized Study 
A placebo control will be used to establish the frequency  and magnitude of changes in clinical 
endpoints that may occur in the absence of active intervention with sirukumab and to characterize 
the safet y profile in this placebo group .
Randomization will be used to minimize bias in the assi gnment of participants to treatment arms , 
to increase the likelihood that known and unknown participant attributes (eg,demographic and 
baseline characteristics) are evenl y balanced across treatment arms , and to enhance the validity of 
statistical comparis ons across treatment arms. 
Double blinded intervention will be used to reduce potential bias during data collection and 
evaluation of clinical endpoints.
Stratif ication will be done by age (<65 and ≥65 years of age) and by use of invasive mechanical 
ventilation (y es/no)at randomization . 
Study Population 
The goal is to identify  a patient population with confirmed critical COVID -19 disease as defined 
in Inclusion Criterium 5 (see Section 5.1) who might benefit most from an anti- IL-6 intervention, 
ie, patients at risk of progressing to severe ARDS .
The initial study  design included enrollment of participants with confirmed severe or critical 
COVID -19 disease. Based on the rapidl y evolving space of COVID -19 therapeutics focusing on 
the highl y impacted population of critical patients together with the results from the interim 
analysis, as of protocol amendment 5, the study population is being limited to a subset of the 
currentl y eligible population, ie, those with confirmed critical COVID -19 disease. 
At the time ofrelease of protocol amendment 5, approximately  100 participants with confirmed 
severe COVID -19 disease had been enrolled. The overall population of participants with 
confirmed severe or critical COVID -19 disease will be analy zed as part of secondary  objectives of 
the study .
DNA and Biomarker Collection
It is recognized that genetic variation can be animportant contributory  factor to interindividual 
differences in response to study  intervention and can also serve as a marker for disease 
susceptibility  and prognosis. Pharmacogenomic research may help to explain interindividual 
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to an intervention . The goal of the pharmacogenomic component is to evaluate potential 
genetic associations with prognosis of clinical outcomes in patients and prediction of 
responsiveness to sirukumab treatment .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Status: Approved ,Date: 17 February 2021Biomarker samples will be collected to evaluate the mechanism of action of sirukumab or to help 
explain interindividual variability in clinical outcomes, to potentially help identify  population 
subgroups that respond differentl y to an intervention or to SARS -CoV -2 infection , and/or to 
characterize markers associated with SARS -CoV -2 infection . The goal of the biomarker anal yses 
is to evaluate the PDof sirukumab and aid in evaluating the intervention -clinical response
relationship. 
Biomarker samples may be used to help address emerging issues and to enable the development 
of safer, more effective, and ultimately  individualized therapies.
4.2.1. Study -Specific Ethical Design Considerations
Potential participants or (legal ly acceptable representative s)will be fully informed of the risks and 
requirements of the study and, during the study , participants (or legally  acceptable representative s) 
will be given an y new information that may affect their decision to continue participa tion. They  will 
be told that their consent to participate in the study is voluntary  and may be withdrawn at any time 
with no reason given and without penalt y or loss of benefits to which they would otherwise be 
entitled. Participants (or legal ly acceptable representatives) who are fully able to understand the 
risks, benefits, and potential AEs of the stud y, and provide their consent voluntaril y will be enrolled. 
In case of emergency  situations due to COVI D-19, when patients are incapable of giving their 
informed consent (eg, under intensive medical care) to enter the study , and the participant's legall y 
acceptable representative is not available (eg, none is in place since the participant had been 
otherwise healthy  before infection with SARS -CoV -2), deferre d consent is permitted if in 
compliance with national law and local regulations. Enrollment procedures should be described in 
the protocol with documented approval/favorable opinion by the IEC/IRB to protect the rights, 
safet y, and well -being of the partic ipant and to ensure compliance with applicable regulatory  
requirements. The participant or legall y acceptable representative should be informed about the 
study  as soon as possible and give consent to continue. In the event the legal ly acceptable
representa tive is not available, a member of the family  can take that role.  
Due to the COVID -19 pandemic, alternative procedures to obtain informed consent may be 
needed, as it is likely  thatthe physical consent form cannot leave the isolation room and is not 
appropriate as study  documentation. In that case, an alternative document (eg, photograph of the 
signature page) can be filed as a signed consent. For any informed consent that cannot be 
performed in person (eg, verbal consent by telephone), the process must be documented and 
confirmed by way of normal consent procedures at the earliest opportunity . An impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personall y date and sign a copy of the ICF (obtained and 
maintained outside the isolation room) after the oral consent of the participant is obtained. 
The primary  ethical concerns arethat sirukumab may not improve clinical outcomes of a 
participant with COVID -19or may worsen clinical outcomes dueto the immunosuppressant effect
of sirukumab . 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 46
Status: Approved ,Date: 17 February 2021The total blood volume to be collected of approximatel y 275 mL , including the optional sample for 
pharmacogenomic research ,is considered to be an acceptab le amount of blood to be collected over 
this time period from the population in this study  based upon the standard of theAmerican Red 
Cross standard blood donation.2
4.3. Justification for Dose
Refer to Section 2.2Dose Rationale .
4.4. End of Study  Definition
End of Study Definition
The end of study  is considered as the last scheduled study  assessment at Week 1 6as shown in the 
Schedule of Activities for the last participant in the study or the discontinuation of the last 
participant , whichever comes last. The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final participant assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
Study Completion Definition
A participant will be considered to have completed the study  if he or she has completed 
assessments at Week 16or has experienced a clinical endpoint that precludes further continuation 
in the study  (eg, early mortality ).
5. STUDY POPULA TION
Screening assessments start after signing of the ICF and can continue on the next calendar day , if 
needed. All screening and baseline assessments may also take place on the same day. Results from 
the blood test, pregnancy  test, ECG, and pulmonary  imaging , completed as SOC , taken up to 
2days prior to screening will be accepted as screening assessments. SARS -CoV -2 positivity , as 
determined locally by real time-PCR, in any specimen at any time prior to randomization is 
acceptable and this should not be repeated for inclusion in the study . If all eligibility  criteria are 
met at screening th en randomization may occur on that same day . 
The inclusion and exclusion criteria for enrolling participants in this stud y are described below . If 
there is a question about the secriteria, the investigator must consult with the appropriate sponsor 
representative and resolve any issues before enrolling a participant in the study . Waivers are not 
allow ed. 
For a discussion of the statistical considerations of participant selection, refer to Section 9.2, 
Sample Size Determination.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Status: Approved ,Date: 17 February 20215.1. Inclusion Criteri a
Each potential participant must satisfy  all of the following criteria to be enrolled in the study :
1.Male or female ≥18 and <85 years of age.
2.Hospitalized .
3.Criterion modified by  Amendment 4
3.1 Has laboratory -confirmed SARS -CoV -2 infection as determined by real time-PCR at 
any time before randomization .
4.Criterion modified per Amendment 3
4.1 Evidence of infiltrates by chest X -ray, chest CT, lung ultrasound, or chest auscultation 
(rales, crackles).
5.Criterion modified per Amendment 2
5.1 Criterion modified per Amendment 3
5.2 Criterion modified per Amendment 5
5.3Critical COVID -19 disease, defined as:
Critical disease: Requires supplemental ox ygen delivered b y nonrebreather mask 
or high-flow nasal cannula OR use of non-invasive or invasive ventilation OR 
requiring treatment in an ICU.
AND,
corresponding to category 4 on the 6 -point ordinal recovery scale (see Section 8.1.1 ), 
ie, 
Requires one of the above modalities to sustain a SpO 2>93%, with an a FiO 2of 
50%aor higher. Note, the use of other devices may fit with category 4 if th e FiO 2 
is 50%aor higher.
OR, corresponding to category  5 on the 6- point ordinal recovery  scale, ie,
PaO 2/FiO 2 ratio <300 mmHg while on invasive mechanical ventilation or veno -
venous ECMO for less than 48 hours prior to screening .
Note: as of protocol amendment 5, patients with confirmed severe COVID -19 disease 
are no longe r eligible in the study. Severe COVID -19 is defined as requiring 
supplemental oxygen administration by nasal cannula, simple face mask, or other 
simil ar oxygen delivery device (ie, above pre-COVID baseline oxygen requirement, 
                                                
aThe conversion between the oxygen flow expressed in L/min to the corresponding FiO 2value in % is the 
following: 
L/min 1 2 3 4 5 6 7 8 9 10
FiO 2% 24 28 32 36 40 44 48 52 56 60
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Status: Approved ,Date: 17 February 2021if any, by the participant) at a FiO 2less than 50%a. This corresponds to category 3 
on the 6 -point ordinal scale (see Section 8.1.1 ).
6.Criterion modified per Amendment 1
6.1 I nformed consent must be obtained from the participant (or their legall y acceptable 
representative must sign based on local regulations) indicating that he or she
understands the purpose of, and procedures required for, the study  and is willing to 
participate in the study .
Note: In case of emer gencies, when participants and their legal lyacceptable
representative are incapable of giving their informed consent (eg, under intensive 
medical care) to enter the study, the sponsor will adhere to local regulations. Refer to 
Section 4.2.1 for more information.
For optional DNA  research:
Separate informed consent must be obtained from the participant (or their legally acceptable 
representative) if he or she agrees to provide an optional DNA  sample for research (where local 
regulations permit). The informed consent for the optional DNA  research will be obtained in the 
main study  informed consent form (ie, bya tick box).
Refusal to give consent for the optional DNA  research sample does not exclude a participant from 
participation in the study .
5.2. Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded from 
participating in the stud y:
1.Criterion modified per Amendment 2
1.1On invasive mechanical ventilation or on veno -venous ECMO for >48 hours at time
of screening.
2.Meets local or global criteria to not receive mechanical ventilation or has designated 
themselves as DNR per a living will.
3.Criterion modified per Amendment 2
3.1Received an investigational intervention (including investigational vaccines) or used 
an invasive investigational medical device within 30 days before the planned dose of 
study  intervention.
Note: the investigator must ensure that the participant is not enrolled in another 
COVID -19 study with an investigational intervention (apart from the exception 
specified below) prior to completion of Day 28 of the current study.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 49
Status: Approved ,Date: 17 February 2021Exceptions : Participation ina single arm study , a non -blinded controlled study, 
expanded acces s,compassionate use program or any other program that is not a 
blinded study is allowed if it is conducted with one of the following:
agents with demonstrated in vitro -effec tagainst SARS -CoV -2, as mentioned in the 
CDC guidelines.6
convalescent plasma .
4.Criterion modified per Amendment 2
4.1 Current confirmed or high suspicion for pulmonary embolus, hemod ynamic significant 
pericardial effusion, m yocarditis, or Class 3 or 4 congestive heart failure as defined by 
the New York Heart Association Functional Classification (Section 10.9,Appendix 9)
AND/OR
Current e vidence of active cardiac ischemia .
5.Criterion m odified per Amendment 1
5.1 Criterion modif ied per Amendment 2
5.2Currently  active clinically significant (eg, causing hemod ynamic instability  and/or 
causing h ypoxemia) and uncontrolled arrhythmia .
6.Liver function impairment defined as Child Pugh Class B/C based on medical history .
7.Has congenital bleeding diathesis based on medical history .
8.Criterion modified per Amendment 2
8.1Has a history  of chronic respiratory  condition (ie, asthma, chronic obstructive 
pulmonary  disease [COPD], cystic fibrosis, fibrotic lung disease) that requires home 
oxygen supplementation, supportive non-invasive ventilation, or is status /postlung 
volume reduction surgery (LVRS)
Exception: Participants with sleep apnea using supportive non-invasive ventilation 
(continuous positive airway pressure [ CPAP ]) at screening may be included. 
9.On renal replacement therap y (defined as peritoneal dialysis or hemodial ysis)
10.Criterion modified per Amendment 1
10.1 Criterion modified per Amendment 2
10.2 Criterion modified per Amendment 3
10.3Screening laboratory  test result as follows:
- Absolute neutrophil count (ANC) <1 .0 × 103cells/μL  (SI: <1 .0 × 109cells/L) 
- Platelet count <5 0× 103cells/μL  (SI: <50 × 109cells/L )
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 50
Status: Approved ,Date: 17 February 2021-Estimated glomerular filtration rate(eGFR ) ≤30mL/min/1.73 m2
-Bilirubin >2xUL N unless bilirubin rise is due to Gilbert’s syndrome or of non-
hepatic origin 
-ALT >5xUL N
-Prothrombin time (PT)/international normalized ratio (INR) >1.5xULN or 
activated partial thromboplastin time (aPTT) >1.5xUL N related to known 
coagulopath y or bleeding disorder (the participant can receive anticoagulant 
therapies for underly ing conditions, or as systematic thromboproph ylaxis due to 
COVID -19, or as part of the treatment of complications of COVID -19, but cannot 
participate in a clinical study with ant icoagulants for COVID -19).
11.Criterion m odified per Amendment 1
11.1 Pregnant or breastfeeding , unless in the opinion of the investigator, the benefit 
outweighs the risks. 
12.Has active hepatitis B or C infection ,or has HIV/AIDS based on medical history and/or
concomitant medication .
13.Criterion m odified per Amendment 4
13.1 Known active or latent TB, history  of incompletely  treated TB, suspected or known 
extrapulmonary  TBbased on medical history and/or concomitant medication.
14.Evidence of active bacterial (including but not limited to bacterial pneumonia), fungal, 
viral or opportunistic infection (other than SARS -CoV -2). 
15.Known allergies, h ypersensitivity , or intolerance to sirukumab or its excipients or to other 
monoclonal antibodies (refer to the IB).29
16.Unlikely  to be able to complete the study  (including but not limited to: likely  to be 
transferred to another hospital, surgery is anticipated to be necessary, in the opinion of the 
investiga tor unlikel y to survive for >48 hours from screening)
17.Any condition for which, in the opinion of the investigator, participation would not be in 
the best interest of the participant (eg, compromise the well-being) or that could prevent, 
limit, or confoun d the protocol -specified assessments.
18.Taken any disallowed therapies as noted in Section 6.8, Concomitant Therap y before the 
planned dose of stud y intervention. 
19.History  of malignancy  within 5 yearsbefore screening (exceptions are squamous and basal 
cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy , which is 
considered cured with minimal risk of recurrence). 
20.Organ transplant recipient on immunosuppressant therapy
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 51
Status: Approved ,Date: 17 February 2021NOTE:
Exclusion criteria based on medical history  or on past/current medications are pragmatic 
criteria. Deviation post randomization from these criteria due to late awareness of medical 
history  and/or comedications are not intended to be qualified as major protocol deviations.
Investigators should ensure that all study  enrollment criteria have been met at screening. 
Retesting of abnormal laboratory  values that may  lead to exclusion will be allowed once. If a 
participant 's clinical status changes after screening but before randomization such that he or 
shenolonger meet sall eligibility  criteri a, then the participant should be excluded from 
participation in the study . The required source documentation to support meeting the 
enrollment criteria are noted in Section 10.4, Appendix 4Regulatory , Ethical, and Study  
Oversight Con siderations.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 52
Status: Approved ,Date: 17 February 20215.3. Lifestyle Considerations
Potential participants must be able to adhere to the following lifest ylerestrictions during the course 
of the study  to be eligible for participation:
1. Refer to Section 6.8,Concomitant Therap yfor details regarding prohibited and 
restricted therap y during the study.
2. A ll requirements must be met during the study  as noted in the Inclusion and Exclusion 
Criteria.
3. Once dismissed from the hospital, female participants should avoid getting pregnant for 
a period of 4 months after the study  intervention .
4. Once dismissed from the hospital, awoman of childbearing potential must practic ea 
highl y effective, preferably  user-independent method of contraception (failure rate of 
<1% per year when used consistently  and correctly ) and agree to remain on a highl y 
effective method until 4 months after the study  intervention or the end of relevant
systemic exposure .The investigator should evaluate the potential for contraceptive 
method failure (eg, noncompliance, recently  initiated) in relationship to the dose of 
study  intervention. Examples of highl y effective methods of contraception are located
in Section 10.6, Appendix 6Contracep tive and Barrier Guidance.
5. A woman must agree not to donate eggs (ova, oocy tes) or freeze for future use for the 
purposes of assisted reproduction for a period of 4 months after the administration of 
study  intervention . 
6. Once dismissed from the hospital, amale participant must wear a condom when 
engaging in an y activity that allows for passage of ejaculate to another person until the 
end of the study . Male participants should also be advised of the benefit for a female 
partner to use a highl y effective method of contraception as condom may break or leak .
7. A male participant must agree not to donate sperm for the purpose of reproduction for
a period of 4 months after the administration of study  intervention.
5.4. Screen Failures
Participant Identification, Enrollment, and Screening Logs
The investigator agrees to complete a participant identification and enrollment log to permit easy  
identification of each participant during and after the study . This document will be reviewed by 
the sponsor study -site contact for completeness.
The participant identification and enrollment log will be treated as confidential and will be filed 
by the investigator in the study  file. To ensure participant confidentiality , no copy  will be made. 
All reports and communications relating to the study  will identify  participants by participant 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 53
Status: Approved ,Date: 17 February 2021identification and age at initial informed consent. In cases where the participant is not randomized 
into the study , the date seen and age at initial informed co nsent will be used.
6. STUDY INTERVENTION AND CONCOMITA NT THERA PY
6.1. Study Intervention (s)Administered
Study  intervention administration must be captured in the source documents and the electronic 
case report form ( eCRF).
Sirukumab will be manufactured and provided under the responsibility  of the sponsor .Refer to the 
IB for a list of excipients.29
Participants need to receive study  intervention preferabl y within 4 hours but no later than 6 hours
after randomization.
Description of Interventions
The study  intervention will be administer ed to the participant via an IV infusion using a 5% 
dextroseaIV bag with a total volume of 50 mL. 
Sirukumab will beinjected into the bag for use in the treatment arm, the volume of the bag will be 
adjusted so that the total bag volume remains 50 mL . 
Nosubstance will be injected in the bag for the placebo arm, and a 5% dextrosea50 mL IV bag 
will be used as such.b
An unblinded pharmacist o rqualified staff member will prepare the IV bags before distribution to 
the clinic. 
                                                
aDextrose is also commonly known and referred to as glucose.
bPlacebo w ill be provided locally by the study site.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Status: Approved ,Date: 17 February 2021Intervention Name Sirukumab (CNTO136)
Type Drug
Dose Form ulation Solution for infusion
Unit Dose Strength(s) Sirukumab: 100mg/mL 
Dosage Level(s) Sirukumab: 5 mg/kg single dose
Route of Adm inistration IV infusion
Use Intervention 
Investigational Medicinal Product (IMP) Yes
Non-Investigational Medicinal Product/Auxiliary Medicinal 
Product (NIMP/AxMP)No
Sourcing Provided centrally by the sponsor
Packaging and Labeling
(Labels will contain information to meet the applicable regulatory 
requirements.)Each unit will be labeled with unique 
medication ID number.
Not in child resistant packaging
Delivery Instructions Refer to IPPI for instructions on IV infusion
Food/Fasting Requirement Regardless of food intake 
6.2. Preparation/Handling/Storage/A ccountability
Preparation/Handling/Storage
Sirukumab must be stored at controlled temperatures ranging from 36°F to46°F (2 °C to 8°C)and 
protected from light .
Refer to the I PPI for additional guidance on study  intervention preparation, handling, and storage. 
Accountability
The investigator is responsible for ensuring that all study  intervention received at the site is 
inventoried and accounted for throughout th e study. 
The study  intervention administered to the participant must be documented on the intervention 
accountability  form. All study  intervention will be stored and disposed of according to the 
sponsor's instructions. Study -site personnel must not combin e contents of the study  intervention 
containers.
Study  intervention must be handled in strict accordance with the protocol and the container label, 
and must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
envir onmental conditions. Unused study  intervention must be available for verification by the 
sponsor's study  site monitor during monitoring visits. The return to the sponsor of unused study  
intervention will be documented on the intervention return form. When the study  site is an 
authorized destruction unit and study intervention supplies are destro yed on-site, this must also be 
documented on the intervention return form.
Potentially  hazardous materials containing hazardous liquids, such as used needles, syringes and 
vials ,should be disposed of immediatel y in a safe manner and therefore will not be retained for 
intervention accountability  purposes. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 55
Status: Approved ,Date: 17 February 2021Study  intervention should be dispensed under the supervision of the investigator or a qualified 
member of the stu dy-site personnel, or by  a ho spital/clinic pharmacist. Study  intervention will be 
supplied only to participants participating in the study . Returned study  intervention must not be 
dispensed again, even to the same participant. Study  intervention may not berelabeled or 
reassigned for use by other participants. The investigator agrees neither to dispense the study  
intervention from, nor store it at, any  site other than the study  sites agreed upon with the sponsor . 
Further guidance and information for the final disposition of unused study  interventions are 
provided in the Pharmacy  Manual.
6.3. Measures to Minimize Bias: Randomization and Blinding
Intervention Allocation
Procedures for Randomization and Stratification
Central randomization will be implemented in this study . Participants will be randomly  assigned 
to 1 of 2intervention groups based on a computer -generated randomization schedule prepared 
before the study  by or under the supervision of the sponsor. The randomization will be balanced 
by using randoml y permuted blocks and will be stratified by age (<65 and ≥65years of age)and 
invasive mechanical ventilation (yes/no)at randomization .The interactive web response system 
(IWRS) will assign a unique interventi oncode, which will dictate the intervention assignment and 
matching study  intervention kit for the participant s assigned to the active study  treatment. The 
requestor must use his or her own user identification and personal identification number when 
conta cting the IWRS, and will then give the relevant participant details to uniquely  identify  the 
participant.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual participant.
Data that may potentially  unblind the intervention assignment (ie,preparation ) will be handled 
with special care to ensure that the integrit y of the blind is maintained and the poten tial for bias is 
minimized. 
The participants, study -site personnel, and investigators will be blinded to treatment allocation 
throughout the study , except for the designated pharmacist(s) or independent qualified staff 
member(s) with primary  responsibilit y for study  preparation. These unblinded members will not 
be part of the team performing the evaluations. The infusion administrator will be blinded and can 
perform other study  evaluations. The sponsor study  team will be blinded to study  treatment 
allocati on until the database release of the primary  analysis.
Under normal circumstances, the blind should not be broken until the database for the primary 
analysis is locked. However, for the IA, the randomization codes and the translation of 
randomization codes into treatment and control groups will be disclosed to those authorized and 
only for those participants included in the IA. Details on the level of unblinding and the parties 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 56
Status: Approved ,Date: 17 February 2021authorized to be unblinded during the interim analy sis will be specified in the SAP. Otherwise, the 
blind should be broken only if specific emergency treatment/course of action would be dictated by 
knowing the treatment status of the participant. In such cases , the investigator may in an emergency 
determine the identit y of the intervention by contacting the IWRS.While the responsibility  to 
break the intervention code in emergency  situations resides solel y with the investigator, it is 
recommended that the investigator contact the sponsor or its designee if possible to discuss the 
particular situation, before breaking the blind. Telephone contact with the sponsor or its designee 
will be available 24hours per day, 7days per week. In the event the blind is broken, the sponsor 
must be informed as soon as possible. The date and reason for the unblinding must be documented 
inIWRS, in the appropriate section of the eCRF and in the source document. The documentation 
received from the IWRS indicating the code break must be retained with the participant's source 
documents in a secure manner.
Participants who have had their intervention assignment unblinded should continue thescheduled 
evaluations.
6.4. Study Intervention Compliance
Study  intervention will be administered as an IV infusion by qualified study -site personnel and the 
details of each administration will be recorded in the source documentation and in the eCRF 
(including date, start and stop times of the I V infusion, and volume infused). 
6.5. Dose Modification
Not applicable.
6.6. Continued A ccess to Study Intervention After the End of the Study
No continued access will be proposed for this study  as one single dose will be administered by 
study  site personnel. 
6.7. Treatment of Overdose
There is no known specific antidote for sirukumab overdose. In the event of an overdose, the 
participant should be monitored for any signs or symptoms of adverse effects and institute 
appropriate s ymptomatic treatment immediatel y.
6.8. Prestudy  and Concomitant Therapy
Sirukumab has immunomodulatory  effects that may predispose participants to opportunistic 
infections. Therefore, all participants are to be managed according to local treatment guidelines, 
including the latest version of CDC Information for Clinicians on Therapeutic Options for Patients 
with COVI D-19. Open -label or off -label use of agents that are intended to inhibit SARS -Cov-2 
viral activity  are permitted in the study , but they must have demonstrated in-vitro effect aslisted 
in the CDC guidelines on Therapeutic Options for patients with COVID -19.6
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Status: Approved ,Date: 17 February 2021Disallowed concomitant medications
Conventional synthetic disease- modifying anti -rheumatic drugs/ immunosuppressive 
agents :
oOral anti-rejection or immunomodulatory  drugs (including tocilizumab )are disallowed 
from 6 months prior to randomization until the end of the study .
oTreatment with other anti-IL-6, anti-IL6R antagonists, Janus kinase inhibitors, 
ustekinumab (anti IL-12/23 ), or anti IL-23 agents (guselkumab) is disallowed within 
5half-lives (Table 1) or from 30 days prior to randomization (whichever is longer )until 
the end of the stud y.
Table 1: Treatm ent Half- life and 5 Half -lives
Drug Half -life 5 half -lives
tocilizumab IV 21.5 days 107.5 days
siltuximab IV 20.6 days 103 days
sarilumab IV 200 mg 10 days 50 days
sarilumab IV 150 mg 8 days 40 days
ustekinumab IV 19 days 95 days
guselkumab IV 15-18 days 75-90 days
ustekinumab SC 14.9-45.6 days 74.5-228 days
upadacitinib 8-14 hours 40-70 hours
baricitinib 12 hours 60 hours
tofacitinib XR 6-8 hours 30-40 hours
Source: Respective US Prescribing Informations
oSystemic treatment with disease -modify ing anti-rheumatic drugs or 
immunosuppressive agents including methotrexate, bucillamine ,azathioprine, oral 
cyclosporine A, tacrolimus, mycophenolate mofetil, oral or parenteral gold, and IL -1ra 
(anakinra) is disallowed from 2 weeks prior to randomization until the end of the study .
Exceptions: sulfasalazine, hy droxy chloroquine and chloroquine
oThe use of cyclophosphamide is disallowed from 12 weeks prior to randomization until 
the end of the study .
oCorticosteroids:
potential participants on chronic (for >3 months in duration) prednisone in a 
dose higher than 10mg/day or other oral corticosteroids at an equivalent dose 
for anycondition are not eligible for the study  
oThe use of leflunomide is disallowed from 8 weeks prior to randomization until the end 
of the study . Potential participants who have undergone standard cholesty ramine 
washout may qualify  ifit is done at least 4 weeks before randomization: cholestyramine 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 58
Status: Approved ,Date: 17 February 2021at a dosage of 8 mg/3 times a day for at least 24 hours, or activated charcoal at a dosage 
of 50 mg/4 times a day  for at least 24 hours.
The participants should not have received an investigational intervention (including 
investigational vaccines) or used an invasive investigational medical device within 30 day s of 
the planned dose of study  intervention and should not receive any  investigational medication, 
other than sirukumab, prior to completion of Day  28. 
Note: the investigator must ensure that the participant is not enrolled in another COVID -19 
study with an investigational intervention (apart from the exception specified below) prior to 
completion of Day 28 of the current study.
Exception s:
Participation ina single arm study , a non-blinded controlled study, an expanded access,
compassionate use program or any other program that is not a blinded study is allowed if 
it is conducted with one of the following: 
oagents with demonstrated in vitro -effect against SARS -CoV-2, as mentioned in the
CDC guidelines.6
oconvalescent plasma .
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
Useof monoclonal antibodies
The use of bamlanivimab, and c asirivimab plus i mdevimab is disallowed during the study  as they  
arenot authori zed in hospitalised participant s or participant s requiring ox ygen. 
Participant s who did receive bamlanivimab or casiriv imab plus imdevimab prior to screening are 
still eligible for the study  as long as the administration was stopped before first hospital admission 
and the participant s fulfil all I nclusion/Exclusion criteria ofthe study .
Any co-administration through co -enrolment in a study investigating the effects of bamlanivimab, 
casirivimab, or imdevimab is not permitted. Similarly , co-enrolment in other clinical studies
investigating the effects of other monoclonal antibodies that arespecifically  directed against the 
spike protein of SARS -CoV -2 and designed to block the virus ’attachment and entry  into human 
cells is not permitted per protocol.
Use of vaccines
Live vaccines should not be given during the stud y.
Administration of a COV ID-19 vaccine during the study  is not allowed at any time between 
screening and the discharge visit.
In case a participant was administered a COVID -19 vaccine outside the hospital prior to the study 
and becomes infected with COVI D-19 the participant can beallowed in the study  if allprotocol 
eligibility  criteria are fulfilled.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Status: Approved ,Date: 17 February 2021Administration of a COVID -19 vaccine is allowed at the time of the discharge visit, provided there 
are no contraindications . The administ ration should be done after the very last blood samplings 
required per protocol at the discharge visit to avoid potential interference of the COVID -19 
vaccine .
Medications to be used with caution as their exposure could be modified by the study medication
Examples include but are not limited to warfarin, theophy lline, digoxin, antiepileptics, 
antiarrh ythmics.
Various in vitro studies have shown that cytokines such as IL-6 can affect the expression and 
activity  of multiple cytochrome P450 (CYP) enzymes, such as CYP3A4, CYP2C9, CYP2C19, and 
CYP1A2. Sirukumab treatment may potentially reverse the effect of IL-6 on CYP enzyme 
activities in patients with elevated IL-6, which could lead to altered metabolism of drugs that are 
CYP substrates. The effect of sirukumab on the CYP enzy mes may  be clinically r elevant for CYP 
substrates with a narrow therapeutic index, where the dose is individually  adjusted. Therefore, it 
is recommended to use these typesof drugs with caution until 12 weeks after sirukumab 
administration (3x half- life); therapeutic monitoring of effect (eg, warfarin) or drug concentration 
(eg, theoph ylline) should be performed and the individual dose of the drug adjusted as needed. 
Caution should be exercised when sirukumab is co-administered with CYP3A4 substrate drugs 
where a decrease in effectiveness would be undesirable (eg, oral contraceptives). The effect of 
sirukumab on CYP enzymes may persist for several weeks after stopping therapy . Therefore, 
female participants using oral contraceptives should use an additional contraceptive method above 
that required per the Section 5.3Lifestyle Considerations .
Data collection of concomitant medications
To the extent possible, prestudy  therapies administered up to 30days before obtaining of informed 
consent must be recorded at screening.
As of obtaining informed consent, concomitant therapies must be recorded in the eCRF throughout 
the study  till16 w eeks after the study  intervention. Recorded information will include a description 
of the type of therapy , duration of use, dosing regimen, route of administration, and indication. 
Modification of an effective preexisting therapy  should not be made for the explicit purpose of 
entering a participant into the study .
7. DISCONTINUA TION OF STUDY INTERVENTION A ND PA RTICIPA NT 
DISCONTINUA TION/ WITHDRA WAL
7.1. Discontinuation of Study Intervention
As this is a single injection study , this section is not applicable.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Status: Approved ,Date: 17 February 20217.2. Participant Discontinuation/ Withdrawal From the Study
A participant will be withdrawn from the study  for any  of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
When a participant withdraws before study completion , the reason for withdrawal is to be 
documented in the eCRF and in the source document. 
Withdrawal of Consent
Participants who withdraw consent will be offered an optional Safety  Follow -up Visit (call), that 
will occur the day of consent withdrawal and will consist of the same assessments as atthe Day 
28 (or day of dischar ge) visit.
7.2.1. Withdrawal From the Use of Research Samples
A participant who withdraws from the study  will have the following options regarding the optional 
research samples:
The collected samples will be retained and used in accordance with the participant's original 
separate informed consent for optional research samples.
The participant may withdraw consent for optional research samples, in which case the 
samples will be destroy ed and no further testing will take place. To initiate the sample 
destruction pr ocess, the investigator must notify  the sponsor study  site contact of withdrawal 
of consent for the optional research samples and to request sample destruction. The sponsor 
study  site contact will, in turn, contact the biomarker representative to execute sample 
destruction. If requested, the investigator will receive written confirmation from the sponsor 
that the samples have been destroy ed.
Withdrawal From the Optional Research Samples While Remaining in the Main Study
The participant may withdraw consent for optional research samples while remaining in the study . 
In such a case, the optional research samples will be destro yed. The sample destruction process 
will proceed as described above.
Withdrawal From the Use of Samples in Future Research
The participa nt may withdraw consent for use of samples for research (refer to Long-Term 
Retention of Samples for Additional Future Research (See Section 10.4.Regulatory , Ethical, and 
Study  Oversight Considerations ). In such a case, samples will be destroy ed after they are no longer 
needed for the clinical study. Details of the sample retention for research are presented in the I CF,
including the separate consent for optional research samples.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Status: Approved ,Date: 17 February 20217.3. Lost to Follow -up
Lost to follow -up concerns the Phone Call Visits. A participant will be considered lost to follow -
up if he or she is unable to be contacted b y the study  site. A participant cannot be deemed lost to 
follow -up until all reasonable efforts made by the study -site personnel to contact the participant 
are deemed futile. The following actions must be taken:
Before a participant is deemed lost to follow up, the investigator or designee must make every  
reasonable effort to regain contact with the participant (where possible, 3 telephone calls, e-
mails, fax, and, if necessary , a certified letter to the participant’s last known mailing address, 
or local equivalent methods ). These contact attempts should be documented in the 
participant’s medical records.
Should participant scontinue to be unreachable, they will be considered to have withdrawn 
from the study and documented as ‘lost to follow -up’ in the eCRF .
Site personnel, or an independent third party, will attempt to collect the vital status of the 
participant within legal and ethical boundaries for all participants randomized, including those 
who did not get study intervention. Public sources may be searc hed for vital status 
information. If vital status is determined as deceased, this will be documented and the 
participant will not be considered lost to follow -up. If the participant withdrew consent ,the 
vital status information available after consent withdrawal will not be collected in the eCRF 
and the participant will be considered to have discontinued from the study  for consent 
withdrawal .Sponsor personnel will not be involved in any attempts to collect vital status 
information.
8. STUDY ASSESSMENTS A ND PROCEDURES
Overview
The Schedule of Activities (SoA) summarizes the frequency  and timing of respiratory  function 
assessment s, virology  a ssessments, pharm acology  a ssessments, exploratory  
biomarkers/pharmacogenomics, and safet ymeasurements applicable to this study .
Screening assessments start after signing of the ICF and can continue on the next calendar day , if 
needed. All screening and baseline assessments may  also take place on the same day .
Results from the blood test, pregnancy  test, ECG, and pulmonary  imaging , completed as SOC , 
taken up to 2 days prior to screening will be accepted for screening assessments. SARS -CoV -2 
positivity , as determined locall y by real time-PCR in any specimen at any time prior to 
randomization is acceptable and this should not be repeated for inclusion i n the study .
Screening/baseline assessments required to verify study  eligibility  criteria and data collection for 
asses sment of the 6-point ordinal clinical recovery  category  should take place prior to 
randomization.
If multiple assessments are scheduled for the same timepoint, it is recommended that procedures 
be performed in the following sequence: ECG, oxygen saturatio n, vital signs, blood sampling . 
Blood collections for PKassessments should be kept as close to the specified time as possible. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 62
Status: Approved ,Date: 17 February 2021Other measurements may be done earlier than specified timepoints if needed. Actual dates and 
times of assessments will be record ed in the source documentation and eCRF.
For those participants discharged prior to Day 28, all Day 28 assessments should be done at day 
of discharge. Laboratory, virology , relevant respiratory  function related assessments, and 
biomarker/pharmacology asses sments completed maximum 1 day before discharge do not need to 
be repeated on the day  of discharge provided that no clinically  relevant changes were noted in the 
results and the participant was declared ‘read y to be discharged’ on the day before discharge .
Leftover samples may  be used for exploratory  biomarker research.
For all laboratory  testsdone onDay 21, Day 28,andevery  week thereafter as needed ,a window 
of ±1 day  for all sampling is allowed .
For participants discharged after Day 28,additional assessments to be taken after Day 28 are listed 
in Schedule of Activities (SoA) .
The amount of blood drawn from each participant in this study  is approximat ely275mL.
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the 
samples.
Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. 
Refer to the Schedule of Activities (SoA) for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manua l.
Study -Specific Materials
The investigator will be provided with the following supplies:
IB
Pharmacy  Manual
Investigational Product P reparation Instruction s
Laboratory  Manual
IWRS Manual 
Sample I CF
Site Blinding Plan Template 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Status: Approved ,Date: 17 February 2021Contact I nformation Page(s)
eDC Manual
8.1. Efficacy  Assessments
Efficacy assessments will bedone per the Schedule of Activities (SoA) and will include all 
information necessary  for the 6-point ordinal clinical recovery  scale, level of consciousness 
(Glasgow coma scale [GCS] ),virology  assessment, supplemental oxygen use, resting SpO 2, 
arterial blood gas results, and pulmonary  imaging . Details for selected assessments are provided 
below.
8.1.1. Six-point Ordinal Clinical Recovery Scale
The 6-point ordinal clinical recovery scale provides 6 mutually  exclusive conditions ordered from 
best to worst, and the score reflects the participant’s worst situation on the day assess ed. The 
sponsor will assign the ordinal scale category based on the assessment of the participant’s clinic al 
status by  the investigator. The ordinal clinical recovery  scale categories are defined below.
Ordinal Clinical Recovery Scale (and Definitions)a
1. Not hospitalizedb
Any of the following:
Discharged from the hospital the day  of assessment 
Hospitalized at the day of assessment but ready for discharge onthe day of assessment, 
as judged b y the investigator (eg, i f still hospitalized i n case of lack of bed availability in 
a skilled nursing facility , lack of social support at home).
2.Hospitalization, not requiring supplemental oxygen
                                                
aAlternate care settings delivering care which would normally be delivered in a hospital setting will be categorized 
as hospitalized.
If a participant was discharged from the hospital “Against Medical Advice” on the day prior to the day of 
assessment, the participant will be categorized per the definitions above in the category the participan t was in at 
the moment of discharge “Against Medical Advice”. The hospital recovery scale category will be considered 
missing on subsequent days. 
If a participant declines medically -indicated mechanical ventilation, the participant will be categorized ac cording 
to the care they would otherwise have received on that day.
bA distinction will be made betw een participants discharged and in need of (score 1.2) or not in need of (score 1.1) 
oxygen supplementation as indicated by  the investigator on the dischar ge questionnaire. This distinction will not 
be made when calculating improvements on the CRS, for which score 1 w ill be used in both cases.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Status: Approved ,Date: 17 February 20213.Hospitalized, requiring low flow supplemental oxygen
Hospitalized on the day of assessment (including readmittance), and supplemental 
oxygen is required b y the participant .
Requiring supplemental ox ygen is defined b y:
Receiving supplemental oxygen for instance through a face mask or nasal cannula , at a 
FiO 2< 50%,aand not being able to sustain a blood oxygen saturation of >93% when 
breathing room air. 
OR
Not receiving supplemental oxygen and having a blood oxygen saturation of 93% 
sustained for 5 minutes .
4.Hospitalized, on non -invasive ventilation, nonrebreather mask, or high flow oxygen 
device
−On supplemental oxygen, on one of the above modalities, with a FiO 2(worst of the day) 
of 50%aor higher unless they satisfy  a  higher category  (eg, oninvasive mechanical 
ventilation). Note, the use of other devices may fit with category  4 if the FiO 2is 50%aor 
higher. 
5.Hospitalized, on invasive mechanical ventilation or ECMO
Any oxygen support requiring intubation or extracorporeal oxy genation .
Invasive mechanical ventilation is used at any  time on the day  of assessment.
6.Death
Participant died at an y time on the day  of assessment or earlier (all- cause mortality ).
In addition, the site will be asked whether or not they are working under (a) restricted material 
resources for supplemental oxygenation/ventilation and/or (b) changes in hospital discharge 
policies.
8.1.2. Level of Consciousness
The participant’s level of consciousness will be assessed using the GCS .TheGCS is a neurological 
scale ranging from 3 (lowest, corresponds to deep coma or death) to 15 (highest, corresponds to a 
fully  awake person) to assess the state of a person’s consciousness. The investi gator should record
the worst total GCS score once a dayin the eCRF, as long as the patient is in I CU.44
                                                
aThe conversion between the oxygen flow expressed in L/min to the corresponding FiO 2value in % is the 
following:  
L/min 1 2 3 4 5 6 7 8 9 10
FiO2 % 24 28 32 36 40 44 48 52 56 60
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Status: Approved ,Date: 17 February 2021The level of sedation of the participant will be derived from the type of medication entered for 
indication sedation on the Concomitant Medication page of the eCRF.
The frequency  and timing of the assessment can be found in the Schedule of Activities (SoA) .
8.1.3. Virology  Assessments 
Respiratory  tract samples
SARS -CoV -2 positivity  should be documented based on local testing on any specimen, by 
RT-PCR anytime before randomization. T his might require a local test using a NP swab obtained 
at screening .
In addition, n asophary ngeal swabs will be collected for central testing. A nNP swab will be used 
to collect secretions from patients to explore quantification of viral load of SARS -CoV -2 virus. At 
baseline ,the presence of other respiratory  pathogens, using multiplex PCR , will also be tested.
Furthermore, sequencing might be performed upon request of the virologist to determine mutations 
in the viral genome.
For participant who are intubated, endotracheal samples need to be taken at the same time as the 
NP swabs. If taking both samples is not feasible, the NP should be given priority . Collected 
samples need to be sent to the central lab to explore quantification of viral load. Sequen cing might 
be performed upon request of the virologist to determine mutations in the viral genome.
Only  one sample should be collected if the NP sample for detection and the NP sample for 
quantification are collected on the same day. This sample should be aliquoted and the remaining 
aliquots of the NP samples should be stored and sent to the central lab for quantification of 
SARS -CoV -2.
For each participant, NP sampling should be done at approximately  the same time (± 4 hours) on 
each sampling day  and from the same nostril. 
Leftover NP swabs and endotracheal samples may be used for exploratory  biomarker anal yses. 
If viral RNA is detected in nasophar yngeal samples at day of discharge, all possible efforts will be 
made to follow -up subjects and collect sampl es every  7 days until viral RNA is negative, 
considering the current pandemic and related logistical challenges. If possible, home visits by a 
healthcare professional may  be conducted to collect samples during the follow -up period.
The frequency  and timing of the assessments can be found in the Schedule of Activities (SoA) . 
Details about sample collection, processing, and shipping will be provided in the laboratory 
manual. 
Blood samples
In addition to NP swabs, plasma samples will be collected to assess SARS- CoV -2 viremia.
Leftover serum samples may be used for exploratory biomarker anal yses.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Status: Approved ,Date: 17 February 2021The frequency  and timing of the assessment scan be found in the Schedule of Activities (SoA) . 
Details about sample collection, processing, and shipping will be provided in the laboratory 
manual . 
Stool Samples (if feasible )
In addition to respiratory  tract and plasma samples, stool samples will be collected to explore 
quantification of viral load of SARS -CoV -2 virus. The stool collections will only be collected if 
feasible forthe site. 
Collected samples need to be sent to the central lab. Leftover stool samples may be used for 
exploratory  biomarker analy ses.
The frequency  and timing of the assessments can be found in the Schedule of Activities (SoA) . 
Details about sample collection, processing, and shipping will be provided in the laboratory 
manual.
8.1.4. Supplemental Oxy gen Use 
Supplemental oxygen/percentage of inspired oxygen (FiO 2) use (if any) will be measured to 
monitor thepatient’s status regarding gas exchange as applicable . The following will be recorded:
Oxygen delivery device (eg, nasal cannula, simple face mask, nonrebreather mask, high flow 
nasal cannula, non -invasive ventilation, invasive mechanical ventilation, extracorporeal life 
support, etc)
Oxygen flow rate in liters/min
Record FiO 2and SpO 2data 4 times per day, and at any time of arterial blood gas 
measurements. Record values that are sustained for at least 1 hour. 
If a patient is using more than one devic e (eg, extracorporeal life support and invasive 
ventilation), the worst value of FiO 2 (and the corresponding SpO 2-and PaO 2if available -) on 
the highest level of intervention will be recorded .The worst (highest) value of FiO 2(and the 
corresponding SpO 2-and PaO 2if available -) on each device will also be recorded.
If a patient does not need oxy gen supplement ation, this should also be recorded .
The frequency  and timing of the assessment can be found in the Schedule of Activities (SoA) .
Note: The use of CPAP at home for obstructive sleep apnea syndrome will not be reported as a 
need of oxygen supplementation information. Only  the information on oxygen supplementation 
that is COVI D-19 related is to be reported.
8.1.5. Resting SpO 2
Resting SpO 2will be measured to assess arterial oxyhemoglobin saturation. SpO 2will be measured 
using a fingertip or similar non-invasive device, while patient is stable, following 5 minutes of rest 
(inactivity ) in supine, semi -recumbent, or sitting position and will only be measured in the 
presence of a good SpO 2wave form. SpO 2must be measured simultaneously  with recorded 
supplemental ox ygen/FiO 2data.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Status: Approved ,Date: 17 February 2021For participants receiving invasive or non-invasive mechanical ventilation, peripheral oxygen 
saturation should be measured with the ventilatory  support in place, and it should be recorded.
The frequency  and timing of the assessment can be found in the Schedule of Activities (SoA) .
General guidelines for measuring SpO 2are provided in Section 10.10 Appendix 10: General 
Guidelines for Measuring Vital Signs and SpO2. 
8.1.6. Arterial Blood Gas Test
An arterial blood test will be conducted to assess the following parameters:
pH: acid- base balance of blood
PaO 2: partial pressure of ox ygen in arterial blood
PaCO 2: partial pressure of carbon dioxide in arterial blood
Supplemental oxygen/FiO 2and resting SpO 2must be recorded at the same time as when an arterial 
blood gas is obtained. Results should be recorded in the eCRF. The frequency  and timing of the 
assessment can be found in the Schedule of Activities (SoA) .
8.2. Safety  Assessments
Safety  and tolerability  will be evaluated throughout the study  from obtaining informed consent
onwards until the last study -related activity . 
Adverse events will be reported and followed by the investigator as specified in Section 8.3, 
Adverse Events, Serious Adverse Events, and Other Safet y Reporting, and Section 10.5, Appendix
5Adverse Events, Serious Adverse Events, Product Qualit y Complaints, and Other Safety 
Reporting: Defin itions and Procedures for Recording, Evaluating, Follow -Up, and Reporting.
Any clinically  significant abnormalities persisting at the end of the stud y/early  withdrawal will be 
followed b y the investigator until resolution or until a clinically  stable cond ition is reached. 
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Schedule of Activities (SoA) .
8.2.1. Physical Examination s
A targeted physical examination will be performed as indicated in the Schedule of Activities 
(SoA) .A targeted physical examination is to be performed as per local SOC and includes, if 
feasible, lung auscultation and any examination as indicated by the patient’s medical history . 
Height and body  weight are only to be measured at screening if not alread y available in the 
participant’s chart and if practicall y feasible. If not feasible, weight for dose calculation can be 
verball y reported b y the participant or a family member.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Status: Approved ,Date: 17 February 2021Clinically  significant findings should be documented as AE in the eCRF if they are serious, 
possibly  related to the study  drug or correspond to an adverse event of interest.
8.2.2. Vital Signs
Temperature, pulse rate, respiratory  rate, and blood pressure (SBP/DBP) will be assessed. The 
frequency  andtiming for each assessment can be found in the Schedule of Activities (SoA) . 
Body temperature will be measured according to local hospital protocols and according to the 
manufacturer ’s instructions for use of the device. Bod y temperature should be measured using the 
same method each time : temperature should be measured after at least 5 minutes of rest (supine or 
sitting) and before taking antipy retics or more than 4 hours after the last dose of antipy retics.
Blood pressure and pulse/heart rate measurements will be assessed with a completely  automated 
device. Manual techniques will be used only  if an automated device is not ava ilable .
Confirmatory  vital signs measurements can be performed if inconsistent with a prior measurement.
Any clinicall y relevant abnormalities or changes in severit y should be documented as AE in the 
eCRF if they are serious, possibly  related to the study  drug or correspond to an adverse event of 
interest .
General guidelines for measuring vital signs are provided in Section 10.10 Appendix 10 : General 
Guidelines for Measuring Vital Signs and SpO2.
8.2.3. Electrocardiogram s
Participants should rest in a supine position for at least 5minutes before ECG collection and should 
refrain from talking or moving arms or legs. If multiple assessments arescheduled for the same 
time point as ECG recording, the procedures should preferabl y be performed in the following 
order: ECG(s), oxygen saturation, vital signs, blood draw.
If an EC Gis performed, the following parameters should be collect ed in the eCRF: Heart rate will 
be recorded from the ventricular rate and the PR, QRS, and QT (identify QT interval corrected for 
heart rate [QTc] using Bazett’s formula [QTcB] or QTc using Fridericia’s formula [QTcF ]) 
intervals will be recorded in the eCR F. The ECG strips or reports will be retained with the source
and may  be requested in case of documentation of a cardiovascular SAE .
The frequency  and timing for each assessment can be found in the Schedule of Activities (SoA) .
Any clinicall y relevant abnormalities or changes in severit y should be documented as AE in the 
eCRF if they are serious, possibly  related to the study  drug or correspond to an adver se event of 
interest .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Status: Approved ,Date: 17 February 20218.2.4. Clinical Safety  Laboratory  Assessments
Blood samples for serum chemistry  and hematology  will be collected as noted in Section 10.2, 
Appendix 2Clinical Laboratory  Tests. The investigator must review the laborat ory results, 
document this review, and record an y clinicall y relevant changes occurring during the stud y in the 
AEsection of the eCRF. The laboratory  reports must be filed with the source documents.
Any clinicall y relevant abnormalities or changes in severit y should be documented as AE in the 
eCRF if they are serious, possibly  related to the study  drug or correspond to an adverse event of 
special interest (AESI) .
8.2.5. Pregnancy  Testing
At screening ,baseline ,and Day 28 (or at discharge, whichever comes first) , absence of pregnancy 
in women of childbearing potential should be confirmed by a urine rapid pregnancy test. Theresult 
of a prior serum pregnancy  test that occurred within 2calendar days(as part of SOC) before 
obtaining consent can be used in lieu of the screening requirement. Self-reported p regnancy status 
of female participants will be recorded during phone call visits on Day 28 (for participants 
discharged or who discontinued the study  prior to Day 28 and did not withdraw consent ) and during 
the post Day  28 follow -up phase phone call visits. Results should be recorded in the eCRF.
8.2.6. Vital Status 
At Day  28 (if discharge dbefore Day  28), and during the post Day  28 follow -up phase ( phone call 
visits ),vital status of study participants will be recorde d,if the participant is alive .If theparticipant 
is deceased, date and cause of mortality should be recorded. Death should be documented as SAE 
in the eCRF. 
8.2.7. Self-reported Oxygen Need
On the Day 28 phone call visit (if discharged before Day 28) and during t he post Day 28 follow -up 
phase (phone call visits) participants will be asked whether they require supplemental oxygen(yes 
or no). The results should be documented in the eCRF. 
8.3. Adverse Events ,Serious A dverse Events , and Other Safety  Reporting
Timely , accurate, and complete reporting and analy sis of safet y information , including AEs, SAEs , 
and product qualit y complaints ( PQC s),from clinical studies are crucial for the protection of 
participants, investigators, and the sponsor, and are mandated by regulatory  agencies worldwide. 
The sponsor has established Standard Operating Procedures in conformity  with regulatory  
requirements worldwide to ensure appropriate reporting of safet y information; all clinical studies 
conducted b y the sponsor or its affiliates will be conducted in accordance with those procedures.
Adverse events will be reported as specified in Section 8.3.1 by the participant (or, when 
appropriate, by a caregiver, surrogate, or the participant's legally  acceptable representative) for the 
duration of the study .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Status: Approved ,Date: 17 February 2021Further details on AEs,SAEs , and PQC scan be found inSection 10.5,Appendix 5Adverse 
Events , Serious Adverse Events, Product Quality  Complaints, and Other Safet y Reporting : 
Definitions and Procedures for Recording, Evaluating, Follow -Up, and Reporting.
8.3.1. Time Period and Frequency  for Collecting A dverse E vent and S erious 
Adverse E vent Information
All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be reported 
from the time a signed and dated ICF is obtained until completion of the participant's last study -
related procedure, which may  include phone call contact for follow -up of safety . 
Serious Adverse Events
All SAEs , as well as PQC s,occurring during the study must be reported to the appropriate sponsor 
contact person b y stud y-site personnel within 24 hours of their knowledge of the event.
Serious adverse events, including those spontaneously  reported to the investigator through the 
Week 16 phone call visit, must be reported using a Serious Adverse Event form. The sponsor will 
evaluate an y safet y information that is spontaneously  reported b yan investigator bey ond the time 
frame specified in the protocol.
Information regarding SAEs will be transmitted to the sponsor using the Serious Adverse Event 
Form and Safety  Report Form of the eCRF, which must be completed and reviewed by a physician 
from the study  site, and transmitted to the sponsor within 24 hours. The initial and follow -up 
reports of anSAE should be transmitted electronically . Telephone reporting should be the 
exception and the reporter should be asked to complete the appropriate for m(s) first.
8.3.2. Method of Detecting A dverse E vents and S erious Adverse E vents
Care will be taken not to introduce bias when detecting AEs or SAEs . Open -ended and nonleading 
verbal questioning of the participant is the preferred method to inquire about adverse event
occurrence. During the hospital stay, in case participants are non-responsive, investigators will 
report AEs as specified in Section 8.3.1 . 
Solicited Adverse Events
Solicited adverse events are predefined local (at the injection site) and sy stemic events for which 
the participant is specifically  questioned. 
Unsolicited Adverse Events
Unsolicited AEs are all AEs for which the participant is not specificall y questioned.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Status: Approved ,Date: 17 February 20218.3.3. Follow -up of A dverse E vents and S erious Adverse E vents
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and evaluations as medically  indicated to elucidate the nature and causality of the AE, SAE , or 
PQC as fully  as possible. This may include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other health care professionals.
Adverse events, including pregnancy , will be followed by  theinvestigator as specified in Section 
10.5,Appendix 5Adverse Events , Serious Adverse Events, Product Quality Compla ints, and Other 
Safety  Reporting : Definitions and Procedures for Recording, Evaluating, Follow -up, and 
Reporting.
8.3.4. Regulatory  Reporting Requirements for S erious Adverse E vents
The sponsor assumes responsibility  for appropriate reporting of AEs to the regul atory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute where 
required) all suspected unexpected serious adverse reactions (SUSARs). The investigator (or 
sponsor where required) must report SUSARs to the appropriate Independent Ethics 
Committee/I nstitutional Review Board (IEC/I RB) that approved the protocol unless otherwise 
required and documented by the IEC/I RB. A SUSAR will be reported to regulatory  authorities 
unblinded. Participating investigato rs and IEC/IRB will receive a blinded SUSAR summary, 
unless otherwise specified. 
8.3.5. Pregnancy
All initial reports of pregnancy  in female participants or partners of male participants must be 
reported to the sponsor by the study -site personnel within 24 hours of their knowledge of the event 
using the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy ) are 
considered serious adverse events and must be reported using a serious adverse event reporting 
form. 
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Status: Approved ,Date: 17 February 20218.3.6. Adverse Events of Special Interest
Adverse events of special interest for the single IV administration of sirukumab (5 mg/kg) are
provided below . 
Table 2: Events of Interest for a Single IV Dose of Interest
Potential Risks of Clinical 
SignificanceSummary of Data/
Rationale for Risk Mitigation Strategy
Serious infections
(Bacterial, fungal, and viral 
infection )Interleukin -6 stimulates hepatic 
acute -phase proteins and Ig 
production and promotes the 
grow th and differentiation of T 
cells, B cells, and tumor cells. 
Interleukin -6 is a mediator of 
inflammation and cellular immune 
responses in the defense against 
some intracellular pathogens. 
Interleukin -6 has been known to 
serve as a marker of disease 
severity for infections. Although 
IL-6 modulates certain physiologic 
acute -phase responses to infec tion, 
a complete lack of IL -6 has not 
been shown to alter mortality rates 
in IL -6 knockout mice. Blockage of 
IL-6 may  blunt the acute -phase 
pyretic response and therefore, 
fever may be masked in participants 
receiving sirukumab. Serious, life -
threatening i nfections such as septic 
shock, some of which have been 
fatal, have occurred in participants 
receiving sirukumab.Inclusion and exclusion criteria; 
hematologic monitoring; safety 
evaluation; and supportive 
treatment.
Hypersensitivity Reactions observed in humans after 
IV or SC administration of mAbs 
include headache, fever, facial 
flushing, pruritus, urticaria, 
dermatitis, myalgia, nausea, chest 
tightness, laryngeal edema, 
dyspnea, vomiting, erythema, 
abdominal discomfort, diaphoresis, 
shivers, hypertens ion, Stevens -
Johnson syndrome, 
lightheadedness, hypotension, 
palpitations, and somnolence.Inclusion and exclusion criteria; 
clinical monitoring; safety 
evaluation; and supportive 
treatment. 
Hem atologic Events Neutropenia and thrombocytopenia 
have occu rred in sirukumab studies, 
including severe thrombocytopenia 
associated with bleeding. In the 
Phase 2 and Phase 3 RA studies, 
decreases in ANC and platelets 
occurred in all sirukumab treatment 
groups. Most patients who 
developed neutropenia while being 
treated w ith sirukumab did not Inclusion and exclusion criteria; 
clinical monitoring; safety 
evaluation; and supportive 
treatment. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 73
Status: Approved ,Date: 17 February 2021develop infections, and most 
patients who developed 
thrombocytopenia did not report 
bleeding events. Changes were not 
observed in participants who 
received placebo, but did occur 
after participants crossed over to 
active treatment. No dose response 
was observed.
Liver enzymes Increases (1 to 3 x ULN, sometimes 
>5 x ULN) in blood ALT and AST 
values were observed in 
participants in completed studies of 
sirukumab; the majority were 
transient, asymptomatic, and not 
associated with an increase in 
bilirubinMonitor ing of liver parameters
(ALT, AST, bilirubin [total, direct 
and indirect], coagulation factors, 
alkaline phosphatase )
For information on the adverse events of interest associated with chronic administration of 
Sirukumab in other disease conditions, such as rheumatoid arthritis, refer to Section 10.7, 
Appendi x 7. 
8.4. Pharmac okinetics and Immunogenicity  
Serum samples will be used to evaluate the pharmacokinet icsofsirukumab , IL-6, as well as 
antibodies to sirukumab. Serum collected for pharmacokinetic and immunogenicity anal ysesmay 
additionally  be used to evaluate biomarkers, safety  or efficacy  aspects that address scientific 
questions relating to sirukumab orSARS -CoV -2 infections. Genetic analyses will not be 
performed on these serum samples. Participant confidentiality  will be maintained.
Details about sample collection, processing, and shipping will be provided in the laboratory 
manual. 
8.4.1. Evaluat ions
At visits where PK, immunogenicit y, and IL-6 will be evaluated (Day  1 predose ,Day 28), one 
venous blood draw will be collected as specified in the Schedule of Activities (SoA) . Serum 
samples will be obtained and split into 3 aliquots (one for sirukumab concentration, one for 
antibodies to sirukumab, and one for IL-6). 
At visits where PK and IL-6 will be evaluated (Day  1 postdose, Day 14, Day 21), one venous blood 
draw will be collected as specified in the Schedule of Activities (SoA) . Serum samples will be 
obtained and split into 2 aliquots (one for sirukumab concentration and one for IL -6). 
Additional information about the collection, handling, and shipment of biological samples can be 
found in the Laboratory  Manual .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 74
Status: Approved ,Date: 17 February 20218.4.2. Analytical Proc edures 
Pharmacokinetics 
Serum samples will be analyzed to determine concentrations of sirukumab using a validated, 
specific, and sensitive immunoassay method by  or under the supervision of the sponsor.
Immunogenicity
The detection and characterization of antibodies to sirukumab will be performed using a validated 
immuno assay  method by or under the supervision of the sponsor. 
8.4.3. Pharmacokinetic Parameters and Evaluations
If feasible, a population PK approach will be use d to characterize the disposition characteristics of 
sirukumab. Total systemic clearance (CL) and volume of distribution (V) after IV administration
may be estimated from population PK modeling using nonlinear mixed effects model (NONMEM) 
approach.
8.4.4. Immunog enicity  Assessments
Antibodies to sirukumab will be evaluated in serum samples collected on Day 1 predose and on 
Day 28.
Serum samples will be screened for antibodies binding to sirukumab and the titer of confirmed 
positive samples will be reported. Other analy ses may be performed to verify  the stability  of 
antibodies to sirukumab and/or further characterize the immunogenicity  of sirukumab .
8.5. Genetics and Pharmacogenomics
An optional pharmacogenomic (host DNA) blood sample may be collected (preferabl y at baseline) 
from those participants who gave consent to allow for host pharmacogenomic research, where 
local regulations permit. Pharmacogenomic research may include expression quantitative trait 
locus (eQTL) mapping, single -nucleotide polymorphisms (SNPs) mapping and whole genome 
sequencing that is related to the IL-6 gene, study  intervention , and/or SARS- CoV -2 infection.
Participant participation in pharmacogenomic research is optional.
8.6. Biomarkers
The frequency  and timing of the assessment can be found in the Schedule of Activities (SoA) .
Biomarker sfor exploratory  endpoint evaluation
Blood samples will be collected to evaluate biomarkers that may be associated with the safety , 
efficacy  and PK of sirukumab and/or with SARS -CoV -2 infection . Evaluations may include, but 
are not limited to, IL-6, procalcitonin, CRP, ferritin, LDH, and D-dimer concentrations. In
addition, humoral immunity  to SARS -CoV -2 will be evaluated bymeasuring SARS -CoV -2 
specific antibodie s.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 75
Status: Approved ,Date: 17 February 2021Biomarker sample collection for research
The study  includes collection of blood samples for exploratory  analysis of host biom arkers at the 
host RNA, protein and cell level. Samples may be analyzed under the supervision of the sponsor 
and results might be reported separatel y.
Samples can only be used for research related to sirukumab or SARS -CoV -2 infection and/or to 
develop tests/assay s related to sirukumab or SARS -CoV -2 infection. This may include target 
pathway  of IL-6 inhibition, and the impact on pneumonia and respiratory  illness associated with 
SARS -CoV -2 infection.
Analy sis of exploratory  biomarkers may  be conducted at the sponsor’s discretion and results may  
be reported separatel y from this study . These samples may be stored for up to 15 years after the 
study  completion.
9. STATISTICA L CONSIDERA TIONS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
9.1. Statistical Hy potheses
The primary  hypothesis of this study  is that sirukumab in combination with SOC results in a 
statistically  significant shorter time to improvement (defined as an improvement of at least 
2categor iesrelative to Baseline on the 6-point ordinal clinical recovery  scale) versus placebo in 
combination with SOC, in participants with confirmed critical COVID -19 disease .
9.2. Sample Size Determination
The study  was targeted to enroll 270 participants with confirmed severe or critical COVID -19 
disease in a 2 :1 manner, with approximately  180 participants in the sirukumab treatment arm and 
approximately  90 participants in the control arm. However, based on the rapidly  evolving space of 
COVID -19 therapeutics focusing on the highl y impacted population of critical patients together 
with the results from the interim analy sis, the study  population is being limited with protocol 
amendment 5 to a subset of the currently  eligible population, ie, those with confirmed critical 
COVID -19 disease.
At the time of release of protocol amendment 5,approximately  100 participants with confirmed 
severe COVID -19 had been enrolled.
The study  aimsto enroll approximately  111 participants with confirmed critical COVID -19 disease
overall in the study , with approximately  74 participants in the sirukumab treatment arm and 
approximately  37 participants in the control arm. 
The primary  endpoint in this study  is the time to improvement of at least 2categor iesrelative to 
Baseline on the 6-point ordinal clinical recovery scale , with participant s who die prior to Day 28 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 76
Status: Approved ,Date: 17 February 2021treated as right censored at Day 28. For the sample size calculation on the primary  endpoint, the 
following assumptions are used for survivors and participants who die prior to Day  28:
For survivors in the contro l arm, it is assumed that the log transformed time to improvement 
(days) follows a normal distribution with mean of log 28 and a standard deviation 0.9. 
Sirukumab is assumed to reduce the median time to clinical improvement from 28 days to 
16.8 days (40% reduction) in the surviving participants and is assumed to have the same 
standard deviation of 0.9.
For the mortality  rate in the control arm, 40% by Day 28is assumed. Sirukumab is assumed 
to reduce the mortalit y with an absolute difference of 20%: from a mortality  rate of 40% in 
the control arm to 20% (50% relative reduction) .
Under these assumptions, at least 111 participants with confirmed critical COVID -19 disease are 
required to have at least 80% power to demonstrate a difference with the log-rank test, at a 
significance level of 5% two- sided. 
The proportion of participants with a clinical improvement of at least 2 categories at Day 28 is a 
key secondary  endpoint. Based on simulations using the above assumptions, the rate with clinical 
improvement a t Day  28 in the control arm is expected to be 30%. T he targeted treatment effect is 
an absolute increase of 25% (from 30% in the control arm to 55% in the sirukumab arm) on this 
key secondary  endpoint . The mortality  by Day  28 is considered another key  secondary  endpoint.
The targeted treatment effect is an absolute reduction in mortality  by 25% (from 40% in the control 
arm to 15% in the sirukumab arm). Under the aforementioned assumptions and with a sample size 
of 111, at least 80% power is obtained forboth key secondary  endpoints a 1-sided significance 
level of 5% .
9.3. Populations for A nalysisSets
For purposes of analy sis, the following populations are defined:
The efficacy  endpoints will be analyzed on the Intent -to-Treat (ITT) and by randomized treatme nt. 
The ITT set consists of all participant s who were randomized and treated.
The primary  and key  secondary  anal yses will be tested on the participants with confirmed critical 
COVID -19 disease. 
All safet y endpoints will be evaluated on the Safety  Population which consists of all randomized 
participant s who received study  intervention and will be anal yzed by actual treatment.
Pharmacokinetic data will be evaluated on participants in the I TT set who received sirukumab.
9.4. Statistical A nalyses
The statistical analy sis plan will be finalized prior to database lock of the primary  analysis and it 
will include a more technical and detailed description of the statistical analy ses described in this 
section. This section is a summary  of the planned statistical analyses of the most important 
endpoints including primary  and key  secondary  endpoints.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Status: Approved ,Date: 17 February 2021An IA was performed when approximately  20% of the planned number of participants with 
confirmed severe and critical COVID -19 disease have reached Day 28, or discontinued earlier 
from the study  (refer to Section. 9.5).
The primary  anal ysis will be done when all participants reached Day  28or discontinued earli er. 
The final analy sis will be done when all participants completed the study . 
A hierarchical testing strategy  will be used for the primary  and key  secondary  endpoints. 
First, the primary  endpoint will be tested for superiority  of sirukumab over placebo at the 2 -sided 
5% significance level. If superiorit y is shown on the primary  endpoint, then the proportion of 
participants with a clinical improvement of at least 2 catego ries at Day 28 will be tested at the 
1-sided 5% significance level. If superiorit y on this endpoint is shown, the mortality  by Day 28 
will be tested, again at the 1 -sided 5% significance level.
9.4.1. General Considerations
For all participant s who receive study  drug descriptive statistics will be provided. All demographic 
characteristics (eg, age, race, ethnicit y, height, body  weight, body  mass index) and other initial 
participant characteristics (eg, medical and surgical history , concomitant diseases) will be 
tabulated and anal yzed descriptivel y.
Subgroup analyses will be performed based on the stratification factors (age [<65 and ≥65 years 
of age] and use of invasive mechanical ventilation [y es/no]) and a selection of the major baseline 
parameters.
A DMC will beestablished as noted in Committees Structure in Section 10.4.6 Committees 
Structure .
9.4.2. Primary  Endpoint
The primary  efficacy  analysis will be based on the ITT analysis set restricted to participants with 
confirmed critical COVID -19 disease and the primary  efficacy  endpoint is the ‘time to 
improvement of at least 2 categor iesrelative to Baseline on a 6-point ordinal clinical recovery 
scale’. The improvement should be sustained until Day  28 (or discharge/discontinuation) .Time to 
clinical improvement will be assessed during the 28-day period after study  drug administration, 
with failure to reach clinical improvement or death before Day  28 considered as right -censored at 
Day 28. 
This primary parameter will be analyzed by a stratified log-rank test (using the stratification 
factor s). Kaplan -Meier curves, overall and by stratum will be used to graphicall y present the 
primary  parameter. The sensitivity  anal yseswill be defined in the statistical ana lysis plan. 
First, the primary  endpoint will be tested for superiority  of sirukumab o ver placebo at the 2 -sided 
5% significance level. If superiority  is shown on the primary  endpoint, then the key secondary 
endpoint swill be tested at the 1-sided 5% significance level. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Status: Approved ,Date: 17 February 20219.4.3. Secondary  Endpoint s
Key and other secondary endpoints will be analy zed graphically  and descriptively  as described in 
the statistical analy sis plan. For continuous variables, descriptive statistics (n, mean, SD, median, 
minimum, maximum , and 95% confidence intervals [CIs]) will be calculated. For categorical 
variables , frequency  tables and corresponding 95% CI s will be presented. 
9.4.3.1. Key Secondary  Endpoint s
The key secondary  endpoints will be analy zed using the Cochrane -Mantel -Haenszel (CMH) test 
for difference in proportions.
9.4.4. Other Secondary  Endpoints
To compare the proportion of participants with an improvement of at least 1 category  relative to 
Baseline on the 6-point ordinal clinical recovery scale relative to Baseline , the proportion of 
participants with a worse score relative to Baseline on the 6 -point ordinal clinical recovery  scale ,
the proportion of participants who progress to mechanical ventilation (for participants not on 
mechanical ventilation at baseline), and the mortality  rates defined as category  6 on the 6-point 
ordinal clinical recovery scale , the difference in cumulative incidence at Day 28 will be estimated 
using the same techniques as for the key  secondary  endpoints.
Total length of hospitalization, total time on invasive mechanical ventilation, number of ventilation 
free days, and total time on ECMO will be analy zed by the stratified Wilcoxon Rank- Sum test and 
using the stratification factors. Corresponding 95% CIs will be derived using the Hodges -Lehmann 
approach. 
Time to improvement of at least 1categor yand other ‘time to event’ parameters will be anal yzed 
using the stratified log-rank test.
The distribution of outcomes on the 6-point ordinal clinical recovery  scale will be described via 
plots (eg, stacked bar plots representing the proportion of participants in each category , by 
treatment arm and over time).
A proportional odds model will be used to analyze the 6-point ordinal clinical recovery  scale of 
the clinical status atDays7, 14, 21 and 28. 
Drugs used in the SOC at baseline and c hanges in the SOC after treatment administration will be
tabulated b y treatment group.
The primary  and secondary  endpoint evaluation will be conducted on the ITT population and on 
the ITT population restricted to the population with confirmed critical COVID -19 disease . 
Analy ses of qualitative comparison between pre-interim analysis and post-interim analysis for 
treatment effect in the population with confirmed critical COVID -19 disease will be conducted to 
check the consistency  in the study . This qualitative assessment will be limited to primary  and key  
secondar y endpoints only.
Other secondary  parameters might be added in the SAP.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Status: Approved ,Date: 17 February 20219.4.5. Exploratory  Endpoint(s) 
Time to viral negativity  will be anal yzed analogously  to that of the primary  efficacy  parameter.
SARS -CoV -2 viral load in NP swabs and in endotracheal, blood, and stool samples will be 
measured by a qRT-PCR assay . These data will be analyzed graphically  and descriptivel y as 
described in the statistical analysis plan. 
Other exploratory  parameters might be added in the SAP.
9.4.6. Safety  Analyses
All safet y analyses will be made on the Safet y Population and on participants with confirmed 
(a)critical and (b) severe or critical COVID- 19 disease .
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the Medical Dictionary  for Regulatory  Activities (MedDRA). Any AE occurring at or after 
the initial administration of study  intervention is considered to be treatment -emergent. All reported
AEs will be included in the analy sis. For each AE, the percentage of participants who experience 
at least 1 occurrence of the given event will be summarized by  intervention group.
Summaries, listings, datasets, or participant narratives may  be provided, as appropriate, for those 
participants who die, who discontinue intervention due to an AE, or who experience a grade 3 or 
4 AE,a serious AE, or an adverse event of special interest (AEOI) .
The incidence of participants with SAEs, the incidence of participants with grade 3 or 4 AEs, the 
incidence of partic ipants with severe or life-threatening, bacterial, invasive fungal, viral or 
opportunistic infections (other than SARS -CoV-2), the incidence of grade 3 and 4 neutropenia and 
lymphocy topenia, and the incidence of increased ALT ≥3xULN combined with increased bilirubin 
>2xUL Nwill bereported. Increase of AL T or AST  combined with increase of bilirubin will be 
investigated b y means of evaluation of drug -induced serious hepatotoxicity  (eDISH) plots .
Clinical Laboratory Tests
Laboratory  data will be summarized by  type of laboratory  test. The laboratory  abnormalities will 
be determined per the criteria specified in the DMID Adult Toxicity  Table (Section 10.8, Appendix
8) and in accordance with the normal ranges of the clinical laboratory  if no gradings are available . 
Tables showing n and percent of participants with treatment -emergent worst toxicity  grades (for 
tests with defined toxicity  grades) and treatment -emergent worst abnormalities (for tests without 
defined toxicity  grades) during treatment phase will be generated .A listing of participants with 
any laboratory  results outside the reference ranges will be provided. A listing of participants with 
any markedly abnormal laboratory  results will also be provided.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Status: Approved ,Date: 17 February 2021Electrocardiogram
Electrocardiogram data will be summarize d by ECG parameter . Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
Vital Signs
Vital signs including temperature , pulse/heart rate, respiratory  rate, and blood pressure (systolic 
and diastolic) will be summarized over time, using descriptive statistics and/or graphicall y. The 
percentage of participants with values bey ond clinically  important limits will be summarize d.
9.4.7. Other A nalyses
Pharmacokinetic Analyses 
Serum sirukumab concentrations will be summarized using descriptive statistics. The 
concentrations below the lowest quantifiable sample concentration of the assay  will be treated as 
zero in the summary  statistics. All concentrations below the lowest quantifiable sample 
concentration of the assay  or missing data will be labeled as such in the concentration data listing 
or statistical anal ysis dataset. 
If feasible, population PK analy sis of serum concentr ation- time data of sirukumab may be 
performed using nonlinear mixed -effects modeling. Data may be combined with other selected 
studies to support a relevant structural model. Available baseline participant characteristics (eg, 
demographics, laboratory variables) may be tested as potential covariates affecting PK parameters. 
The results of the population PK analy sis will be presented in a separate report. 
Biomarkers Analyses 
Analy sis of the relationship between various blood biomarkers, such as cytokines, and viral 
parameters, immunogenicity , safet y and clinical outcome may be conducted.
Descriptive statistics for actual values and ( relative ) changes from baseline for the different blood 
biomarkers assessed, will be tabulated for each biomarker at each applicable time point specified 
in the Schedule of Activities (SoA) . Statistics include n, mean, SD, geometric mean, median, 
minimum, and maximum.
Statistical approaches to explore correlations between clinical outcome and blood biomarkers vary 
and depend on the different data types of the applied technology  platforms, as well as on the extent 
of observed differences between participant s. Analy ses will be conducted at the sponsor’s 
discretion and may  be reported separatel y from this study . 
Immunogenicity Analyses
The incidence of antibodies tosirukumab will be summarized for all participants in the ITT 
population with appropriate samples for detection of antibodies to sirukumab (ie, participants with 
at least predose and the Day  28 sample obtained ). 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Status: Approved ,Date: 17 February 2021Virology Analyses 
SARS -CoV -2 viral load summaries will be presented with descriptive statistics by intervention 
arm. If the virology  endpoint is continuous, the descriptive statistics will include the number of 
participants, mean, standard deviation (SD), median, and range. If the virology  endpoint is binary 
or categorical, the frequency  distribution with the number and percentage of participants in each 
category  will be calculated. For time-to-event variables, a summary  table including number of 
participants included in the analysis, number of participants censored, 25thand 75thpercentiles and 
median time-to event will be shown by intervention arm. Graphic displays will also be used to 
summarize the data. Comparison between viral load in NP, endotracheal, blood and stool samples 
might be performed.
Amino acid and/or nucleic acid substitutions in the SARS -CoV -2 genome will be tabulated and 
described.
Additional exploratory  characterization may  be performed and reported separately.
Pharmacodynamic Analyses 
Associations between baseline levels of biomarkers, immunogenicit y tests, PK parameters and 
clinical response (primary endpoint and a selection of secondary  endpoints) will be explored. 
More details will be provided in the statistical analysis plan.
Pharmacogenomic Analyses 
DNA samples will beanaly zed if it is hypothesized that this may help resolve issues with the 
clinical data. 
DNA samples will be used for research related tothe IL-6 gene, sirukumab , orSARS -CoV -2 
infection . Pharmacogenomic research may consist of the anal ysis of one or more candidate genes ,
of the anal ysis of genetic markers throughout the genome ,or theanalysis of the entire genome (as 
appropriate) to evaluate potential genetic associations with prognosis of clinical outcomes in 
patients and prediction of responsivenes s to active treatment.
Results will be presented in a separate report.
9.5. Interim A nalysis
A non-binding unblinded IAfor futility was performed by the sponsor on the primary  endpoint 
when approximately 20% of the planned number of participants with confirmed severe and critical 
COVID -19 disease hadreached Day 28 or discontinued earlier.
The randomization codes and the translation of randomization codes into treatment and control 
groups wasdisclosed to those authorized and only for those participants included in the IA.The 
following implementation was followed for the non-binding IA for futility while considering the 
severe and critical participants in the study .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Status: Approved ,Date: 17 February 2021The futility  criterion was based on the conditional power approach for the primary  endpoint. The 
conditional power wascalculated for the primary  hypothesis using the observed data and assuming 
a mortality  rate of 30% in the control arm versus 21% in the sirukumab arm in the remaind er of 
the study . The effect size and outcomes for the primary endpoint in the survivors wassimulated as 
used for the study  sample size calculation. A non-binding futility  stopping boundary  of 80% for 
the conditional power wasused. Assuming the outcome for the primary  endpoint as used for the 
sample size calculations was true, with a 30% mortality  rate in the control arm, the chance of 
stopping for futility at the time of the IA was2.5%. Otherwise, if the null hypothesis was true and 
again with a 30% mort ality rate in the control arm, the chance of stopping for futility  was60%. If, 
at the time of the IA, the probability of a successful study was lower than the futility  boundary , the 
sponsor could have takenthe decision to stop for futility  after evaluati on of all available data. In 
addition to the conditional power calculations, descriptive analyses of the primary  and key 
secondary  endpoints wereperformed on the available data. The safet y outputs planned for the 
regular DMC safet y reviews will be provide d too.
No additional non-binding IA for futility  is planned for the critical participants to be enrolled in 
the remainder of the study .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Status: Approved ,Date: 17 February 202110. SUPPORTING DOCUMENTA TION A ND OPERA TIONA LCONSIDERA TIONS
10.1. Appendix 1: Abbrev iations and Definitions
AE adverse event
AEOI adverse event of interest
AESI adverse event of special interest
ALI acute lung injury
ALP Alkaline phosphatase
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
ARDS acute respiratory distress syndrome
AST aspartate aminotransferase
AxMP Auxiliary Medicinal Product (also known as NIMP)
BAL bronchoalveolar lavage
BIPAP bilevel positive airw ay pressure
BUN blood urea nitrogen
CAR chimeric antigen receptor
CDC Center of Disease Control and Prevention
CI confidence interval
CMH Cochrane -Mantel -Haenszel
COVID -19 coronavirus disease 2019
CPAP continuous positive airway pressure
CPK creatine phosphokinase
CRF case report form(s) (paper or electronic as appropriate for this study)
CRP C-reactive protein
CRS cytokine release syndrome
CRS cytokine release syndrome
CT computerized tomography
D day
DBP diastolic blood pressure
DMC data monitoring committee
ECG electrocardiogram
ECMO extracorporeal membrane oxygenation
eCRF electronic case report form
eDC electronic data capture
eDISH evaluation of drug -induced serious hepatotoxicity
EOT end of trial
eQTL expression quantitative trait locus
FiO 2 percentage of inspired oxygen
FOIA Freedom of Information Act
GCP Good Clinical Practice
GCS Glasgow coma scale
gG1κ Immunoglobulin G1 kappa 
GGT gamma -glutamyltransferase
gp glycoprotein
GVHD graft -versus -host disease
HDL high-density lipoprotein
HIV human immunodeficiency virus
IB Investigator’s brochure
ICF informed consent form
ICH International Conference on Harmonisation
ICU intensive care unit
IEC Independent Ethics Committee
IL interleukin
IL6R IL-6 receptor 
IMP Investigational Medicinal Product
IND Investigational New Drug
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Status: Approved ,Date: 17 February 2021INR international normalized ratio
IRB Institutional Review Board
ITT intent -to-treat
IV intravenous
IWRS interactive web response system
JAK Janus activated kinase
Kd equilibrium dissociation constant
LDH lactate dehydrogenase
LDL low-density lipoprotein
mAb monoclonal antibody
MCH mean corpuscular hemoglobin
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
MERS -CoV Middle East respiratory syndrome coronavirus
MT mid-turbinate
NIMP Non-Investigational Medicinal Product
NP nasopharyngeal
PaCO2 partial pressure of carbon dioxide in arterial blood
PaO 2 partial pressure of oxygen in arterial blood
PBO placebo
PCR polymerase chain reaction
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PQC Product Quality Complaint
PT prothrombin time
PTT partial thromboplastin time
QTcB QT interval corrected for heart rate using Bazett’s formula
QTcF QT interval corrected for heart rate using Fridericia’s formula
RBC red blood cell
RT-PCR reverse -transcriptase polymerase chain reaction
SAA serum amyloid A
SAE serious adver se event
SAP statistical analysis plan
SARS severe acute respiratory syndrome
SARS -CoV( -2) severe acute respiratory syndrome coronavirus (2)
SBP systolic blood pressure
sIL-6R soluble form of IL -6 receptor 
SNP single -nucleotide polymorphisms
SoA Schedule of Activities
SOC standard of care
SpO 2 peripheral capillary oxygen saturation
STAT -3 signal transducer and activator of transcription 3
SUSAR suspected unexpected serious adverse reaction
US United States
W week
WBC white blood cell
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 85
Status: Approved ,Date: 17 February 2021Definitions of Terms
Critical COVID -19 disease Requires supplemental oxygen delivered by nonrebreather mask or high -flow nasal 
cannula OR use of non -invasive or invasive ventilation OR requiring treatment in an 
ICU.
Severe COV ID-19 disease Requires supplemental oxygen administration by nasal cannula, simple face mask, 
or other similar oxygen delivery device (ie, above pre- COVID baseline oxygen 
requirement, if any, by the participant).
Study Interventions
Sirukumab (CNTO136) Sirukumab solution for infusion (100 mg/mL) at a dose of 5 mg/kg injected into a 
50mL dextroseabag (5% dextrose) with the total volume of the bag adjusted to 
50mL. 
placebo 50 mL dextroseibag (5% dextrose) w ithout any substance injected in the bag.
                                                
aDextrose is also commonly known and referred to as glucose.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 86
Status: Approved ,Date: 17 February 202110.2. Appendix 2: Clinical Laboratory  Tests
The following tests will be performed according to the Schedule of Activities bylocal laboratories
unless specified otherwise .
Protocol -Required Laboratory Assessments
Laboratory 
AssessmentsParameters Tests to be done by a
Local 
laboratoryCentral 
laboratory
Safety 
assessments
Hematology Platelet count
Red blood cell 
count
Hemoglobin
HematocritRBC Indices:
MCV
MCH
% 
ReticulocytesWhite Blood Cell 
(WBC) count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsAll tests
Note: A WBC evaluation may include any abnormal cells, 
which will then be reported by the laboratory. A RBC 
evaluation may include abnormalities in the RBC count, 
RBC parameters, or RBC morphology, which will then be 
reported by the laboratory. In addition, any other abnormal 
cells in a blood smear will also be reported.
Blood
ChemistrySodium
Potassium
Chloride
Bicarbonate
Calcium
Phosphate
Magnesium
Blood urea nitrogen (BUN)
Creatinine
Aspartate aminotransferase 
(AST)/Serum glutamic -
oxaloacetic transaminase
Alanine aminotransferase 
(ALT)/Serum glutamic -
oxaloacetic pyruvic 
transaminase
Alkaline phosphatase (ALP)
Total bilirubin
Conjugated bilirubin (direct)b
Unconjugated bilirubin 
(indirect)bCreatine phosphokinase 
(CPK)
Lactic acid 
dehydrogenase (LDH)
Lactate
Albumin
Total protein
Glucose
Troponin I or T
Total cholesterol
LDL
HDL
TriglyceridesAll tests
Coagulation 
testsProthrombin time (PT) and international normalized ratio 
(INR) or, activated partial thromboplastin time (aPTT), 
fibrinogenAll tests
Arterial 
blood gasespH, PaO 2, PaCO 2(as per local SOC, collect if available) All tests
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Status: Approved ,Date: 17 February 2021Laboratory 
AssessmentsParameters Tests to be done by a
Local 
laboratoryCentral 
laboratory
Other Tests
 Urine pregnancy testing for all women of childbe aring 
potential (at screening, baseline, and Day 28 or at day 
of discharge ).Alltests
 Bacterial, fungal, or viral infection testing (as per local 
SOC).Alltests
 NP swabs to determine SARS -CoV -2 positivity, refer 
to the Schedule of Activities (SoA) for more detailsa.Any time 
before 
randomiza t
ion
 NP swabs for infections testing (PCR quantification 
of SARS -CoV -2 and multiplex PCR for detection of 
co-infections).All time
points as 
from Day 1
 Endotracheal aspirate (only if intubated) for virology 
testing (PCR SARS -CoV -2).Any time 
before 
randomizat
ionAll time
points as 
from Day 1
 Stool sample (if feasible) for virology.
 Blood samples for SARS -CoV -2viremia.
 Blood samples for cellular profiling.
 Blood samples for RNA profiling.
 Whole blood for DNA profiling (optional).
 Pharmacology samples (including testing for IL-6 and 
antibodies to sirukumab).
 Blood samples to evaluate biomarkers .
 Blood samples for SARS -CoV -2specific antibodies.
 CRP, Ferritin, D -dimer, Procalcitonin.All time
points
a.SARS -CoV- 2 positivity should be documented based on local testing on any specimen, by RT -PCR any time 
before randomization. This might require a local test using a NP sw ab obtained at screening .
b.Only if ALT or AST >3xULN or if 3x the entry level (if these w ere >ULN) .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Status: Approved ,Date: 17 February 202110.3. Appendix 3: Clinical and Laboratory  Assessments Described per Day
From Screening to Baseline
Screening 
Phasea
Day Screening 1 (Baseline)
General Screening/Baseline assessments
ICFcX
Inclusion/Exclusion criteria X Xd
Dem ographics, medical historyeX
Targeted physical examhX
Treatm ent administration
RandomizationiX
Administration of study interventioniX
Concom itant medication
Concomitant medication recording X X
Respiratory function related assessments
Type of supplemental oxygen X X
Resting SpO 2, FiO 2(if any)jX X
Arterial pH, PaO 2, PaCO 2jAs available per day
Level of consciousness (Glasgow comascale score)kX X
Pulmonary X -ray (or CT imaging or lung ultrasound if X -ray not available) Xg,bb
General safety related assessments
Standard 12 -lead ECG Xg bb
Vital signs (body temperature, pulse, SBP/DBP, respiratory rate) X X
Any AE X X
Safety laboratory assessmentsdd
Hem atologylXgX
Chemistr y: General SafetylXgX
Chem istry:Total Cholesterol, LDL, HDL, Triglycerides XgX
Coagulatio n: PT T/INR or aPTT ,fibrinogen XgX
Pregnancy assessment urinefXgX
Bacterial, fungal, viral infection testing (blood, other)mPer SOC, any infection to be reported as 
AESI
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Status: Approved ,Date: 17 February 2021Screening 
Phasea
Day Screening 1 (Baseline)
Virology Assessments
Blood sample for SARS -CoV -2 viremia X●
Nasopharyngeal swab for infections testing (PCR quantification of SARS -CoV- 2 and multiplex PCR for 
detection of co -infections)p,q Xq,rX●,s
If participants are intubated, an endotracheal sample for quantification of SARS -CoV -2is to be taken in addition 
to the NP sw abt Xq,rX●,s
Stool sample (if feasible) X●,bb
Biom arker/Pharmacology Assessmentsdd
CRP, Ferritin, D -dimer, Procalcitonin X●
Blood samples for cytokines, chemokines X●
Blood samples for various biomarkers X●
Blood sample for SARS -CoV -2 specific antibodies X●
Blood samples for pharmacologywX●predose    / X●postdose
Blood samples for cellular profiling X
Exploratory Biom arkers/Pharm acogenomicsdd
PAXgene blood for RNA profilingxX●
Whole blood for DNA profiling (optional)yX●,z
●Laboratory testing to be performed centrally .
Note : If multiple a ssessments are scheduled for the same timepoint, it is recommended that procedures be performed in the following sequence: EC G, oxygen 
saturation, vital signs, blood sampling.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Status: Approved ,Date: 17 February 2021Hospitalization Follow -Up Day 2 until Day 14
Hospital Follow -Up (Day)
Day 2 3 4 5 6 7 8 9 10 11 12 13 14
Week 1 2
General Screening/Baseline assessments
Targeted physical examhX X X X X X X X X X X X X
Any clinically significant findings to be reported
Concom itant medication
Concomitant medication recording X X X X X X X X X X X X X
Respiratory function related assessments
Type of supplemental oxygen X X X X X X X X X X X X X
1x per day
Resting SpO 2, FiO 2(if any)jX X X X X X X X X X X X X
Minimum 4x per day
Arterial pH, PaO 2, PaCO 2jX X X X X X X X X X X X X
As available per day
Level of consciousness 
(Glasgow comascale score)kX X X X X X X X X X X X X
1x per day in I CU
Pulmonary X -ray (or CT imaging or lung 
ultrasound if X -ray not available)X X X X X X X X X X X X X
Per SOC, report upon w orsening and last available
General safety related assessments
Standard 12 -lead ECG Once between Day 4and Day 8
Vital signs (body temperature, pulse, 
SBP/DBP, respiratory rate)X X X X X X X X X X X X X
Per SOC, minimum 4x per day in ICU/ 1x per day non -ICU
Any AE X X X X X X X X X X X X X
Record discharge from ICU, discharge 
from hospitalX X X X X X X X X X X X X
As applicable
Safety l aboratory assessmentsdd
Hem atologylX X X
Chemistry general safetylX X X
Bacterial, fungal, viral infection testing 
(blood, other)mX X X X X X X X X X X X X
Per SOC, any infection to be reported as AESI
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 91
Status: Approved ,Date: 17 February 2021Hospital Follow -Up (Day)
Day 2 3 4 5 6 7 8 9 10 11 12 13 14
Week 1 2
Virology Assessments
Blood sample for SARS -CoV -2 viremia X●X●
Nasopharyngeal swab for infections 
testing (PCR quantification of SARS -
CoV- 2 and multiplex PCR for detection of 
co-infections)p,qX●(X●) (X●) X●(X●) X●X●
If participants are intubated, an 
endotracheal sample for quantification of 
SARS -CoV-2 is to be taken in addition to 
the NP swabtX●(X●) (X●) X●(X●) X●X●
Stool sample (if feasible) X●(X●) (X●) X●(X●) X●X●
Biom arker/Pharmacology Assessmentsdd
CRP, Ferritin, D -dimer, Procalcitonin X●X●X●X●
Blood samples for cytokines, chemokines X●X●
Blood samples for various biomarkers X●
Blood sample for SARS -CoV -2 specific 
antibodiesX●
Blood samples for pharmacologywX●
Blood samples for cellular profiling X●
Exploratory Biom arkers/Pharm acogenomicsdd
PAXgene blood for RNA profilingxX●
●Laboratory testing to be performed centrally .
Note : If multiple assessments are scheduled for the same timepoint, it is recommended that procedures be performed in the following sequence: ECG, oxygen 
saturation, vital signs, blood sampling
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 92
Status: Approved ,Date: 17 February 2021.Hospitalization Follow -Up Day 15 until Day 28
Hospital Follow -Up (Day)
Day 15 16 17 18 19 20 21 22 23 24 25 26 27 28b
Week 3 4
General Screening/Baseline assessments
Targeted physical examhX X X X X X X X X X X X X X
Any clinically significant findings to be reported
Concom itant medication
Concomitant medication recording X X X X X X X X X X X X X X
Respiratory function related assessments
Type of supplemental oxygen X X X X X X X X X X X X X X
1x per day
Resting SpO 2, FiO 2(if any)jX X X X X X X X X X X X X X
Minimum 4x per day
Arterial pH, PaO 2, PaCO 2jX X X X X X X X X X X X X X
As available per day
Level of consciousness 
(Glasgow comascale score)kX X X X X X X X X X X X X X
1x per day in ICU
Pulmonary X -ray (or CT imaging or 
lung ultrasound if X -ray not available)X X X X X X X X X X X X X X
Per SOC, report upon w orsening and last available
General safety related assessments
Vital signs (body temperature, pulse, 
SBP/DBP, respiratory rate)X X X X X X X X X X X X X X
Per SOC, minimum 4x per day in ICU, 1x per day non -ICU
Any AE X X X X X X X X X X X X X X
Record discharge from ICU, discharge 
from hospitalX X X X X X X X X X X X X X
As applicable
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 93
Status: Approved ,Date: 17 February 2021Hospital Follow -Up (Day)
Day 15 16 17 18 19 20 21 22 23 24 25 26 27 28b
Week 3 4
Safety l aboratory assessmentsdd
Hem atologylX X
Chemistry general safetylX X
Chem istry: Total Cholesterol, LDL, 
HDL, Triglycerides
Coagulatio n: PT T/INR or aPTT ,
fibrinogen
Pregnancy assessment urinefX
Bacterial, fungal, viral infection testing 
(blood, other)mX X X X X X X X X X X X X X
Per SOC, any infection to be reported as AESI
Virology Assessments
Blood sample for SARS -CoV -2 viremia X●
Nasopharyngeal swab for infections 
testing (PCR quantification of SARS -
CoV- 2 and multiplex PCR for detection 
of co -infections)p,qX●X●,u,v
If participants are intubated, an 
endotracheal sample for quantification 
of SARS -CoV -2is to be taken in 
addition to the NP sw abtX●X●,u,v
Stool sample (if feasible) X●X●
Biom arker/Pharmacology Assessmentsdd
CRP, Ferritin, D -dimer, Procalcitonin X●X●
Blood samples for cytokines, 
chemokinesX●X●
Blood samples for various biomarkers X●
Blood sample for SARS -CoV -2 specific 
antibodiesX●
Blood samples for pharmacologywX●X●
Blood samples for cellular profiling X●
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 94
Status: Approved ,Date: 17 February 2021Hospital Follow -Up (Day)
Day 15 16 17 18 19 20 21 22 23 24 25 26 27 28b
Week 3 4
Exploratory Biom arkers/Pharm acogenomicsdd
PAXgene blood for RNA profilingxX●
●Laboratory testing to be performed centrally .
Note : If multiple assessments are scheduled for the same timepoint, it is recommended that procedures be performed in the following sequence: ECG, oxygen saturation, 
vital signs, blood sampling.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 95
Status: Approved ,Date: 17 February 2021Hospitalization after Day 28, Discharge/Discontinuation Visit after Day 28, and Post -Hospitalization Follow -Up
Hospital 
Follow -UpDischarge / Discontinuation Visit Post-hospitalization Follow -Up Phone Call 
DayAfter Day 28b
(ifhospitalized ) Discharge 
uptoDay 28aaDischarge post 
Day 28aaDay 28 if
discharged 
earlier ( ±3
days)Day 56
(±7 d ays)Day 84
(±7 d ays)Day 112
(±7 d ays)
WeekEvery Week
(Once on the day of 
assessment unless 
specified differently 
below)Week 4 Week 8 Week 12 Week 16
General Screening/Baseline assessments
Targeted physical examhX X X
Any clinically significant findings to be reported
Concom itant medication
Concomitant medication recording X X X XnXnXnXn
Respiratory function related assessments
Type of supplemental oxygen X X X
Resting SpO 2, FiO 2(if any)jX X X
Minimum 4x per day on the day of assessment
Arterial pH, PaO 2, PaCO 2jX X X
As available per day
Level of consciousness (Glasgow  
coma scale score)kX (if still in 
ICU)
Pulmonary X -ray (or CT imaging 
or lung ultrasound if X -ray not 
available)X X X
per SOC, report upon w orsening and last available
General safety related assessments
Vital signs (body temperature, 
pulse, SBP/DBP, respiratory rate)X X X
Any AE X X X XnXnXnXn
Record discharge from ICU, 
discharge from hospitalAs applicable As applicable As applicable
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 96
Status: Approved ,Date: 17 February 2021Hospital 
Follow -UpDischarge / Discontinuation Visit Post-hospitalization Follow -Up Phone Call 
DayAfter Day 28b
(ifhospitalized ) Discharge 
uptoDay 28aaDischarge post 
Day 28aaDay 28 if
discharged 
earlier ( ±3
days)Day 56
(±7 d ays)Day 84
(±7 d ays)Day 112
(±7 d ays)
WeekEvery Week
(Once on the day of 
assessment unless 
specified differently 
below)Week 4 Week 8 Week 12 Week 16
Safety l aboratory assessmentsdd
Hem atologylXccX X
Chemistry general safetylXccX X
Chem istryl: Total Cholesterol, 
LDL, HDL, TriglyceridesX X
Coagulatio n: PT T/INR or aPTT ,
fibrinogenX X
Pregnancy assessment urinefX
Bacterial, fungal, viral infection 
testing (blood, other)mX X X
per SOC, any infection to be reported as AESI
Virology Assessments
Blood sample for SARS -CoV -2 
viremiaX●X●X●
Nasopharyngeal swab for 
infections testing (PCR 
quantification of SARS -CoV- 2 and 
multiplex PCR for detection of co -
infections)p,qX●X●,u,vX●,u,vX●,vX●,vX●,v
If participants are intubated, an 
endotracheal sample for 
quantification of SARS -CoV-2 is 
to be taken in addition to the NP 
swabtX●
Stool samp le (if feasible) X●X●X●
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 97
Status: Approved ,Date: 17 February 2021Hospital 
Follow -UpDischarge / Discontinuation Visit Post-hospitalization Follow -Up Phone Call 
DayAfter Day 28b
(ifhospitalized ) Discharge 
uptoDay 28aaDischarge post 
Day 28aaDay 28 if
discharged 
earlier ( ±3
days)Day 56
(±7 d ays)Day 84
(±7 d ays)Day 112
(±7 d ays)
WeekEvery Week
(Once on the day of 
assessment unless 
specified differently 
below)Week 4 Week 8 Week 12 Week 16
Biom arker/Pharmacology Assessmentsdd
CRP, Ferritin, D -diner, 
ProcalcitoninX●,ccX●X●
Blood samples for cytokines, 
chemokinesX●
Blood samples for various 
biomarkersX●
Blood sample for SARS -CoV -2 
specific antibodiesX●
Blood samples for pharmacologywX●
Blood samples for cellular 
profilingX●
Exploratory Biom arkers/Pharm acogenomicsdd
PAXgene blood for RNA 
profilingxX●
Phone call assessments
Record vital statusoXnXnXnXn
Self-reported oxygen needed 
(yes/no)XnXnXnXn
Self-reported pregnancy status XnXnXnXn
Record readmission(s) post 
discharge and reasonXnXnXnXn
●Laboratory testing to be performed centrally .
Note : If multiple assessments are scheduled for the same timepoint, it is recommended that procedures be performed in the following se quence: ECG, oxygen 
saturation, vital signs, blood sampling.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 98
Status: Approved ,Date: 17 February 2021Abbreviations: AE: adverse event, AESI: adverse event of special interest; aPPT: activated partial thromboplastin 
time; CRP: C-reactive protein; CT: computed tomography; DBP: diastolic blood pressure; FiO 2:percentage of 
inspired oxygen; ECG: electrocardiogram; HDL: low-density lipoprotein; ICF: informed consent form; ICU: i ntensive 
care unit; INR: international norm alized ratio; LDL: low-density lipoprotein; PaCO 2: partial pressure of carbon 
dioxide in arterial blood; PaO 2: partial pressures of oxygen in arterial blood; PCR: polymerase chain reaction; PT: 
prothrombin time; S AE: serious adverse event; SBP: systolic blood pressure; SOC: standard of care; SpO 2: peripheral 
capillary oxygen saturation.
Footnotes:
a.Screening assessments start after signing of the ICF and can continue on the next calendar 
day, if needed. All screeni ng and baseline assessments may  also take place on the same day . 
Screening/Baseline assessments required to verify  study eligibility  and data collection for 
assessment of the 6-point ordinal clinical recovery  category  should take place prior to 
randomizati on. All Screening/Baseline procedures should take place prior to study  drug 
administration.
b.The assessment schedule will be on a weekl yfor participants still hospitalized after Day  28.
c.Consent to be obtained before the first study -related activity . An exception is in the case of an 
emergency  enrollment in which the informed consent can be obtained as soon as possible.
d.If a participant's clinical status changes after screening but before randomization such that he 
or she no longer meets all eligibility  criteria, then the participant should be excluded from 
participation in the study .
e.Medical history  should include collecting onset of COVID -19 symptoms, prior therap y, and 
date of SARS -CoV -2 diagnosis if available.
f.A urine pregnancy  test is to be performed in women of childbearing potential only .
g.Results from the blood chemistry , hematology , and coagulation test, pregnancy  test, ECG, and 
pulmonary  imaging , completed as SOC, taken up to 2 days prior to screening will be accepted 
as screening assessments. 
h. T argeted physical examination is to be performed as per local SOC and includes, if feasible, 
lung auscultation and any examination as indicated by the patient’s medical history .Height 
and body  weight are only to be measured at screening if not alread y available in the 
participant’s chart and if practicall y feasible. If not feasible, weight for dose calculation can 
be verball y reported b y the participant or a famil y member.
i.Participants need to receive study  intervention preferabl y within 4 hours but no later than 6 
hours after randomization.
j.Supplemental oxygen/percentage of inspired oxygen (FiO 2) use (if any) will be measured 
(simultaneously  with SpO 2, and at any time of arterial blood gas measurements) to monitor 
the patient’s status regarding gas exchange as applicable. The following will be recorded:
-Oxygen delivery  device (eg, nasal cannula, simple face mask, nonrebreather mask, high 
flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, 
extracorporeal life support, etc).
-Oxygen f low rate in liters/min.
-Record FiO 2 and SpO 2data 4 times per day, and at any time of arterial blood gas 
measurements. Record values that are sustained for at least 1 hour. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 99
Status: Approved ,Date: 17 February 2021-If a patient is using more than one device (eg, extracorporeal life support and invasive 
ventilation), the worst value of FiO 2 (and the corresponding SpO 2-and PaO 2if available -)
on the highest level of intervention will be recorded. The worst (highest) value of FiO 2(and 
the corresponding SpO 2-and PaO 2if available -) on each device will also be recorded 
separately .
-If a patient does not need oxy gen supplementation, this should also be recorded.
k.The final worst score of the Glasgow Coma Scale of the day needs to be recorded in the eCRF. 
The level of sedation of the participant will be derived from the type of medication entered for 
indication sedation on the Concomitant Medication page of the eCRF.
l.Laboratory  testing to be performed includes:
-Hematology : hemoglobin, hematocrit, platelet count, red blood cell (RBC) count, RBC 
indices (mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], % 
reticulocy tes), white blood cell (WBC) count with differential (neutrophils, lymphocy tes, 
monocy tes, basophils, eosinophils).
-General safety  chemistry : total protein, albumin, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, glucose, sodium, 
potassium, calcium, phosphate, magnesium, chloride, bicarbonate, creatinine, blood urea 
nitrogen (BUN), creatine phosphokinase (CPK), lactate dehy drogenase (LDH), lactate, and 
troponin. If ALT or AST >3x ULN or 3x the entry  level (if entry  levels were >ULN) also 
provide conjugated bilirubin (direct), unconjugated bilirubin (indirect).
m.Culture results (bacterial, fungal, or viral) including site of infection and specimen source 
(bronchoalveolar lavage [BAL ], tracheal aspirate, sputum, blood, urine, etc.), performed as 
part of patients’ workup for new infections, should be reported. Analy ses will be performed 
by the local laboratory .
n.For partic ipants discharged or who discontinued the study  prior to Day 28 and did not 
withdraw consent, phone calls will be conducted on Day 28 and during the post Day 28 
Follow -up Phase to record concomitant medication, the vital status, the occurrence of AEs, 
self-reported oxygen need, self-reported pregnancy  status and the history  of readmission since 
last contact.
o.Whenever possible, vital status will be recorded if the patient is alive. If the participant is 
deceased, date and cause of mortality  should be recorde din the eCRF. Death should be 
documented as SAE.
p.NP swabs will be used to collect secretions from participants to explore quantification of viral 
load of SARS -CoV -2. For each participant, NP sampling should be done at approximately  the 
same time (±4 hours ) on each sampling day  and from the same nostril.
q.If an NP sample for detection of SARS -CoV -2 (local SOC) will be collected on the same day 
as the NP sample for quantification of SARS -CoV -2 (central lab), only one NP sample should 
be collected. The sample should be aliquoted and the remaining aliquots of the NP samples 
should be stored and sent to the central lab for quantification of SARS -CoV -2.
r.SARS -CoV -2 positivity  should be documented based on local testing on any specimen, by 
RT-PCR any time before randomization. This might require a local test using an NP swab 
obtained at screening.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 100
Status: Approved ,Date: 17 February 2021s.After randomization, SARS -CoV -2 positivity  will be confirmed in a central lab by quantitative 
RT-PCR. The baseline sample needs to be collected predose, as close as possibl e to dosing.
t.If the participant is intubated, endotracheal samples need to be taken at the same time as the 
NP swab. If taking both NP and endotracheal samples is not feasible, the NP sample should 
be given priorit y.
u.Lab testing for detection of SARS -CoV -2on the NP swab at day of hospital discharge. If 
SARS CoV -2 positive, an additional NP swab will be taken every  7days, if feasible for the 
site and tested, until SARS -CoV -2 negative.
v.If viral RNA is detected in NP samples at day of discharge, all possible efforts will be made 
to follow -up participants and collect samples every  7  d ays until viral RNA is negative, 
considering the current pandemic and related logistical challenges. If possible, home visits by 
a healthcare professional may  be conducted to coll ect samples during the follow- up period.
w.Includes serum samples for measurement of PK, antibodies to sirukumab, and IL-6. On Day 1, 
a predose and a postdose (within 30 minutes after the end of infusion) sample should be 
collected. The postdose sample should be collected from the arm contralateral to that used for 
IV infusion. On Day 1 (predose) and Day 28 the PK, antibodies to sirukumab, and IL-6 will 
be evaluated. On Day  1 (postdose), Day  14, and Day  21 the PK and IL -6 will be evaluated.
x.PAXgene RNA tubes should alway s be used last for an y blood draw.
y.An optional pharmacogenetics blood sample (DNA) will be obtained from those participants 
who gave consent (where local regulations permit).
z.Sample can be also taken at an y other time point after study drug int ervention on Day  1.
aa.For those participants discharged prior to Day 28, all Day 28 assessments should be done at 
day of discharge. Laboratory, virology, relevant respiratory function related assessments, and 
biomarker/pharmacology assessments completed maxi mum 1 day before discharge do not 
need to be repeated on the day of discharge provided that no clinically relevant changes were 
noted in the results and the participant was declared ‘read y to be discharged’ on the day before 
discharge .
bb.Assessments done at screening do not need to be repeated at baseline.
cc.For participants still hospitalized post Day 28, additional blood sampling should be done every 
7 day s(±1 day ) and at day  of discharge.
dd.For all laboratory  tests done on Day 21, Day 28, and every  week thereafter as needed, a 
window of ±1 day  for all sampling is allowed.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 101
Status: Approved ,Date: 17 February 202110.4. Appendix 4: Regulatory , Ethical, and Study Oversight Considerations
10.4.1. Regulatory  and Ethical Considerations
Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  participants are protected, consisten t with the principles that originated in the Declaration of 
Helsinki, and that the study  data are credible.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment b y 
the sponsor. All protocol amend ments must be issued b y the sponsor, and signed and dated b y the 
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
neces sary to eliminate immediate hazards to the participants, in which case the amendment must 
be promptly  submitted to the IEC/I RB and relevant competent authority . Documentation of 
amendment approval b y the investigator and IEC/IRB must be provided to the spo nsor. When the 
change(s) involve onl y logistic or administrative aspects of the study , the IEC/IRB (where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigato r or other physician in attendance will contact the appropriate sponsor representative 
listed in the Contact Information page(s), which will be provided as a separate document. Except 
in emergency  situations, this contact should be made before implementing any departure from the 
protocol. In all cases, contact with the sponsor must be made as soon as possible to discuss the 
situation and agree on an appropriate course of action. The data recorded in the eCRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements are met.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 102
Status: Approved ,Date: 17 February 2021Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study  intervention
to the study  site:
 Protocol a nd amendment(s), if an y, signed and dated by the principal investigator
 A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applica ble, participant compensation programs. This approval must clearly identify  the 
specific protocol by title and number and must be signed (or sealed, where appropriate per 
local regulations) b y the chairman or authorized designee.
 Name and address of the IE C/IRB, including a current list of the IEC/I RB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vot e/opinion 
of the study .
 Regulatory  authority  approval or notification, if applicable
 Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
 Documentation of investigator qualifications (eg, curriculum vitae)
 Completed investigator financial disclosure form from the principal investigator, where 
required
 Signed and dated clinical trial agreement, which includes the financial agreement
 Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first 
participant:
 Completed investigator financial disclosure forms from all subinvestigators
 Documentation of subinvestigator qualifications (eg, curriculum vitae)
 Name and address of any local laboratory  conducting tests for the study, and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
 Local laboratory  documentation demonstrating competence and test reliability  
(eg,accreditation/license), if applicable
Independent Ethics Committee or In stitutional Review Board
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/I RB 
with current and complete copies of the following documents (as required by  local regulations):
 Final protocol and, if applicable, amendments
 Sponsor -approved ICF (and any  other written materials to be provided to the participants)
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 103
Status: Approved ,Date: 17 February 2021 IB (or equivalent information) and amendments/addenda
 Sponsor -approved participant recruiting materials
 Information on compensation for study -related injuries or payment to participants for 
participation in the study , if applicable
 Investigator's curriculum vitae or equivalent information (unless not required, as documented 
by the IEC/IRB)
 Information regarding funding, name of the sponsor, institutional af filiations, other potential 
conflicts of interest, and incentives for participants
 Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
participants, data or study  conduct, unless required locall y), the ICF, applicable recruiting 
materials, and participant compensation programs, and the sponsor has received a copy of this 
approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to t he IEC/IRB for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely  administrative, with no 
consequences for participants, data or stud y conduct)
 Revision(s) to I CF and any  other written materials to be provided to participants
 If applicable, new or revised participant recruiting materials approved by  the sponsor
 Revisions to compensation for study -related injuries or payment to participants for 
participation in the study , if applicable
 New edition(s) of the IBand amendments/addenda
 Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
 Reports of adverse events that are serious, unlisted/unexpected, and associated with the study 
intervention
 New info rmation that may adversel y affect the safety of the participants or the conduct of the 
study
 Deviations from or changes to the protocol to eliminate immediate hazards to the participants
 Report of deaths of participants under the investigator's care
 Notifi cation if a new investigator is responsible for the study  at the site
 Development Safet y Update Report and Line Listings, where applicable
 Any other requirements of the IEC/I RB
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 104
Status: Approved ,Date: 17 February 2021For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for participants, data or study  conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/IRB about 
the study  completion.
Other Ethical Considerations
For stud y-specific ethical design considerations , refer to Section 4.2.1 .
10.4.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
inform ation in accordance with local regulations to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study  and for 1 y ear after completion of the study .
Refer to Required Prestudy  Documentation (above) and contracts for details on financial 
discl osure.
10.4.3. Informed Consent Process 
Consent of e ach participant (or legall y acceptable representative based on local regulations ) must 
be obtained according to local requirements after the nature of the study has been fully explained. 
The informed consent (s) must be obtained before performance of any  study -related activity . The 
ICF(s) that is/are used must be approved by both the sponsor and by the reviewing IEC/I RB and 
be in a language that the participant can read and understand. The informed consent should be in 
accordance with principles that originated in the Declaration of Helsinki, current ICH and GCP 
guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential participants or their legall y acceptable representative (based 
on local regulations) the aims, methods, reasonably anticipated benefits, and potential hazards of 
the study ,and any discomfort participation in the study  may entail. Theywill be informed that 
participation is voluntary and that they may withdraw consent to participate at an y time. They  will 
be informed that choosing not to participate will not af fect the care the participant will receive for 
the treatment of his or herdisease. Finally , they will be told that the investigator will maintain a 
participant identification register for the purposes of long-term follow up if needed and that their 
records may  be accessed by  health authorities and authorized sponsor personnel w ithout violating 
the confidentiality  of the participant, to the extent permitted by the applicable law(s) or regulations. 
For more information on emergency  situations due to COVI D-19, see also Section 4.2.1.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 105
Status: Approved ,Date: 17 February 2021By obtaining the informed consent the participant or legall y acceptable representative (based on 
local regulations) is authorizing such access , which includes permission to obtain information 
about his or her survival status. I t also denotes that the participant agrees to allow his or her study 
physician to recontact the participant for the purpose of obtaining consent for additional safet y 
evaluations, and subsequent disease- related treatments, if needed. 
The participant or legally  acceptable representative (based on local regulations) will be given 
sufficient time to read the ICF and the opportunity  to ask questions. After this explanation and
before entry  into the study , consent should be appropriatel y recorded by means of either the 
participant's or his or her legally  acceptable representative (based on local regulations) personall y 
dated signature. After having obtained the consent, a copy of the ICF must be given to the 
participant.
Where local regulations require, separate consent needs to be obtained for the optional DNA  
component of the study .
If the participant or legally acceptable representative (based on local regulations) is unable to read 
or write, or consent is given verball y by phone, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information) and 
should personally  date and sign the ICF after the oral consent of the participant or legally 
acceptable representative (based on local regulations) is obtained.
When prior consent of the participant is not possible and the participant's legall y acceptable 
representative (based on local regulations )is not available, enrollment procedures should be 
described in the protocol with documented approval/favorable opinion by  the IEC/I RB to protect 
the rights, safety , and well- being of the participant and to ensure compliance with applicable 
regulatory  requirements. The participant or legally  acceptable representative (based on local 
regulations) must be informed about the study  as soon as possible and give consent to continue.
10.4.4. Data Protection
Privacy of Personal Data
The collection and processing of perso nal data from participants enrolled in this study  will be 
limited to those data that are necessary  to fulfill the objectives of the stud y.
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or alteration must be p ut in place. 
Sponsor personnel whose responsibilities require access to personal data agree to keep the identity 
of participants confidential.
The informed consent obtained from the participant or his or her legally  acceptable representative 
(based on local regulations) includes explicit consent for the processing of personal data and for 
the investigator/institution to allow direct access to his or her original medical records (source 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 106
Status: Approved ,Date: 17 February 2021data/documents) for study -related monitoring, audit, IEC/IRB review, andregulatory  inspection. 
This consent also addresses the transfer of the data to other entities and to other countries.
The participant has the right to request through the investigator access to his or her personal data 
and the right to request rectificati on of an y data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  pharmacogen omic and biomarker research is not conducted under standards 
appropriate for the return of data to participants. In addition, the sponsor cannot make decisions as 
to the significance of any findings resulting from exploratory  research. Therefore, explorato ry 
research data will not be returned to participants or investigators, unless required by law or local 
regulations. Privacy  and confidentiality  of data generated in the future on stored samples will be 
protected b y the same standards applicable to all oth er clinical data.
10.4.5. Long -Term Retention of Samples for A dditional Future Research
Samples collected in this study  may be stored for up to 15 y ears (or according to local regulations) 
for additional research. Samples will only be used to understand sirukumab , to understand 
COVID -19, to understand differential intervention responders, and to develop tests/assay s related 
to sirukumab and COVID -19. The research may begin at any time during the study  or the 
post-study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Participants may withdraw their consent for their samples to be 
stored for research (refer to Section 7.2.1 , Withdrawal From the Use of Research Samples ).
10.4.6. Committees Structure
Data Monitoring Committee (DMC)
A DMC will be established to activel y monitor interim data to review the ongoing safety of the 
participants in this study and to make recommendations about early study closure or changes to 
the conduct of the study .This committee will consist of sponsor personnel not directly  involved 
in the conduct of the study  and who have expertise in clinical study  conduct, at least one medical 
expert in the relevant therapeutic area ,at least one statistician and a safety expert . In addition, at 
least 2 exter nal experts, are also included in this DMC. The committee will convene regularl y at 
the discretion of the DMC chair during the study  conduct, according to their charter, to evaluate 
the cumulative safety  data of all participants in the study . The study  responsible physician will 
inform the D MC of an y AE of concern. 
As soon as the first 30 participants with confirmed severe and critical COVID -19 disease had 
received stud y intervention and had at least 7 da ys of follow -upafter study intervention, the D MC 
perform edan interim data review focused on safety . All data available at the time of the interim 
data review wasincluded. During this data review enrollment wascontinued, however, recruitment 
would have been halted should 60 patients had been enrolled before the outcome of the data review 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 107
Status: Approved ,Date: 17 February 2021was known. In case recruitment was halted, it would have been resumed upon a positive 
assessment of results of these interim data b y DMC.
While futility  or stopping of the study  will be based on totality  of emerging safet y data, the D MC 
will consider either of the following non -binding futility  criteria as recommendation for stopping 
the study . 
-Excess mortality  in the treatment arm, beyond the realm of chance (Fisher’s Exact test at a 
1-sided significance level of 10%).
-Excess in “Worsening by at least 1 category ” in the treatment arm, beyond the realm of 
chance (Fisher’s exact test at a 1 -sided significance level of 10%).
A non-binding unblinded IA for futility  was performed by the sponsor on the primary  endpoint 
when approximately  20% of the planned number of participants with confirmed severe and critical 
COVID -19 disease had reached Day 28 or discontinued earlier (see Interim Analysis Section 9.5).
Results have been discussed with the DMC .
The D MC is also instructed to use their assessment of individual cases to evaluate even if data do 
not meet the criteria.
10.4.7. Publication Policy /Dissemination of Clinical Study  Data
All information, including but not limited to information regarding sirukumab or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including pharmacogenomic or exploratory  biomarker 
research data, generated as a result of this study , are considered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and use 
this informatio n only to accomplish this study  and will not use it for other purposes without the 
sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued develo pment ofsirukumab , and thus may be disclosed 
as required to other clinical investigators or regulatory  agencies. To permit the information derived 
from the clinical studies to be used, the investigator is obligated to provide the sponsor with all 
data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain data from all study  sites that participated in the study  as per protocol. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator for the study . Results of PK, 
pharmacogenomic or exploratory  biomarker analy ses performed after the Clinical Study  Report 
has been issue d will be reported in a separate report and will not require a revision of the Clinical 
Study  Report. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 108
Status: Approved ,Date: 17 February 2021Study  participant identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from copyright 
protection (except an y publication by the investigator as provided for below) shall be the propert y 
of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and Interna tional Committee of Medical Journal 
Editors (ICMJE) guidelines, the sponsor shall have the right to publish such primary (multicenter) 
data and information without approval from the investigator. The investigator has the right to 
publish study  site-specifi c data after the primary  data are published. If an investigator wishes to 
publish information from the study , a copy  of the manuscript must be provided to the sponsor for 
review at least 60 days before submission for publication or presentation. Expedited reviews will 
be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor will 
not mandate modifications to scientific content and does not have the right to suppress information.
For multicenter study  designs and sub-study  approaches, secondary  results generall y should not 
be published before the primary  endpoints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study  by not submitting for publication data derived 
from the individual study  site until the combined results from the completed study  have been 
submitted for publication, within 18months after the study  end date, or the sponsor confirms there 
will be no multicenter study  publication. Authorship of publications resulting from this study  will 
be based on the guidelines on authorship, such as those described in the ICMJE Recommendations 
for the Conduct, Reporting, Editing and Publication of Scholarl y Work in Medical Journ als, which 
state that the named authors must have made a significant contribution to the conception or design 
of the work; or the acquisition, analy sis, or interpretation of the data for the work; and drafted the 
work or revised it critically  for important intellectual content; and given final approval of the 
version to be published; and agreed to be accountable for all aspects of the work in ensuring that 
questions related to the acc uracy  or integrity of any part of the work are appropriatel y investigated 
and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required 
by law. The disclosure of the final study  results will be performed after the end of study  in order 
to ensure the statistical analy ses are relevant.
10.4.8. Data Quality  Assurance
Data Quality Assurance/Quality Control
Quality  tolerance limits (QTLs) will be pre-define d to identify  systematic issues that can impact 
participant safety  and/or reliability  of study  results. These pre -defined parameters will be 
monitored during the study  and important deviations from the QTL s and remedial actions taken 
will be summarized in the clinical study report.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 109
Status: Approved ,Date: 17 February 2021Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , and periodic monitoring visits by the sponsor. Written 
instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -site personnel before 
the sta rt of the stud y. 
The sponsor will review eCRF for accuracy  and completeness during monitoring visits and after 
transmission to the sponsor; any  discrepancies will be resolved with the investigator or designee, 
as appropriate. After upload of the data into the study  database they  will be verified for accuracy 
and consistency  with the data sources.
10.4.9. Case Report Form Completion
Case report forms are prepared and provided by the sponsor for each participant in electronic 
format. All data relating to the study  must be recorded in eCRF. All eCRF entries, corrections, and 
alterations must be made by the investigator or authorized study -site personnel. The investigator 
must verify  that all data entries in the eCRF are accurate and correct.
The study  data will be transcribed by study-site personnel from the source documents onto an 
eCRF, if applicable. Study -specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any
such worksheets will become part of the participant's source documents. Data must be entered into 
the eCRF in English. The eCRF must be completed as soon as possible after a participant visit and 
the forms should be available for review at the next schedu led monitoring visit.
All participative measurements (eg, pain scale information or other questionnaires) will be 
completed by the same individual who made the initial baseline determinations whenever possible.
If necessary , queries will be generated in t he eDC tool. I f corrections to a n eCRF are needed after 
the initial entry  into the eCRF, this can be done in either of the following way s:
Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response t o an auto query  (generated by  the eDC tool).
Sponsor or sponsor delegate can generate a query for resolution b y the investigator and stud y-
site personnel.
10.4.10. Source Documents
At a minimum, source documents consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
participant identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by the 
protocol; record of all adverse events and follow -up of adverse events; concomitant medication; 
intervention receipt/dispensing/return records; study  intervention administration information; and 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 110
Status: Approved ,Date: 17 February 2021date of study  completion and reason for earl y discontinuation of study  intervention or withdrawal 
from the study , if applicable. 
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document).
The following data may be recorded directl y into the e CRF and may  be considered source data:
Race
History  ofall nicotine use, eg,cigarettes (including e- cigarettes or the equivalent of e-
cigarettes), cigars, chewing tobacco, patch, gum
Blood pressure and pulse/heart rate
Height and weight
Details of ph ysical examination
Investigator -compl eted scales and assessments
The minimum source documentation requirements for Section 5.1, Inclusion Criteria and 
Section 5.2, Exclusion Criteria that specify  a need for documented medical history  may include:
Referral letter from treating ph ysician 
Complete history  of medical notes at the site
Discharge summaries
Hospital admission records
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by participant interview or other protocol required assessment (eg, physical 
examination, laboratory  assessment) and documented in the source documents.
An eSource system may be utilized, which contains data traditionally  maintained in a hospital or 
clinic record to document medical care (eg, electronic source documents) as well as the clinical 
study -speci fic data fields as determined by the protocol. This data is electronically extracted for 
use by  the sponsor. If eSource is utilized, references made to the eCRF in the protocol include the 
eSource s ystem but information collected through eSource may  not be limited to that found in the 
eCRF.
10.4.11. Monitoring
The sponsor will use a combination of monitoring techniques, iecentral, remote, and/or on-site 
monitoring to monitor this study .
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 111
Status: Approved ,Date: 17 February 2021The sponsor will conduct monitoring activities as frequentl y as necessar y. The first post -initiation 
visit will be made as soon as feasible . At these visits, the monitor will compare the data entered 
into the eCRF with the source documents (eg, hospital/clinic/physician’s office medical records) , 
if possible . The nature and location of all source documents will be identified to ensure that all 
sources of original data required to complete the eCRF are known to the sponsor and study -site 
personnel. If electronic records are maintained at the study  site, the method of verification must be 
discussed with the study -site personnel. 
If possible, given the current pandemic, d irect access to source documents (medical records) must 
be allowed for the purpose of verify ing that the recorded data are consistent with the original source 
data. Findings from this review will be discussed with the study -site personnel. The sponsor 
expects that, during monitoring visits, the relevant study -site personnel will be available, the 
source documents will be accessible, and a suitable environment will be provided for review of 
study -related documents. The monitor will meet with the investigator on a regular basis during the 
study  to provide feedback on the study  conduct.
In addition to on -site monitoring visits, remote contacts can occur. It is expected that during these 
remote contacts, study- site personnel will be available to provide an update on the progress of the 
study  at the site. 
Central monitoring will take place for data identified by  the sponsor as requiring central r eview.
10.4.12. Audits
Representatives of the sponsor's clinical quality assurance department may conduct an audit 
remote and/or on-site (when feasible) at any time during or after completion of the study  in 
compliance with regulatory guidelines and company policy. These audits will require access to all 
study  records, including source documents, for inspection. Participant privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and available 
for consultation during routinely  scheduled study -site audit visits conducted by  the sponsor or its 
designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or she has 
been contacted b y a regulatory agency  concerning an upcoming inspection.
10.4.13. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each participant, as well as all study 
documents as specified in I CH/GCP Section 8, Essential Docum ents for the Conduct of a Clinical 
Trial, and all study  documents as specified by the applicable regulatory  requirement(s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 112
Status: Approved ,Date: 17 February 2021Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an I CH region or until at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents will be retained for a longer period 
if required by the applicable regulatory  requirements or by an agreement with the sponsor. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transfer red to a person who will accept 
the responsibility . The sponsor must be notified in writing of the name and address of the new 
custodian. Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such reports.
10.4.14. Study and Site Start and Closur e
First Act of Recruitment
The first site open is considered the first act of recruitment and it becomes the study  start date.
Study /Site Termination
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been collected 
and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earl y clo sure of a study  site by the sponsor or investigator may include but are not 
limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  the investigator
Discontinuation of further study  intervention development
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 113
Status: Approved ,Date: 17 February 202110.5. Appendix 5: Adverse Events , Serious A dverse Events, Product Quality  
Complaints, and Other Safety  Reporting : Definitions and Procedures for 
Recording, Evaluating, Follow- up, and Reporting
10.5.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any  untoward medical occurrence in a clinical study  participant administered 
a pharmaceutical (investigational or non-investigational) product. An adverse event does not 
necessarily  have a causal relationsh ip with the intervention . An adverse event can therefore be an y 
unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational or non -investigational) product, whether or 
not related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [ICH]28)
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events as oftime ofobtaining consent, as specified in 
Section 8.3.1 , Time Period and Frequency  for Collecting Adverse E vents and Serious Adverse 
Events Information.
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The participant was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or signi ficant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be immediatel y 
life threatening or result in death or hospitalization but may jeopardize the participant or may 
require intervention to prevent one of the other outcomes listed in the definition above. These 
should usually  be considered serious.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 114
Status: Approved ,Date: 17 February 2021If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  intervention and the event (eg, death from anaph ylaxis), the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a component 
of the study  endpoint.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safet y information. For sirukumab , the expectedness of an adverse event will be 
determined by whether or not it is listed in theIB. For SOC treatment with a marketing 
authorization, the expectedness of an adverse event will be determined by whether or not it is listed 
in the local product information.
10.5.2. Attribution Definitions
Assessment of Causality
The causal relationship to study  intervention is determined by the Investigator. The following 
selection should be used to assess all adverse events (AE).
Related
There is a reasonable causal relationship between study  intervention administration and the AE.
Not Related
There is not a reasonable causal relationship between study  interventio nadministration and the 
AE.
The term "reasonable causal relationship" means there is evidence to support a causal relationship.
10.5.3. Severity Criteria
An assessment of severity  grade will be made by the investigator using the general categorical 
descriptors outlined in the Microbiology  and Infectious Diseases (DMID) toxicity  table (see 
Section 10.8, Appendix 8DMID Table).
10.5.4. Special Reporting Situations
Safety  events of interest on a sponsor study  intervention in aninterventional study that may require 
expedited reporting or safety  evaluation include, but are not limited to:
Overdose of a sponsor study  intervention
Suspected abuse/misuse of a sponsor study  intervention
Accidental or occupational exposure to a sponsor study  intervention
Medication error, intercepted medication error, or potential medication error involving a 
Johnson & Johnson medicinal product (with or without patient exposure to the Johnson & 
Johnson medicinal product, eg, produc t name confusion, product label confusion, intercepted 
prescribing or dispensing errors )
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 115
Status: Approved ,Date: 17 February 2021Exposure to a sponsor study  intervention from breastfeeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
10.5.5. Procedures
All Adverse Events
Adverse events, collected as specified in Section 8.3.1 ,must be recorded using medical 
terminology  in the source document and the eCRF. Whenever possible, diagnoses should be given 
when signs and symptoms are due to a common etiology  (eg,cough, runny  nose, sneezing, sore 
throat, and head congestion should be reported as "upper respiratory  infection"). Investigators must 
record in the eCRF their opinion concerning the relationship of the adverse event to study  therap y. 
All measures required for adverse event management must be recorded in the source document 
and reported according to sponsor instructions.
The participant, once discharged, will beprovided with a "wallet (study ) card" and instructed to 
carry this card wit h them for the duration of the study  indicating the following: 
Study  number
Statement, in the local language(s), that the participant is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical personnel only)
Site number
Participant number
Any other information that is required to do an emergency  breaking of the blind
Serious Adverse Events
All serious adverse events that have not resolved by the end o f the stud y, or that have not resolved 
upon the participant's discontinuation from the study , must be followed until any  of the following 
occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  intervention or to factors unrelated 
to study  conduct
It becomes unlikely  that any additional information can be obtained (participant or health care 
practitioner refusal to provide additional inf ormation, lost to follow -up after demonstration of 
due diligence with follow -up efforts)
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 116
Status: Approved ,Date: 17 February 2021Any event requiring hospitalization (or prolongation of hospitalization) that occurs during 
participation in thestudy  must be reported as a serious adverse event.
Thecause of death of a participant in a study , whether or not the event is expected or associated 
with the study  intervention , is considered a serious adverse event.
Information regarding serious adverse events will be transmitted to the sponsor using a serious 
adverse event reporting form and safety  report form of the eCRF, which must be completed and 
reviewed by a physician from the study  site, and transmitted in a secure manner to the sponsor 
within 24 hours. The initial and follow -up reports of a serious adverse event should be transmitted 
in a secure manner electronically . Telephone reporting should be the exception and the reporter 
should be asked to complete the appropriate form(s) first.
10.5.6. Product Quality  Complaint Handling
Definition
A product quality  complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , reliability , orperformance of a distributed product, including its labeling , drug delivery 
system, or package integrity . A PQC may have an impact on the safet y and efficacy  of the product.
In addition, it includes any technical compla ints, defined as any complaint that indicates a potential 
quality  issue during manufacturing, packaging, release testing, stability  monitoring, dose 
preparation, storage or distribution of the product or the drug delivery s ystem.
Procedures
All initial PQC s must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
A sample of the suspected product should be maintained under the correct storage conditions until 
a shipment request is received from the sponsor.
10.5.7. Contacting Sponsor Regarding Safety , Including Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues , PQC, or questions regarding the study  are listed in the Contact Informa tion 
page(s), which will be provided as a separate document.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 117
Status: Approved ,Date: 17 February 202110.6. Appendix 6: Contraceptive and Barrier Guidance
Participants must follow contraceptive measures as outlined in Section 5.1, Inclusion Criteria 5.3, 
Lifesty leConsiderations . Pregnancy  information will be collected and reported as noted in 
Section 8.3.5 , Pregnancy and Section 10.5, Appendix 5Adverse Events , Serious Adverse Events, 
Product Quality  Complaints, and Other Safet y Reporting : Definitions and Procedures for 
Recording, Evaluating, Follow- up, and Reporting .
Definitio ns
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanentl y sterile (see below).
Woman Not of Childbearing Potential
premenarchal
A premenarchal state is one in which men arche has not y et occurred.
postmenopausal
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause. 
permanentl y sterile (for the purpose of this stud y)
Permanent sterilization methods include hy sterectomy , bilat eral salpingectomy , and bilateral 
oophorectom y.
Note: If the childbearing potential changes after start of the study  (eg, a premenarchal woman 
experiences menarche) or the risk of pregnancy  changes (eg, a woman who is not heterosexually  
active becomes active), a woman must begin a highl y effective method of contraception, as 
described throughout the lifesty le considerations.
Contraceptive (birth control) use by men or women should be consistent with local regulations 
regarding the acceptable methods of cont raception for those participating in clinical studies.
Typical use failure rates may differ from those when used consistently  and correctl y. Use should 
be consistent with local regulations regarding the use of contraceptive methods for participants in 
clinical studies.
Examples of Contraceptives
EXAMPLES OF CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
USER INDEPENDENT (preferable)
Highly Effective Methods That Are User Independent Failure rate of <1% per year when used 
consistently and correctly.
Implantable progestogen -only hormone contraception associated with inhibition of ovulationb
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
Bilateral tubal occlusion
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 118
Status: Approved ,Date: 17 February 2021Azoospermic partner (vasectomized or due to medical cause)
(Vasectomized partner is a highly effective contraceptive method provided that the partner is the 
sole sexual partner of the woman of childbearing potential and the absence of sperm has been 
confirmed. If not, additional highly effective method of contrace ption should be used. 
Spermatogenesis cycle is approximately 74 days.)
USER DEPENDENT
Highly Effective Methods That Are User Dependent Failure rate of <1%  per year when used 
consistently and correctly.
Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulationb
oral
intravaginal
transdermal
injectable
Progestogen -only hormone contraception associated with inhibition of ovulationb
oral
injectable
Sexual abstinence
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study
and the preferred and usual lifestyle of the participant.)
NOT ALLOWED AS SOLE METHOD OF CONTRACEPTION DURING THE STUDY (not 
considered to be highly effective -failure rate of 1% per year)
Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action.
Male or female condom with or without spermicidec
Cap, diaphragm, or sponge with spermicide
A combination of male condom with either cap, diaphragm, or sponge with spermicide (double -
barrier methods)c
Periodic abstinence (calendar, symptothermal, post -ovulation methods)
Withdrawal (coitus -interruptus)
Spermicides alone
Lactational amenorrhea method (LAM)
a)Typical use failure rates may differ from those when used consistently and correctly. Use should be 
consistent with local regulations regarding the use of contraceptive methods for participants in 
clinical studies.
b)Hormonal contraception may be suscepti ble to interaction with the study intervention, which may 
reduce the efficacy of the contraceptive method.
c)Male condom and female condom should not be used together (due to risk of failure with friction).
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 119
Status: Approved ,Date: 17 February 202110.7. Appendi x 7: Risks Associated with Sirukumab 
Note: t he below listed risks associated with sirukumab are largel y based upon data from studies in 
immune -mediated diseases which involved chronic subcutaneous repeat dosing over an extended 
period of time (eg, 1 year).
Potential Risks of Clinical Signifi canceSummary of Data/
Rationale for Risk
Serious infections Interleukin -6 stimulates hepatic acute -phase proteins 
and Ig production and promotes the grow th and 
differentiation of T cells, B cells, and tumor cells. 
Interleukin -6 is a mediator of inflammation and 
cellular immune responses in the defense against some 
intracellular pathogens. Interleukin -6 has been known 
to serve as a marker of disease severity for infections. 
Although IL -6 modulates certain physiologic acute -
phase responses to infection, a complete lack of IL -6 
has not been shown to alter mortality rates in IL -6 
knockout mice. Blockage of IL -6 may blunt the acute -
phase pyretic response and therefore, fever may be 
masked in participant s receiving sirukumab. Serious, 
life-threatening infections such as septic shock, some 
of which have been fatal, have occurred in participant s 
receiving sirukumab.
Hypersensitivity Reactions observed in humans after IV or SC 
administration of mAbs include headache, fever, facial 
flushing, pruritus, urticaria, dermatitis, myalgia, 
nausea, chest tightness, laryngeal edema, dyspnea, 
vomiting, erythema, abdominal discomfort, 
diaphoresis, shivers, hypertension, Stevens -Johnson 
syndrome, lightheadedness, hypoten sion, palpitations, 
and somnolence.
Gastrointestinal Perforation Events of gastrointestinal (GI) perforation have been 
reported in clinical studies with sirukumab, primarily 
as a complication of peptic ulcer disease or 
diverticulitis in RA patients. Most patients who 
developed gastrointestinal perforations were taking 
concomitant nonsteroidal anti -inflammatory drugs, 
corticosteroids, and/or MTX. The relative contribution 
of these concomitant medications versus sirukumab to 
the development of GI perforation s is not known.
Hem atologic Events Neutropenia and thrombocytopenia have occurred in 
sirukumab studies, including severe thrombocytopenia 
associated with bleeding. In the Phase 2 and Phase 3 
RA studies, decreases in ANC and platelets occurred in 
all sirukumab treatment groups. Most patients who 
developed neutropenia while being treated with 
sirukumab did not develop infections, and most 
patients who developed thrombocytopenia did not 
report bleeding events. Changes were not observed in 
participant s who received placebo, but did occur after 
participant s crossed over to active treatment. No dose 
response was observed.
Lipids Increases in blood total cholesterol, LDL, HDL, and 
triglycerides have occurred in sirukumab treated 
participant s. No dose response w as observed.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 120
Status: Approved ,Date: 17 February 2021Potential Risks of Clinical Signifi canceSummary of Data/
Rationale for Risk
Liver enzymes Increases (1 to 3 x ULN, sometimes >5 x ULN) in 
blood ALT and AST values were observed in 
participant s in completed and ongoing studies of 
sirukumab; the majority were transient, asymptomatic, 
and not associated with an increase in bilirubin
Drug -drug interactions Inflammatory cytokines, including IL -6, are known to 
down-regulate activity and expression of multiple CYP 
enzymes. Hypothetically, IL -6 inhibition in a patient 
with an inflammatory condition will restore the CYP 
enzyme activity, and, in turn, increase the hepatic 
metabolism and clearance of drugs that are substrates 
for those enzymes.
Geriatric patients (>65 years of age) Of the 2,926 participant s treated w ith sirukumab in RA 
studies, 498 w ere 65 years and older. The incidence of 
serious infections among elderly  participant s (65 years 
and older) treated w ith sirukumab w as higher than 
participant s younger than 65 years.
Pediatric patients (<18 years of age) The safety of sirukumab in children has not been 
studied.
Renal impairment/hepatic dysfunction/fail ure There is no experience with the use of sirukumab in 
patients with hepatic insufficiency.
Pregnancy It is not known whether sirukumab can cause fetal 
harm when administered to a pregnant w oman or affect 
reproductive capacity.
Nursing Sirukumab was not detectable in most cynomolgus 
monkey milk samples. It is not known whether 
sirukumab is excreted in human milk.
Acute and subacute toxicity No information is available on acute and subchronic 
toxicity in humans.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 121
Status: Approved ,Date: 17 February 202110.8. Appendix 8: DIVISIO N OF MICROBIOLOGY AND INFECTIOUS DISEA SES 
(DMID) ADULT TOXICITY TA BLE45–NOVEMBER 2007
ABBREVIATIONS : Abbreviations utilized in the Table:
ULN = Uppe r Limit of Normal LLN = Lower Limit of Normal 
Rx= Therap y Req = Required
Mod = Moderate IV = Intravenous
ADL = Activities of Daily Living Dec = Decreased
ESTIMATING SEVERITY GRADE
For abnormalities NOT found elsewhere in the Toxicity  Tables use the scale below to estimate 
grade of severit y:
GRADE 1 Mild Transient or mild discomfort (< 48 hours); no medical 
intervention/therap y required
GRADE 2 Moderate Mild to moderate limitation in activity  -some assistance may  be 
needed; no or minimal medical intervention/therapy  required
GRADE 3 Severe Marked limitation in activity , some assistance usuall y required; 
medical intervention/therapy  required, hospitaliz ations possible
GRADE 4 Life-threatening Extreme limitation in activity , significant assistance 
required; significant medical intervention/therap y required, hospitalization or 
hospice care probable
SERIOUS OR LIFE -THREATENING AEs
ANY clinical event deemed by  the clinician to be serious or life -threatening should be considered 
a grade 4 event. Clinical events considered to be serious or life-threatening include, but are not 
limited to: seizures, coma, tetan y, diabetic ketoacidosis, disseminated intrav ascular coagulation, 
diffuse petechiae, paral ysis, acute ps ychosis, severe depression.
COMMENTS REGARDING THE USE OF THESE TABLES
Standardized and commonly  used toxicity  tables (Division of AIDS, NCI’s Common 
Toxicity  Criteria (CTC), and World Health Organ ization [WHO]) have been adapted for 
use by  the Division of Microbiology  and Infectious Diseases (DM ID) and modified to 
better meet the needs of participants in DMID trials.
For parameters not included in the following Toxicity  Tables, sites should refer t o the 
“Guide For Estimating Severit y Grade” located above.
Criteria are generall y grouped by  body  system.
Some protocols may  have additional protocol -specific grading criteria, which will 
supersede the use of these tables for specified criteria.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 122
Status: Approved ,Date: 17 February 2021HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin 9.5 -10.5 gm/dL 8.0 -9.4gm/dL 6.5 -7.9 gm/dL < 6.5 gm/dL
Absolute Neutrophil Count 1,000 -1,500/ mm3750-999/ mm3500-749/ mm3<500/ mm3
Absolute Lymphocyte 
Count, Lowa
aged >5 years 
(not HIV -infected) 600 to <650 / mm3
0.600×109to 
<0.650×109500 to <600 / mm3
0.500×109to 
<0.600×109350 to <500 / mm3
0.350×109to 
<0.500×109<350 / mm3
<0.350×109
Platelets 75,000 -
99,999/ mm350,000 -
74,999/ mm320,000 -49,999/ mm3<20,000/ mm3
WBCs 11,000 -13,000/
mm313,000 -
15,000 / mm315,000 -
30,000/ mm3>30,000 or
<1,000 / mm3
% Polymorphonuclear
Leucocytes + Band Cells> 80% 90 –95% >95% ----------
Abnorm al Fibrinogen Low:
100-200 mg/dL
High:
400-600 mg/dLLow:
<100 mg/dL
High:
>600 mg/dLLow:
< 50 mg/dL
----------Fibrinogen
associated with gross 
bleeding or w ith 
disseminated 
coagulation
Fibrin Split Product 20-40 mcg/ mL 41-50 mcg/ mL 51-60 mcg/ mL > 60 mcg/ mL
Prothrombin Time (PT) 1.01 -1.25 x ULN 1.26-1.5 x ULN 1.51 -3.0 x ULN >3 x ULN
Activated Partial 
Thromboplastin (APPT)1.01 -1.66 x ULN 1.67 -2.33 x ULN 2.34 -3 x ULN > 3 x ULN
Methemoglobin 5.0 -9.9 % 10.0 -14.9 % 15.0 -19.9% > 20.0 %
aAdded by the sponsor, based on Division of AIDS (DAIDS) table for grading the severity of adult and
pediatric adverse events, version 2.1, July 2017.21
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 123
Status: Approved ,Date: 17 February 2021CHEMISTRIES
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130-135 mEq/ L 123-129 mEq/ L 116-122 mEq/ L < 116 mEq/ L or abnormal sodium 
with mental
status changes or seizures
Hypernatremia 146-150 mEq/ L 151-157 mEq/ L 158-165 mEq/ L > 165 mEq/ L or abnormal sodium 
with mental
status changes or seizures
Hypokalemia 3.0 -3.4 mEq/ L 2.5 -2.9mEq/ L 2.0 -2.4 mEq/ L or 
intensive replacement 
therapy or 
hospitalization 
required< 2.0 mEq/ L or abnormal 
potassium with
paresis, ileus or life -threatening 
arrhythmia
Hyperkalemia 5.6 -6.0 mEq/ L 6.1 -6.5 mEq/ L 6.6 -7.0 mEq/l > 7.0 mEq/ L or abnormal
potassium with life-threatening 
arrhythmia
Hypoglycemia 55-64 mg/dL 40-54 mg/dL 30-39 mg/dL <30 mg/dL or abnormal glucose 
with mental
status changes or coma
Hyperglycemia
(nonfasting and no 
prior diabetes)116 -160 mg/dL 161-250 mg/d L 251 -500 mg/dL > 500 mg/dL or abnormal glucose 
with ketoacidosis or seizures
Hypocalcemia
(corrected for 
albumin)8.4 -7.8 mg/dL 7.7 -7.0 mg/dL 6.9 -6.1 mg/dL < 6.1 mg/dL or abnormal
calcium with life -threatening 
arrhythmia or tetany
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 124
Status: Approved ,Date: 17 February 2021CHEMISTRIES (continued)
Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia (correct for 
albumin)10.6 -11.5 mg/dL 11.6 -12.5
mg/d L12.6 -13.5 mg/dL > 13.5 mg/dL or abnormal 
calcium with life -
threatening arrhythmia
Hypomagnesemia 1.4 -1.2 mEq/ L 1.1 -0.9 mEq/ L 0.8 -0.6 mEq/ L < 0.6 mEq/ L or abnormal 
magnesium with life-
threatening arrhythmia
Hypophosphatemia 2.0 -2.4 mg/dL 1.5 -1.9 mg/dL or
replacement Rx 
required1.0 -1.4 mg/dL 
intensive therapy or 
hospitalization 
required< 1.0 mg/dL or abnormal
phosphate with life-
threatening arrhythmia
Hyperbilirubinemia (when 
accompanied by any 
increase in other liver 
function test)1.1 -<1.25 x ULN 1.25 -<1.5 x 
ULN1.5 –1.75 x ULN > 1.75 x ULN
Hyperbilirubinemia (when 
other liver function are in 
the normal range)1.1 -<1.5 x ULN 1.5 -<2.0 x ULN 2.0 –3.0 x ULN > 3.0 x ULN
BUN 1.25 -2.5 x ULN 2.6 -5 x ULN 5.1 -10 x ULN > 10 x ULN
Hyperuricemia (uric acid) 7.5 –10.0 mg/dL 10.1 –12.0 
mg/dL12.1 –15.0 mg/d L >15.0 mg/d L
Creatinine 1.1 -1.5 x ULN 1.6 -3.0 x ULN 3.1 -6 x ULN >6 x ULN or dialysis 
required
ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.1 -<2.0 x ULN 2.0 –<3.0 x ULN 3.0 –8.0 x ULN > 8 x ULN
ALT (SGPT) 1.1 -<2.0 x ULN 2.0 –<3.0 x ULN 3.0 –8.0 x ULN > 8 x ULN
GGT 1.1 -<2.0 x ULN 2.0 –<3.0 x ULN 3.0 –8.0 x ULN > 8 x ULN
Alkaline Phosphatase 1.1 -<2.0 x ULN 2.0 –<3.0 x ULN 3.0 –8.0 x ULN > 8 x ULN
Amylase 1.1 -1.5 x ULN 1.6 -2.0 x ULN 2.1 -5.0 x ULN > 5.1 x ULN
Lipase 1.1 -1.5 x ULN 1.6 -2.0 x ULN 2.1 -5.0 x ULN > 5.1 x ULN
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 125
Status: Approved ,Date: 17 February 2021URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Proteinuria 1+
or
200 mg -1 gm 
loss/day2-3+
or
1-2 gm loss/day4+
or
2-3.5 gm loss/daynephrotic syndrome
or
>3.5 gm loss/day
Hem aturia microscopic only
<10 rbc/hpfgross, no clots
>10 rbc/hpfgross, with or w ithout 
clots, OR RBC castsobstructive or 
required
transfusion
CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Rhythm asymptomatic, 
transient signs, no
Rx requiredrecurrent/persistent; 
symptomatic Rx 
requiredunstable dysrythmia;
hospitalization
and treatment 
required
Hypertension transient increase
>20 mm/ Hg; no 
treatmentrecurrent, chronic 
increase
> 20mm/ Hg
/treatment requiredacute treatment 
required; outpatient 
treatment or 
hospitalization
possibleend organ damage or 
hospitalization 
required
Hypotension transient orthostatic
hypotension with 
heart rate increased 
by <20 beat/min or 
decreased by <10 
mm Hg systolic BP, 
No treatment 
requiredsymptoms due to 
orthostatic 
hypotension or BP 
decreased by <20 
mm Hg sy stolic; 
correctable w ith oral 
flu id treatmentrequires IV fluids; no 
hospitalization 
requiredmean arterial 
pressure
<60mm/ Hg or end 
organ damage or 
shock; requires 
hospitalization and 
vasopressor treatment
Pericarditis minimal effusion mild/ moderate 
asymptomatic 
effusion, no 
treatmentsymptomatic 
effusion; pain; EKG 
changestamponade; 
pericardiocentesis or 
surgery required
Hem orrhage, Blood Loss microscopic/occult mild, no transfusion gross blood loss;
1-2 units transfusedmassive blood loss; 
>3 units transfused
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 126
Status: Approved ,Date: 17 February 2021RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Cough transient - no 
treatmentpersistent cough; 
treatment responsiveParoxysmal cough; 
uncontrolled w ith 
treatment--------------------
Bronchospasm, Acute transient; no 
treatment;
70% - 80% FEV1
of peak flowrequires
treatment; normalizes 
with bronchodilator; 
FEV1 50% -
70%
(of peak flow)no normalization 
with bronchodilator; 
FEV1 25% -50%
of peak flow; or
retractions presentcyanosis: FEV1
<25%
of peak flow or 
intubation necessary
Dyspnea dyspnea on exertion dyspnea with normal 
activitydyspnea at rest dyspnea requiring 
oxygen therapy
GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Nausea mild or transient; 
maintains
reasonable intakemoderate discomfort; 
intake decreased
significantly; some 
activity limitedno significant intake; 
requires IV flu idshospitalization 
required;
Vom iting 1 episode in 24 hours 2-5 episodes in
24 hours>6 episodes in 
24hours or needing 
IV fluidsphysiologic 
consequences 
requiring
hospitalization or 
requiring parenteral 
nutrition
Constipation requiring stool
softener or dietary 
modificationrequiring
laxativesobstipation
requiring manual 
evacuation or enemaobstruction or
toxic megacolon
Diarrhea mild or transient; 3 -4 
loose
stools/day or mild
diarrhea last <1 w eekmoderate or 
persistent; 5 -7 loose 
stools/day or diarrhea
lasting >1 week>7 loose stools/day
or bloody diarrhea; or 
orthostatic 
hypotension or 
electrolyte imbalance 
or >2L IV fluids 
requiredhypotensive shock or 
physiologic 
consequences 
requiring
hospitalization
Oral Discomfort/Dysphagia mild discomfort; no 
difficulty
swallowingsome limits on 
eating/drinkingeating/talking very 
limited; unable to 
swallow solid foodsunable to drink flu 
ids; requires IV fluids
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 127
Status: Approved ,Date: 17 February 2021NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Neuro -Cerebellar slight incoordination 
dysdiadochokinesisintention tremor, 
dysmetria,
slurred speech; 
nystagmuslocomotor ataxia incapacitated
Psychiatric mild anxiety or 
depressionmoderate anxiety or 
depression; therapy 
required; change in 
norm al routinesevere mood changes 
requiring therapy; or 
suicidal ideation; or 
aggressive ideationacute psychosis 
requiring 
hospitalization; or 
suicidal 
gesture/attempt or 
hallucinations
Muscle Strength subjective weakness 
no objective
symptoms/ signsmild objective
signs/symptoms no 
decrease in functionobjective w eakness 
function limitedparalysis
Paresthesia (burning, 
tingling, etc.)mild discomfort; no 
treatment requiredmoderate discomfort;
non-narcotic 
analge sia requiredsevere discomfort; or 
narcotic analgesia 
required w ith 
symptomatic 
improvementincapacitating; or not 
responsive to narcotic 
analgesia
Neuro -sensory mild impairment in 
sensation
(decreased
sensation, eg, 
vibratory, pinprick, 
hot/cold in great toes) 
in focal area or 
symmetrical
distribution; or 
change in taste, 
smell, vision and/or 
hearingmoderate
impairm ent (mod 
decreased sensation, 
eg, vibratory, 
pinprick, hot/cold to 
ankles) and/or joint 
position or mild
impairm ent that is 
not
symmetricalsevere impairment 
(decreased or loss of 
sensation to knees or 
wrists) or loss of 
sensation of at least 
mod degree in 
multiple
different body areas 
(ie, upper and low er
extremities)sensory loss involves 
limbs and trunk; 
paralysis; or seizures
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 128
Status: Approved ,Date: 17 February 2021MUSCULOSKELATEL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia (joint pain) mild pain not 
interfering with 
functionmoderate pain, 
analgesics and/or pain 
interfering with 
function but not with 
activities of daily 
livingsevere pain; pain 
and/or analgesics 
interfering with 
activities of daily 
livingdisabling pain
Arthritis mild pain with
inflammation,
erythema or joint
swelling –but not
interfering with
functionmoderate pain with
inflammation,
erythema or joint 
swelling –interfering 
with function, but not 
with activities of
daily livingsevere pain with
inflammation,
erythema or joint
swelling –and
interfering with
activities of daily
livingpermanent and/or 
disabling joint
destruction
Myalgia Myalgia with no 
limitation of activitymuscle
tenderness (at other 
than injection site) or 
with moderate
impairm ent of 
activitysevere muscle
tenderness with
marked impairment 
of activityfrank
myonecrosis
SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Mucocutaneous erythema; pruritus diffuse, 
maculopapular rash, 
dry desquamationvesiculation or
moist desquamation 
or ulcerationexfoliative
dermatitis, mucous 
membrane
involvement or 
erythema,
multiforme or 
suspected
Stevens -Johnson
or necrosis requiring 
surgery
Induration <15mm 15-30 mm >30mm
Erythema <15mm 15-30 mm >30mm
Edema <15mm 15-30 mm >30mm
Rash at Injection Site <15mm 15-30 mm >30mm
Pruritus slight itching at 
injection sitemoderate itching at 
injection extremityitching over entire 
body
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 129
Status: Approved ,Date: 17 February 2021SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Allergic Reaction pruritus without rash localized urticaria generalized urticaria; 
angioedemaanaphylaxis
Headache mild, no treatment 
requiredtransient, moderate; 
treatment requiredsevere; responds to 
initial narcotic 
therapyintractable; requires 
repeated narcotic 
thera py
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 130
Status: Approved ,Date: 17 February 202110.9. Appendix 9: The New York Heart A ssociation Classification Sy stem
Class New York Heart Association functional classification
I Patients have cardiac disease but without the resulting limitations of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpitation, dyspnoea or anginal pain
II Patients have cardiac disease resulting in slight limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpitation, dyspnoea or anginal pain
III Patients have cardiac disease resulting in marked limitation of physical activity. They are comfortable at 
rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnoea or anginal pain
IV Patie nts have cardiac disease resulting in inability to carry on any physical activity without discomfort. 
Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical 
activity is undertaken, discomfort is increased
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 131
Status: Approved ,Date: 17 February 202110.10. Appendix 10: General Guidelines for Measuring Vital Signs and SpO 2
Variability in the measurement of vital signs and SpO 2is to be expected due to a number of reasons; 
therefore, general guidelines for measuring vital signs and SpO 2have been developed to have a more 
consistent approach across sites and countries related to the methodology for measuring these clinical 
parameters. 
Parameter General Instructions
Blood Pressure  While participant is hospitalized, if possible, use the same blood pressure 
measurement methodology for all patients enrolled at the site.
 Prior to the measurement, participant needs to be rested for at least 5 minutes 
and preferably 10 minutes in a quiet setting without distractions.
 Participant can be in either a sitting or supi ne position. In the sitting position, 
the participant should be comfortably seated, with the legs uncrossed. When 
measurements are taken in the supine position, the arm should be supported 
with a pillow.
 Blood pressure measurements should preferentially beassessed with a 
completely automated device. Manual techniques will be used only if an 
automated device is not available.
 If an automated device is not available, a properly maintained mercury 
sphygmomanometer is preferred over aneroid and hybrid 
sphygmom anometers. When using a mercury sphygmomanometer, the 
mercury column should be deflated at 2 to 3 mm/s, and the first and last 
audible sounds should be taken as systolic and diastolic pressure. The column 
should be read to the nearest 2 mm Hg.
 Preferential ly, the standard location for blood pressure measurement is the 
upper arm, with the stethoscope at the elbow crease over the brachial artery 
(with manual technique). Clothing that covers the arm should be removed 
prior to the placement of the cuff.
Heart Rate  While participant is hospitalized, if possible, use the same heart rate 
measurement methodology for all patients enrolled at the site.
 Prior to the measurement, participant needs to be rested for at least 5minutes, 
and preferably 10 minutes in a quiet setting without distractions.
 Participant can be in either a sitting or supine position.
 Heart rate measurements should preferentially be assessed with a completely 
automated device.
 Manual techniques will be used only if an automated device is not available.
 If manual measurement, auscultation of the heart or pulse (radial, brachial) 
determination isconsidered acceptable.
 If manual measurement, 30 seconds (minimum) or 1 minute (preferred) 
count sare considered acceptable.
Respiratory Rate  While participant is hospitalized, if possible, use the same respiratory rate 
measurement methodology for all patients enrolled at the site.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 132
Status: Approved ,Date: 17 February 2021 Prior to the measurement, participant needs to be rested for at least 5 minutes, 
and preferably 10 minutes in a quiet setti ng without distractions.
 Participant can be in either a sitting or supine position.
 Respiratory rate measurements can be assessed with an automated device or 
with manual measurement (no preference).
 If manual measurement is used, inspection (preferred) or auscultation of the 
lungs (alternative) are considered acceptable.
 If manual measurement, 30 seconds (minimum) or 1 minute (preferred) count 
are considered acceptable.
Temperature  While participant is hospitalized, if possible, use the same type of 
temper ature measurement methodology for all participants enrolled at the 
site.
 Electronic devices (tympanic, oral) are preferred over traditional mercury 
thermometers (for oral temperature).
 Tympanic (preferred) or oral (alternative) temperature measurements are
considered acceptable. Axillary temperature should be avoided since it 
provides the worst estimate of core temperature and it is largely influenced 
by environmental conditions.
SpO 2  While participant is hospitalized, if possible, use the same type of probe for 
all patients enrolled at the site.
 Prior to the measurement, participant needs to be rested for at least 5 minutes, 
and preferably 10 minutes in a quiet setting without distractions.
 Participant can be in either a sitting or supine position.
 Pulse oximetry measurements using finger, toe, earlobe or frontal sensors are 
considered acceptable. If using the digits, assess for warmth and capillary 
refill, since adequate arterial pulse strength is necessary for obtaining 
accurate SpO 2 measurements.
 Avoid placing the sensor on sites distal to indwelling arterial catheters, blood 
pressure cuffs, or venous engorgement (eg, arteriov enous fistulas, blood 
transfusions).
 For hospitalized participants receiving supplemental O2, the measurement 
should be performed after 5 minutes on room air.
 If it is determined by the investigator that it is unsafe to remove the 
participant’s supplemental O2for assessment of O2saturation (eg, participant 
is on high-flow mask), then it should be recorded in the source documentatio n 
as not assessed and the reason should be documented.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 133
Status: Approved ,Date: 17 February 202110.11. Appendix 11: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is located 
directly  before the Table of Contents.
Amendment 4 (15 September 2020 )
Overall Rationale for the Amendment: The protocol has been amended to allow for an Interim Analysis 
(IA) to be performed when approximately 20% of the planned number of participants have reached Day 28 
or discontinued earlier.
Activation of sites outside t he US is delayed until availability of the IA results.
In addition, to accommodate for feedback received from investigators about the challenges when using a 
central laboratory, the safety laboratory assessments (hematology, chemistry, coagulation tests) will be 
performed by local laboratories.
Further, to accommodate for feedback received from investigators ,the sponsor has optimized the 
mandatory laboratory tests to be performed .
Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.1Synopsis
1.2Schema
4.1Overall Design
6.3Measures to Minimize Bias: Randomization 
and Blinding
9.5Interim Analysis
10.4.6 Committees StructureA non-binding unblinded Interim 
Analysis (IA)for futility will be 
performed by the sponsor on the primary 
endpoint when approximately 20% of the 
planned number of participants have 
reached Day 28 or discontinued earlier.In view of the mixed 
results of emerging 
clinical data with IL -6 
receptor inhib itors, 
the purpose of th is IA 
is to perform a futility 
analysis to determine 
further study conduc t.
1.3Schedule of Activities (SoA)
5.1Inclusion Criteria
8STUDY ASSESSMENTS AND 
PROCEDURES
8.1.3 Virology Assessments
10.2 Appendix 2: Clinical Laboratory Tests
10.3 Appendix 3: Clinical and Laboratory 
Assessments Described per DayOnly PCR -based tests are allowed for 
detection of SARS -CoV -2 infection.To prevent possible 
false positive results 
by using a rapid 
antigen test at time of 
screening.
1.3Schedul e of Activities (SoA)
10.2 Appendix 2: Clinical Laboratory TestsTherequired use of a central laboratory 
for the safety laboratory assessments
(hematology, chemistry, coagulation 
tests) is no longer in place .To limit changes in 
the laboratory safety 
assessment s and allow 
fast availability of 
laboratory results .
1.3Schedule of Activities (SoA)
8STUDY ASSESSMENTS AND 
PROCEDURES
8.2.5 Pregnancy TestingThe mandatory laboratory tests to be 
performed have been optimized.To accommodate for 
feedback received 
from investigators .
10.3 Appendix 3: Clinical and Laboratory 
Assessments Described per DayThe assessments as described in the 
Schedule of Activities have now also 
been described per day in a protocol 
appendix.To add clarity and be 
more user -friendly .
5.2 Exclusion Criteria Exclusion criterion 13 has been rew orded. To accommodate for 
feedback from 
investigators.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 134
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
Throughout the protocol Minor grammatical, formatting, or 
spelling changes were made.Minor errors w ere 
noted .
Amendment 3 (23 July 2020 )
Overall Rationale for the Amendment: The protocol has been amended to state that all clinical laboratory 
tests are to be performed by the central laboratory, except for screening visit assessments, and to allow 
flexibility concerning the sourcing of placebo as the study has been extended from a single -country trial to 
a global trial. The frequency of Data Monitoring Committee (DMC) review has been adapted to allow for 
flexibility in alignment with recruitment rates. A separate sample for SARS -CoV -2 specific antibodies 
testing has been added. Furthermore, clarifications, minor updates and corrections have been made 
throughout the protocol.
Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.3 Schedule of Activities (SoA)
8.3.6 Adverse Events of Special Interest
10.2 Appendix 2: Clinical Laboratory TestsHem atology, chemistry, coagulation and 
pregnancy tests will be done by the 
central laboratory instead of the local 
laboratory, w ith exception of the tests that 
are performe d during the screening visit.As the study is 
extended to become a 
global trial, central 
laboratory testing is 
being implemented.
1.1 Synopsis
1.2 Schema
10.1 Appendix 1: Abbreviations and Definitions
10.3.6 Committees StructureThe DMC review frequency has been 
changed from weekly to regularly.Allow for flexibility 
in alignment with 
recruitment rates.
6.1 Study Intervention(s) Administered Footnote has been added to clarify that 
placebo w ill be provided locally by the 
study site or centrally by the sponsor.Allow flexibility 
concerning the 
sourcing of placebo 
based on local 
regulations in 
participating 
countries.
1.3 Schedule of Activities (SoA)
8.2.5 Pregnancy Testing
10.2 Appendix 2: Clinical Laboratory TestsPregnancy assessment has been added t o 
the baseline visit. Furthermore, it has 
been clarified that urine pregnancy testing 
is only acceptable for the screening visit 
(in emergency situations).Allow for pregnancy 
testing by central 
laboratory at baseline. 
1.3 Schedule of Activities (SoA) A separate sample for SARS -CoV- 2 
specific antibody testing has been added 
to the baseline, Day 14, and Day 28 visit.Allow flexibility on 
the type of assays to 
be performed on these 
samples.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 135
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.3 Schedule of Activities (SoA) Hem atology, chemistry and coagu lation 
testing has been added to the baseline 
visit and footnote dd has been removed 
for the screening visit. The statement 
'preferred daily testing if per local 
standard of care, otherwise as a minimum 
on' has been removed. Furthermore, 
footnote l and foo tnote ee have been 
reworded.Allow for 
hematology, 
chemistry and 
coagulation testing by 
the central laboratory 
at baseline and at 
specific time points 
betw een Day 2 and 
discharge.
Optional time points for collection of 
blood samples for biomarker research 
have been removed. In addition, 
footnote v has been removed for the 
Day 28 visit and footnote x has been 
reworded.Separate sample for 
central procalcitonin 
testing no longer 
required betw een 
Day 2 and Day 28.
Footnote cc has been edited to clar ify that 
the relevant respiratory function 
assessments, completed maximum 1 day 
before discharge do not need to be 
repeated on the day of discharge provided 
that no clinically relevant changes were 
noted in the results and the participant was 
declared ‘ready to be discharged’ on the 
day before discharge. Clarification
1.1 Synopsis
1.3 Schedule of Activities (SoA)
8.6 Biomarkers
10.2 Appendix 2: Clinical Laboratory TestsThe w ords 'sample collection' have been 
removed from the subtitle to clarify that 
multiple samples will be used for the 
assessment of the exploratory biomarkers. 
Furthermore, the description of the type 
of biomarker parameters to be evaluated 
in the biomarker blood samples has been 
removed. Clarification.
1.3 Schedule of Activities (SoA)
5.1 Inclusion Criteria #4Lung ultrasound has been added as an 
option for the assessment of inclusion 
criterion 4 and to the SoA if a pulmonary 
assessment with X -ray would not be 
available.Allow flexibility to 
assess eligibility 
based on local 
standard of care 
practices. 
5.1 Inclusion Criteria #5 The requirement of supplemental oxygen 
to sustain a SpO 2>93% is to be 
documented by an SpO 2of ≤93% on room 
air or on supplemental oxygen.Clarification
5.2 Exclusion Criteria #10 Participants can receive anticoagulant 
therapies for underlying conditions, or as 
systematic thromboprophylaxis due to 
COVID -19, or as part of the treatment of 
complications of COVID -19, but cannot 
participate in a clinical study with 
anticoagulants for COVID -19. This has 
been add ed to exclusion criterion 10.Broadening of the 
eligible patient 
population.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 136
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
6.1 Study Intervention(s) Administered
6.2 Preparation/Handling/Storage/Accountability
10.1 Appendix 1: Abbreviations and DefinitionsFootnote has been added to clarify that 
dextrose is commonly known and referred 
to as glucose.Clarification.
6.3 Measures to Minimize Bias: Randomization 
and BlindingIt has been specified that the interactive 
web response system (IWRS) will assign 
a unique intervention code for the 
participants a ssigned to the active study 
treatment.Clarification.
8.1.3 Virology Assessments Stool sample collection post hospital 
discharge has been removed.Correction.
Throughout protocol Minor updates, corrections or additions 
have been made.Correction, 
clarification and 
consistency .
Amendment 2 (17 June 2020)
Overall Rationale for the Amendment: Following investigator feedback and given the evolving 
COVID -19 landscape, the protocol has been amended to allow enrollment of a broader patient population 
into the study . In addition, incidence of all-cause mortality has been elevated to be a key secondary 
endpoint. Furthermore, clarifications, minor updates and corrections have been made throughout the 
protocol.
Main Changes 
Section Number and Name Descr iption of Change Brief Rationale 
1.1 Synopsis
1.3 Schedule of Activities (SoA)
3 OBJECTIVES AND 
ENDPOINTS
8.6 BiomarkersIgG and IgM are no longer specified as SARS -CoV- 2 
specific antibodies to evaluate the humoral immune 
response to SARS -CoV -2. Th e humoral immune 
response assays are still to be determined. Allow flexibility as the 
immunity assays are 
still to be determined.
1.1 Synopsis
3 OBJECTIVES AND 
ENDPOINTS
9.2 Sample Size Determination
9.4 Stat istical Analyses
9.4.2 Primary Endpoint
9.4.3.1 Key Secondary Endpoints
9.4.4 Other Secondary EndpointsIncidence of all -cause mortality (up to Day 28) has 
been elevated to be a key secondary endpoint 
(instead of ot hher secondary endpoint). 
A hierarchical testing strategy will be used for the 
primary and key secondary endpoints. 
For the mortality rate in the control arm, a range from 
30% to 50% is considered for the sample size 
determination. For the considered absolute difference 
in mortali ty rate, a pow er of at least 80% is retained 
for this range and the pow er will be higher in case the 
mortality rate in the control arm will be near the 
lower end of the considered range. Updated to be able to 
assess the mortality rate 
as a key secondary 
analysis.
A stratified log -rank test (instead of a Gehan -
Wilcoxon test) will be used in the analyses of the 
primary parameter. 
Key secondary endpoints will be analyzed using the 
Cochrane -Mantel -Haenszel test for difference in 
proportions.
A graphical presentation over time to analyze the 
6-point ordinal clinical recovery scale of the clinical Update on statistical 
tests to be used 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 137
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Descr iption of Change Brief Rationale 
status has been added to the protocol. The 
proportional odds model has been updated from each 
day up to Day 28 to Day s7, 14, 21 and 28.
1.1 Synopsis
1.2 Schema
4.1 Overall Design
9.4 Statistical Analyses
9.5 Interim Analysis
10.3.6 Committees StructureThe Data Monitoring Committee (DMC) interim data 
review will focus o n safety data. Therefore, the DMC 
details have been removed from the interim analysis 
sections. Clarification 
1.1 Synopsis
9.3 Populations for Analysis Sets
9.4.2 Primary Endpoint
9.4.7 Other AnalysesThe ITT (Intent -to-Treat) population will be used for 
statistical analyses instead of the ITT -i (or ITT -
infected, defined as the population with a central 
laboratory confirmed SARS -COV -2 test at baseline). 
The ITT population comprises all study participant s; 
all participants are required to have a local 
laboratory -confirmed SARS -CoV- 2 infection prior to 
randomization per inclusion criterion 3. Update of the 
population to be used 
for statistical analyses
1.3 Schedule of Activities (SoA) Footnote added to clarify that in participants still 
hospitalized post Day 28 additional blood sampling 
for hematology, chemistry and coagulation should be 
done per SOC w ith a minimum of every 7 days and 
at Day of discharge. Clarification
Footnote clarifying that, for participants discharged 
prior to Day 28, assessments completed maximum 1 
day before discharge do not need to be repeated on 
the day of discharge .Clarification 
Footnote clarifying that pulmonary X -ray, 12-lead 
ECG, hematolo gy, chemistry, coagulation sample,
and stool sample do not need to be repeated at 
baseline if done at screening. Screening and baseline 
cells in SoA have therefore been merged. Clarification
Stool sample collection post Day 28 has been 
removed in the So A as this sample cannot be 
collected at home due to safety reasons. Removal of stool 
sample collection post 
Day 28 due to 
non-feasibility for 
safety reasons
1.2 Schema
1.3 Schedule of Activities (SoA)
5 STUDY POPULATION
8 STUDY ASSESSMENTS AND 
PROCEDURESFurther clarifying text on timing of screening and/or 
baseline assessments to be conducted prior to 
randomization has been added.Clarification
1.3 Schedule of Activities (SoA)
5 STUDY POPULATION
5.1 Inclusion Criteria #3
8 STUDY ASSESSMENTS AND 
PROCEDUR ES
8.1.3 Virology AssessmentsIt has been added that the any other commercial or 
public health assay that could be used to determine 
SARS -CoV- 2 positivity, must be approved or 
authorized for (emergency) use.Clarification
2.1.1 Background
2.2 Dose Rationale
11 REFERENCESAdditional information regarding sirukumab IL -6 
affinity and serum concentrations has been added to Clarification
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 138
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Descr iption of Change Brief Rationale 
clarify the expected free IL -6 suppression for at least 
4 weeks.
1.3 Schedule of Activities (SoA)
5.1 Inclusion Crite ria #5Participants not receiving supplemental oxygen and 
having a blood oxygen saturation ≤93% sustained for 
5 minutes have been added as being eligible. The 
required supplemental oxygen flow  rate of ≥6 L/min 
has been removed.
The limitation of the invasi ve mechanical ventilation 
to <24h at screening has been extended to <48h.
Furthermore, it has been added that participants on 
veno -venous ECMO <48h are also allow ed.
The note concerning the requirement of supplemental 
oxygen at ≥6 L/min has been removed.Broadening of the 
eligible patient 
population   
1.2 Schema
1.3 Schedule of Activities (SoA)
2.3.1 Risks for Study Participation
5.2 Exclusion Criteria #1Participants on veno -venous ECMO for >48 hours at 
time of screening are excluded.Clarification
2.3.1 Risks for Study Participation
5.2 Exclusion Criteria #3
6.8 Prestudy and Concomitant 
Therapy
11 REFERENCESAdministration of agents with demonstrated in 
vitro -effect against SARS -CoV -2 (as mentioned in 
the CDC guidelines) or convalescent plasma within 
30days prior to the planned study intervention or 
during the study is allowed provided it is not via a 
blinded clinical study. 
The risk of an additional protein load associated with 
co-administration of convalescent plasma has been 
added to the Benefit -Risk Assessment. Broadening of the 
eligible patient 
population and of the 
accepted concomitant 
therapies  
5.2 Exclusion Criteria #4 Exclusion criterion #4 is now  limited to: Current 
confirmed or high suspicion for pulmonary embolus, 
hemodynamic significant pericardial effusion, 
myocarditis, or Class 3 or 4 congestive heart failure 
as defined by the New York Heart Association 
Functional Classification AND/OR Current Evidence 
of active car diac ischemia.Broadening of the 
eligible patient 
population   
5.2 Exclusion Criteria #5 Exclusion criterion #5 is now  limited to: Currently 
active clinically significant (eg, causing 
hemodynamic instability and/or causing hypoxemia) 
and uncontrolled arrhythmia. Broadening of the 
eligible patient 
population  
5.2 Exclusion Criteria #8 Exclusion criterion #8 is now  limited to: 
Has a history of chronic respiratory condition (ie, 
asthma, chronic obstructive pulmonary disease 
[COPD], cystic fibrosis, fibrotic lung disease) that 
requires home oxygen supplementation, supportive 
non-invasive ventilation, or is status/post lung 
volume redu ction surgery (LVRS).
Participants with sleep apnea using a supportive non -
invasive ventilation (continuous positive airway 
pressure [CPAP]) at screening may be included. This 
has been added as exception to exclusion criterion 8. Broadening of the 
eligibl e patient 
population   
5.2 Exclusion Criteria #10 Absolute neutrophil count (ANC) values have been 
adjusted from <2.0 × 103cells/ μL to 
<1.0 ×103cells/ μL (SI: <1.0 × 109cells/L). Broadening of the 
eligible patient 
population   
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 139
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Descr iption of Change Brief Rationale 
Platelet count values have been adjusted from 
<100 ×103cells/ μL to <5 0 ×103cells/ μL (SI: 
<50×109cells/L).
Transaminase values have been adjusted from 
ALT/AST > 5x ULN to ALT > 5x ULN.
6.8 Prestudy and Concomitant 
TherapyParticipants on chronic (for >3 months in duration) 
prednisone in a dose higher than 10mg/day or other 
oral corticosteroids at an equivalent dose for any 
condition are not eligible for the study.Clarification 
Throughout protocol Minor updates, corrections or additions have been 
made.Correctio n, clarification 
and consistency
Amendment 1 (24 April 2020)
Overall Rationale for the Amendment: Following Health Authority, Data Monitoring Committee and 
investigator feedback, the protocol has been amended to allow enrollment of a diverse patient population 
into the study (by removing the requirement for participants to understand English), to also allow 
enrollment of breastfeeding women if the benefit outweighs the risk, to ensure that at least one 12-lead ECG 
is taken after study intervention andto simplify the requirements for nasopharyngeal swabs and other 
specimens (by making one more time point optional). Furthermore, clarifications, additions and corrections 
have been made throughout the protocol. 
Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.1Synopsis
1.2Schema
2.3.1 Risks for Study Participation
2.3.3 Benefit -Risk Assessment for 
Study Participation
4.1Overall Design
6.3Measures to Minimize Bias: 
Randomization and Blinding
9.4Statistical Analyses
9.4.1 General Considerations
9.5Interim Analysis
10.1 Appendix 1: Abbreviations and 
Definitions
10.3.6 Committees StructureA Data Monitoring Committee (DMC) instead of a 
Data Review Committee will be established in this 
study.Correction on 
terminology
It has been added that the DMC will also weekly 
evaluate the accumulating safety data of all 
participants in the study.Clarification
1.1Synopsis
9.4.3.1 Key Secondary Endpoint
9.4.4 Other Secondary EndpointsThe difference in cumulative incidence at Day 28 
will be estimated using the Nelson -Aalen estimator 
of the cumulative hazard in each treatment group. 
This has been added instead of a logistic regression 
model.Update on more 
appropriate statistical 
test to be used 
1.1Synopsis
9.4.7 Other Analy sesDetails addressing the statistical analysis on the 
SARS -CoV- 2 viral loads have been added. Clarification, for 
completeness.
1.3Schedule of Activities (SoA)
8.1.6 Arterial Blood Gas Test
10.2 Appendix 2: Clinical 
Laboratory TestsSaO 2has been removed as blood gas parameter to be 
assessed, as it is not captured in the CRF.
In addition, blood gas has been specified as arterial. Correction
For completeness and 
consistency
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 140
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
1.3Schedule of Activities (SoA) It has been added that one ECG is to be taken 
betw een Day 4 and Day 8, as a minimum.To ensure that at least 
one 12 -lead ECG is 
taken after study 
intervention
1.3Schedule of Activities (SoA) The Day 5 nasopharyngeal swab, endotracheal 
sample and stool sample have been made optional.Decrease sampling 
burden for participants 
and the sites
1.3Schedule of Activities (SoA)
8.1.3 Virology AssessmentsStool samples will only be collected if feasible for 
the site. ‘Optional’ has been removed and replaced 
by ‘if feasible’.Clarification 
1.3Schedule of Activities (SoA)
8STUDY ASSESSMENTS AND 
PROCEDURESClarifying text on which screening or baseline 
assessments are to be conducted prior to 
randomization (ie, those to verify study eligibility 
criteria and those allowing baseline assessment of the 
6-point ordinal clinical recovery category) has been 
added.Clarification
1.3Schedule of Activities (SoA)
5.2Exclusion CriteriaText regarding exclusion of a participant from study 
participation if he or she no longer meets eligibility 
criteria due to clinical status changes occurring after 
screening but before the study intervention is given 
has been corrected to before randomizat ion. Correction
1.3Schedule of Activities (SoA)
8.2.1 Physical ExaminationsTargeted physical examinations are to be performed 
as per local standard of care. Clarification
It has been added, that if body w eight cannot be 
measured at screening or is not already available in 
the participant’s chart, w eight for dose calculations 
can be verbally reported. Clarification
1.3Schedule of Activities (SoA)
8.1.4 Supplemental Oxygen UseWording has been added to clarify that if more than 
one device is being used for supplemental oxygen 
delivery, the w orst (highest) FiO 2value measured on 
the highest level of intervention will be recorded as 
well as the worst recording on each device 
separately.Clarification and 
consistency
1.3Schedule of Activities (SoA)
10.2 Appendix 2: Clinical 
Laboratory TestsFollow ing lab parameters also need to be tested and 
have thus been added: conjugated bilirubin (direct), 
unconjugated bilirubin (indirect), and international 
norm alized ratio (INR). For completeness and 
consistency 
1.3Schedule of Activities (SoA)
8.1.3 Virology AssessmentsThe possibility of home visits by health care 
professionals during follow -up period, has been 
added. Allow health care 
professional home visits 
during follow -up
1.3Schedule of Activities (SoA)
8STUDY ASSESSMENTS AND 
PROCEDURESA statement has been added as footnote ‘ee’ to clarify 
that for those participants discharged prior to Day 28, 
all Day 28 assessments should be done at day of 
discharge. Clarification 
2.3.1 Risks for Study Participation
6.8Prestudy and Concomitant 
TherapyIt has been added that antivirals must have 
‘demonstrated in -vitro effect’, as mentioned in the 
CDC Guidelines to be allow ed as concomitant 
medication.For completeness and 
consistency
5.1Inclusion Criteria The requirement to understand English language has 
been removed from the inclusion criterion 6. To increase participant 
diversity in this clinical 
study
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 141
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
The informed consent for the optional DNA research 
will be obtained in the main study informed conse nt 
form (ie, by a tick box) instead of through a separate 
informed consent form. Clarification
5.2Exclusion Criteria Participants with currently active uncontrolled 
arrhythmia will be excluded if ‘clinically significant’. 
Clinically significant has been added.Clarification and 
consistency across the 
section
Participants with prothrombin time/international 
norm alized ratio >1.5xULN or (instead of ‘and’) 
activated partial thromboplastin time >1.5xULN 
(unless abnormalities are unrelated to coagulopat hy 
or bleeding disorder) screening laboratory test results 
will be excluded. Correction
It has been added that breastfeeding women should 
be excluded unless, in the opinion of the investigator, 
the benefits outweigh the risks. Clarification
6.2Preparation/Handling/Storage/
AccountabilityThe IV infusion rate has been changed from 
100mL/min to 100 mL/h. Correction 
6.4Study Intervention Compliance The w eight of IV infusion bag, including the infusion 
line before and after the completion of t he IV 
infusion does not need to be recorded and has thus 
been removed.Correction
6.8Prestudy and Concomitant 
TherapyLeflunomide has been removed from the list of drugs 
disallow ed from  2 weeks prior to randomization, as it 
is later stated that leflunomide is disallowed from 8 
weeks prior to randomization until the end of the 
study. 
It has also been adjusted that prestud y therapies must 
be recorded if taken up to 30 days before obtaining 
informed consent (instead of drugs taken up to 
30days before study intervention having to be 
recorded).Consistency across the 
section
Correction 
8.1.1 Six-point Ordinal Clinical 
Recovery ScaleText regarding declining care that requires an ICU 
level of intervention, has been removed from the 
footnote (as ICU stay is not part of the 6 -point 
ordinal scale).Correction 
8.1.6 Arterial Blood Gas Test Supplemental oxygen/FiO2 ‘and resti ng SpO 2’ must 
be recorded at the same time as when an arterial 
blood gas is obtained. Resting SpO 2has been added.Consistency across the 
section
8.2.3 Electrocardiograms It has been added that ECG strips or reports may be 
requested in case of documentati on of a 
cardiovascular SAE.Clarification
8.2.6 Vital Status Vital status recording at Day 28 if discharge occurred 
before Day 28, has been added.Clarification and 
consistency
8.3.1 Time Period and Frequency 
for Collecting Adverse Event and 
Serious Adverse Event InformationSpontaneously reported SAEs through the Week 16 
visit instead of within 30 days after the last dose of 
study intervention, must be reported using an SAE 
form.Clarification and 
consistency
9.4.4 Other Secondary Endpoints Clarific ations on the analyses are provided. 
It has also been added that drugs used in the SOC at 
baseline will also be tabulated by treatment group. Clarification
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 142
Status: Approved ,Date: 17 February 2021Main Changes 
Section Number and Name Description of Change Brief Rationale 
9.4.5 Exploratory Endpoint(s) In addition to NP sw abs, SARS -CoV- 2 viral load w ill 
also be measured in endotracheal, blood, and stool 
samples.Clarification and 
consistency
6.2Preparation/Handling/Storage/
Accountability
10.3.8 Data Quality Assurance
10.3.11 Monitoring
10.3.12 AuditsLanguage on on -site monitoring visits and on -site 
audits has been updated to allow  flexibility during 
the COVID- 19 pandemic. Allow flexibility 
regarding on -site visits 
and audits. 
1.1Synopsis
1.2Schema
1.3Schedule of Activities (SoA)
2.2Dose Rationale
3OBJECTIVES AND 
ENDPOINTS
6.3Measures to Minimize Bias: 
Randomization and Blinding
6.8Prestudy and Concomitant 
Therapy
8.1Efficacy Assessments
8.1.1 Six-point Ordinal Clinical 
Recovery Scale
8.1.2 Level of Consciousness
8.1.3 Virology Assessm ents
8.2.7 Self-reported Oxygen Need
9.3Populations for Analysis Sets
9.4.4 Other Secondary Endpoints
9.5Interim Analysis
10.1 Appendix 1: Abbreviations and 
Definitions
10.2 Appendix 2: Clinical 
Laboratory Tests
10.3.6 Committees StructureMinor correcti ons or additions have been made. Correction, clarification 
and consistency
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 143
Status: Approved ,Date: 17 February 202111. REFERENCES
1. Actemra® USPI. Revised August 2017. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf. Accessed 29 March 2020 .
2. American Red Cross Blood donor eligibility requirements. Available from: 
http://www.redcrossblood.org/learn -about -blood/blood -facts -and-statistics. Accessed 28 March 2020. 
3. Baas T, Taubenberger JK, Chong PY, Chui P, Katze MG. SARS -CoV virus -host interactions and compar ative 
etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of 
formalin -fixed paraffin -embedded tissues. J Interferon Cytokine Res. 2006;26(5):309 -317. 
4. Banerjee S, Narayanan K, Mitzutani T, Makino S. Murine coronavirus replication -induced p38 mitogen -
activated protein kinase activation promotes interleukin -6 production and virus replication in cultured cells. J 
Virol. 2002;76(12):5937 -5948.
5. Bai B, hu Q, hu H, et al. Virus -like particles of SARS -like coron avirus formed by membrane proteins from 
different origins demonstrate stimulating activity in human dendritic cells. PLoS One. 2008;3(7):e2685. 
6. Baran P, Hansen S, Waetzig GH, et al. The Balance of Interleukin (IL) -6, IL- 6·soluble IL -6 Receptor (sIL -6R), 
and IL -6·sIL -6R·sgp130 Complexes Allows Simultaneous Classic and Trans -Signaling. J Biol Chem. 
2018;293(18):6762 -6775. doi: 10.1074/jbc.RA117.001163.
7. Bhatraju PK , Ghassemieh BJ, Nichols M, et al. Covid -19 in Critically Ill Patients in the Seattle Region —
Case Series. NEJM March 30, 2020 DOI: 10.1056/NEJMoa2004500
8. Butt Y, Kurdowska A, Allen TC .Acute lung injury: a clinical and molecular review. Arch Pathol Lab Med. 
2016;140(4):345 -350.
9. Center sfor Disease Control and Prevention. Coronavirus Disease 2019 (COVID -19) Symptoms and 
Com plications. Available at: https://www.cdc.gov/coronavirus/2019 -ncov/about/symptoms.html. 
Accessed: 27March 2020.
10. Center sfor Disease Control and Prevention. Transcript -CDC Media Telebriefing: Update on COVID -19. 
Available at: https://www.cdc.gov/media/releases/2020/t0309 -covid -19-update.html. Accessed on: 
27March2020.
11. Centers for Disease Control and Prevention. Transcri pt -CDC Media Telebriefing: Update on COVID -19. 
Available at: https://www.cdc.gov/media/releases/2020/t0309 -covid -19-update.html. Accessed on: 
27March 2020.
12. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: 
another zoonotic betacoronavirus causing SARS -like disease. Clin. Microbiol. Rev. 2015; 28:465 –522.
13. Channappanavar R ,Perlm an S. Pathogenic human coronavirus infections: causes and consequences of 
cytokine storm and immunopathology. Semin immunopathol. 201 7;39(5):529 -539. 
14. Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome 
coronavirus (SARS -CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of 
SARS -CoV infection. J Virol. 2010;84(3 ):1289 -1301. 
15. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel 
coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507 -513.
16. Chen X, Zhao B, Qu Y, et al. Detectable serum S ARS -CoV -2 viral load (RNAaemia) is closely associated w ith 
drastically elevated interleukin 6 (IL -6) level in critically ill COVID -19 patients. MedRxiv. 2020. Available at 
doi:https://doi.org/10.1101/2020.02.29.20029520. Accessed 30 Mar 2020.
17. Conti P, Ron coni G, Caraffa A. Induction of pro -inflammatory cytokines (IL -1 and IL -6) and lung 
inflammation by Coronavirus -19 (COVI -19 or SARS -CoV- 2): anti -inflammatory strategies. J Biol Regul 
Hom eost Agents. 2020;34(2). pii: 1. 
18. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute 
respiratory syndrome- related coronavirus: classifying 2019 -nCoV and naming it SARS -CoV -2. Nat Microbiol. 
2020 Mar 2. doi: 10.1038/s41564 -020-0695 -z. [Epub ahead of print]
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 144
Status: Approved ,Date: 17 February 202119. Day CW, Bari c R, Cai SX, et al. A new mouse -adapted strain of SARS -CoV as a lethal model for evaluating 
antiviral agents in vitro and in vivo. Virology. 2009;395(2):210 -222. 
20. Day M. Covid -19: four fifths of cases are asymptomatic, China figures indicate. BMJ 2020;369: m1375 doi: 
10.1136/bmj.m1375 (Published 2 Apr 2020)
21. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Corrected 
Version 2.1, July 2017. Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcor rectedv21.pdf. 
Accessed: 6 April 2020.
22. Dom inquez SR, Travanty EA, Qian Z , Mason RJ. Human coronavirus HKU1 infection of primary human type 
II alveolar epithelial cells: cytopathic effects and innate immune response. PLoS One. 2013;8(7): e70129.
23. Dong Y, Mo X, Hu Y, et al. Epidem iological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus 
Disease in China. Pediatrics. 2020 Mar 16. pii: e20200702. [Epub ahead of print]
24. Dosch SF, Mahajan SD, Collins AR. SARS coronavirus spike protein -induced inna te immune response occurs 
via activation of the NF -kappaB pathw ay in human monocyte macrophages in vitro. Virus Res. 2009;142(1 -
2):19 -27.
25. Eske J. What to know about the protein test and results . MedicalNewsToday, May 29, 2019 . Available at: 
https://www.medicalne wstoday.com/articles/325320. Accessed 12 June 2020.
26. European Centre for Disease Prevention and Control. Factsheet for health professionals on coronaviruses. 
Available at: https://www.ecdc.europa.eu/en/factsheet -health -professionals -coronaviruses. 
Accessed: 15Feb2020.
27. Grun JL, Lublin FD, Knobler RL. Interleukin -6 induction in vitro in mouse brain endothelial cells and 
astrocytes by exposure to mouse hepatitis virus (MHV -4, JHM). J Neuroimmunol. 1993;42(1):47 -52.
28. International Conferenc e on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. ICH Harmonized Tripartite Guideline E14: Clinical evaluation of QT/QTc interval prolongation 
and proarrhythmic potential for non -antiarrhythmic drugs. ICH 12 Ma y 2005.
29. Investigator’s Brochure: CNTO136 (sirukumab) Edition 1 3. Janssen Research & Development, April 2020. 
30. Ishii K, Hasegawa H, Nagata N, et al. Neutralizing antibody against severe acute respiratory syndrome 
(SARS) -coronavirus spike is highly effective for the protection of mice in the murine SARS model. Microbiol 
Immunol. 2009;53(2):75 -82. 
31. Jacques A, Bleau C, Turbide C, Beauchemin N, Lamontagne L. Macrophage interleukin -6 and tumour necrosis 
factor -alpha are induced by coronavirus fixation to Toll -like receptor 2/heparan sulphate receptors but not 
carcinoembryonic cell adhesion antigen 1a. Immunology. 2009; 128(1 Suppl):e181 -192.
32. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory 
syndrome. Am J Res pir Crit Care Med. 2005;171(8):850 -870
33. Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H. Development of a Physiologically Based Pharmacokinetic Model 
to Predict Disease- Mediated Therapeutic Protein –Drug Interactions: Modulation of Multiple Cytochrome P450 
Enzymes b y Interleukin -6. The AAPS Journal. 2016;18(3)767 -776.
34. Johns Hopkins CSSE. Coronavirus COVID -19 Global Cases. Available at: 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. 
Accessed: 6Apr2020.
35. Joyner MJ, W right RS, Fairweather D, et al. Early Safety Indicators of COVID -19 Convalescent Plasma in 
5,000 Patients. MedRxiv preprint doi: https://doi.org/10.1101/2020.05.12.20099879 , May 2020. Available at: 
https://www.medrxiv.org/content/10.1101/2020.05.12.2009987 9v1.full.pdf . Accessed 12 June 2020. 
36. Kevzara® USPI. Revised May 2017. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf. Accessed 29 March 20202.
37. Lam CW, Chan MH, Wong CK. Severe acute respiratory syndrome: clinical and laboratory manifestations. 
Clin Biochem Rev. 2004;25(2):121 -132. 
38. Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU -rich single -strand RNA identified from 
SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2 013;15(2):88 -95. 
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 145
Status: Approved ,Date: 17 February 202139. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus -Infected 
Pneumonia. N Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa2001316. [Epub ahead of print].
40. Liang B, Gardner DB, Grisw old DE, Bugelski PJ, Song XY. Anti-interleukin -6 monoclonal antibody inhibits 
autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119:296 -305.
41. Liang B, Song Z, Wu B, Gardner D, et al. Evaluation of anti -IL-6 monoclonal antibody therapy using murine 
type II collagen -induced arthritis. J Inflamm. 2009;6(10).
42. Liao Y, Wang X, Huang M, Tam JP, Liu DX. Regulation of the p38 mitogen -activated protein kinase and dual -
specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with 
coronavirus infectious bronchitis virus. Virology. 2011; 420(2):106 -116. 
43. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications 
for virus origins and receptor binding. La ncet. 2020 Jan 30. pii: S0140 -6736(20)30251 -8.
44. McNarry AF, Bateman DN. Simple bedside assessment of level of consciousness: comparison of two simple 
assessment scales with the Glasgow Coma scale. Anaesthesia. 2004;59:34 –37.
45. Mihara M, Kasutani K, Okazaki M, etal. Tocilizumab inhibits signal transduction mediated by both mIL -6R 
and sIL -6R, but not by the receptors of other members of IL-6 cytokine family. International 
Immunopharmacology .2005 (5);1731 –1740 .
46. National Institute of Allergy and Infectious Disease s. Division of Microbiology and Infectious Diseases 
(DMID) Adult toxicity tables. November 2007 (draft). Available at: 
https://www.niaid.nih.gov/sites/default/files/dmidadulttox.pdf. Accessed on 2 April 2020. 
47. Nieto -Torres JL, DeDiego ML, Verdiá -Báguena C, et al. Severe acute respiratory syndrome coronavirus 
envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 
2014;10(5):e1004077. 
48. Paessler S and Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013; 8:411 -440. 
49. Park WY, Goodman RB, Steinberg KP, et al. Cytokine Balance in the Lungs of Patients with Acute 
Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2001;164:1896 –1903.
50. Priestnall SL, Mitchell JA, Brooks HW, Brownlie J, and Erles K. Quantification of mRNA encoding cytokines 
and chemokines and assessment of ciliary function in canine tracheal epithelium during infection with canine 
respiratory coronavirus (CRCoV). Vet Immunol Immunopathol. 2009;127(1 -2):38 -46.
51. Prom petchara E, Ketloy C, Palaga T. Immune responses in COVID -19 and potential vaccines: Lessons learned 
from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1 -9. 
52. roActemra® SmPC. Revised 25 September 2013. Available at: 
https://www.ema.europa.eu/en/documents/prod uct-information/roactemra -epar-product -information_en.pdf. 
Accessed 3 Apr 2020.
53. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID -19 based on 
analysis of data of 150 patients from Wuhan China. Intensive Care Med. 2020. doi: 10.1007/s00134 -020-
05991 -x. [Epub ahead of print]
54. Shi Y, Wan Y, Shao C, et al. COVID -19 infection: the perspectives on immune responses. Cell Death Differ 
2020. doi: 10.1038/s41418 -020- 0530 -3. [Epub ahead of print].
55. Shimabukuro -Vornhagen A, Gödel P, S ubklew e M, et al. Cytokine release syndrome. J Immunother Cancer. 
2018 15;6(1):56. doi: 10.1186/s40425 -018-0343 -9.
56. Smits SL, van den Brand JM, de Lang A, et al. Distinct severe acute respiratory syndrome coronavirus -induced 
acute lung injury pathways in two different nonhuman primate species. J Virol. 2011;85(9):4234 -4245. 
57. Stone JH, Frigault MJ, Serling -Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid -19. 
N Engl J Med 2020; 383: 2333 -44.
58. The REMAP -CAP Investigators, Interleukin -6 Receptor Antagonists in Critically Ill Patients with Covid -19 –
Preliminary report, medRxiv preprint . Available at: doi: https://doi.org/10.1101/2021.01.07.21249390 . 
Accessed on 8 February 2021.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 146
Status: Approved ,Date: 17 February 202159. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, an d Katze MG. Into the eye of the cytokine storm. 
Microbiol Mol Biol Rev. 2012;76(1):16 -32. 
60. Tseng CT, Peronne LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate 
immune responses: modulation of effector cell function without pro ductive infection. J Immunol. 
2005;174(12):7977 -7985. 
61. Unver N, McAllister F. IL -6 fam ily cytokines: key inflammatory mediators as biomarkers and potential 
therapeutic targets. Cytokine Growth Factor Rev. 2018;41:10 -17. 
62. Wang WK, Chen SY, Liu IJ. Temporal relationship of viral load, ribavirin, interleukin (IL) -6, IL -8, and 
clinical progression in patients with severe acute respiratory syndrome. Clin Infect Dis. 2004;39(7):1071 -1075. 
63. Wang W, Ye L, Ye L, et al. Up -regulation of IL -6 and TNF -alpha induced by SARS -coronavirus spike protein 
in murine macrophages via NF -kappaB pathw ay. Virus Res. 2007;128(1 -2):1-8. 
64. Wang SF, Tseng SP, Yen CH, et al. Antibody -dependent SARS coronavirus infection is mediated by 
antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208 -214. 
65. Wang Y, Wang H, Zhang C, et al. Lung fluid biomarkers for acute respiratory distress syndrome: a systematic 
review and meta -analysis. Crit Care. 2019;23(1):43. 
66. Wang D, Hu B, Hu C. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus –
Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585. [Epub ahead of 
print].
67. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases w ith coronavirus disease in 2019 in 
Wuhan Ch ina. Clin Infect Dis. 2020. pii: ciaa272
68. Wolf J, Rose- John S, and Garbers C. Interleuking -6 and its receptors: highly regulated and dynamic system. 
Cytokine. 2014;70(1):11 -20. 
69. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute 
respiratory syndrome. Clin Exp Immunol. 2004;136(1):95 -103. 
70. World Health Organization (WHO). Global surveillance for COVID- 19 caused by human infection with 
COVID -19 virus. Interim guidance 20 March 2020. Available at: 
https://apps.who.int/iris/bitstream/handle/10665/331506/WHO -2019 -nCoV -SurveillanceGuidance -2020.6 -
eng.pdf?sequence=1&isAllowed=y. Accessed 14 Apr 2020. 
71. World Health Organization (WHO). Clinical management of severe acute respiratory infectio n when 
COVID -19 is suspected. Interim guidance 13 March 2020. Available at: https://www. who.int/publications -
detail/clinical -management -of-severe- acute -respiratory -infection -when -novel -coronavirus -(ncov) -infection -is-
suspected. Accessed 14 Apr 2020.
72. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) 
Emergency Committee regarding the outbreak of novel coronavirus (2019 -nCoV). Available at: 
https://www.who.int/news -room/detail/30 -01-2020 -statement -on-the-second- meeting -of-the-international -
health -regulations -(2005) -emergency -committee -regarding -the-outbreak -of-novel -coronavirus -(2019 -ncov).
Accessed 14 Apr 2020. 
73. World Health Organization. WHO Director -General's opening remarks at the media briefing on COV ID-19 -
11 March 2020. Available at: https://www.who.int/dg/speeches/detail/who -director -general -s-opening -
remarks- at-the-media -briefing -on-covid -19---11-march -2020. Accessed 12 Mar 2020.
74. World Health Organization. WHO guidelines for the global surveillanc e of severe acute respiratory syndrome 
(SARS). Updated recommendations, October 2004. Available at: 
https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1/en/. Accessed: 15 Feb 2020.
75. Wu F, Zhao S, Yu B, et al. A new coronavirus associated wi th human respiratory disease in China. Nature. 
2020;579(7798):265 -269.
76. Xu X, Han M, Li T, et al. Effective treatment of severe COVID- 19 patients with tocilizumab. 
chinaXiv:202003.00026v1.
CNTO136   (sirukumab ) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 147
Status: Approved ,Date: 17 February 202177. Yoshikawa T, Hill T, Li K, Peters CJ, and Tseng CT. Severe acute res piratory syndrome (SARS) coronavirus -
induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of 
monocyte- derived macrophages and dendritic cells. J Virol. 2009; 83(7):3039 -3048. 
78. Yu D, Zhu H, Liu Y, Cao J, and Zhang X. Regulation of proinflammatory cytokine expression in primary 
mouse astrocytes by coronavirus infection. J Virol. 2009;83(23):12204 -12214. 
79. Zhang Y, Li J, Zhan Y. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect 
Imm un. 2004;72(8):4410 -5.
80. Zhang X, Wu K, Wang D et al. Nucleocapsid protein of SARS -CoV activates interleukin -6 expression through 
cellular transcription factor NF -kappaB. Virology. 2007;365(2):324 -335. 
81. Zhou J, Chu H, Li C, et al. Active replication of Middl e East respiratory syndrome coronavirus and aberrant 
induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J 
Infect Dis. 2014;209(9):1331 -1342. 
82. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses -drug discovery and therapeutic options. Nat 
Rev Drug Discov. 2016;15(5):327 -347.
CNTO136  (sirukumab) Clinical Protocol CNTO136COV2001
AMENDMENT 5
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 148
Status: Approved, Date: 17 February 2021INVESTIGATOR AGREEMENT
PPD
PPD